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Abstract 
Mutations in mitochondrial DNA (mtDNA) lead to a genetically and phenotypically 
heterogeneous group of human diseases, mitochondrial disorders. Though patients with 
mtDNA disease present with multisystemic abnormalities, the central nervous system is usually 
severely affected. Of the neurological deficits, cerebellar ataxia is the most frequently 
presenting symptom of patients recruited to the UK MRC Mitochondrial Disease Patient cohort, 
with a prevalence of 70%. Furthermore, stroke-like episodes are prominent, but not restricted, 
to patients with the Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like 
episodes (MELAS) syndrome, due to the m.3243A>G point mutation. Both neurological 
symptoms are associated with pronounced neurodegeneration. The aim of this thesis was to 
gain further insights into the mechanisms responsible for neuronal loss in patients who manifest 
with cerebellar ataxia and stroke-like episodes.   
A reliable, reproducible and quantitative quadruple immunofluorescent technique has been 
developed that allowed the quantification of respiratory chain protein expression in specific 
neuronal domains and cellular populations. Furthermore, three-dimensional reconstruction 
helped examine the structural characteristics of sub-cellular compartments. Close investigation 
of the intracerebellar microcircuitry provided evidence for respiratory chain protein expression 
defects in Purkinje cell bodies, dendrites and presynaptic terminals. Altered Purkinje cell 
innervation of respiratory chain deficient dentate nuclei neurons likely leads to neuronal 
disinhibition and is accompanied by partially disturbed glutamatergic connectivity to the 
region.  
Additionally, respiratory chain deficiencies were detected in the vasculature of vulnerable to 
stroke-like episodes brain regions (cerebellum, occipital and temporal lobe) in patients 
harbouring the m.3243A>G point mutation. Preliminary data suggest that stroke-like episode 
manifestation and cortical lesion development is due to an additive effect between 
neuronal/interneuronal and vascular pathology. 
These observations set the basis for studying the impact of mtDNA defects in synaptic, neuronal 
and vascular health in-vitro and have important implications for identifying good candidates 
for drug targeting in mitochondrial disease. 
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Chapter 1 Introduction 
1.1 Mitochondria 
Mitochondria are highly dynamic cytoplasmic organelles present in all nucleated mammalian 
cells (with the exception of red blood cells). Although they are most well known for their 
capacity for energy production (in the form of adenosine triphosphate – ATP), their importance 
in calcium homeostasis (Vandecasteele et al., 2001), reactive oxygen species (ROS) production 
(Sena and Chandel, 2012), iron-sulphur (Fe-S) cluster biogenesis (Rouault and Tong, 2005) and 
apoptosis (Wang and Youle, 2009) places mitochondria at the centre of cellular life and death.  
According to evolutionary biology, mitochondria have derived from a mutually beneficial 
relationship between free-living bacteria (Gray, 2012). The “serial hypothesis” suggests that an 
alpha-proteobacterium was incorporated into a primitive eukaryote cell, which originated from 
an Archaebacterium and lacked mitochondria, to eventually become the mitochondrion (proto-
mitochondrion) (Margulis, 1970). However, more recent observations have led to the 
“hydrogen hypothesis” which states that mitochondria have evolved after an endosymbiotic 
relationship between a hydrogen-dependent Archaebacterium and a hydrogen-producing 
Eubacterium (Martin and Muller, 1998). Regardless of the evolutionary mechanisms that gave 
rise to modern day mitochondria, a single endosymbiotic event occurred which was followed 
by either partial loss or transfer of genetic material from the proto-mitochondrion to the cell 
nucleus (Timmis et al., 2004). 
1.1.1 Mitochondrial structure 
Upon electron microscopy, mitochondria appear as double-membraned organelles that have a 
rod or ovoid shape and measure 1-4μm in length x 0.3-0.7μm in diameter (Palade, 1953). The 
intermembrane space separates the outer from the inner mitochondrial membrane, whereas the 
interior of the mitochondrion is termed the matrix (Figure 1- 1) (Palade, 1953). The 
mitochondrial matrix contains multiple copies of the mitochondrial genome and the machinery 
necessary for its expression.  
The outer mitochondrial membrane (OMM) very much resembles normal cell membranes. Its 
lipid layer is enriched for the voltage-dependent anion channel (VDAC) protein porin, which 
allows for the exchange of small molecules and ions, <5kDa, between the cytoplasm and the 
intermembrane space (Alberts B, 2002). 
In contrast to the OMM, the high proportion of cardiolipin present within the lipid bilayer of 
the inner mitochondrial membrane (IMM), accounts for the membranes’ impermeability to 
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macromolecules and ions. Instead, the membrane only allows the perfusion of O2, CO2 and H2O 
into the matrix, whereas transport proteins located throughout the membranous layer allow 
small molecules to enter the interior of mitochondria. The IMM is extremely rich in protein 
(75% protein content) and has traditionally been though to project into the mitochondrial matrix 
through highly folded conformations, known as cristae (Palade, 1952; Ardail et al., 1990). 
However, advances in high-resolution microscopy have revealed that the IMM is in fact 
comprised of the inner boundary membrane (IBM) and the cristae membrane (CM), which are 
connected through crista junctions (Perkins et al., 1997; Frey and Mannella, 2000). Complexes 
of the oxidative phosphorylation system (OXPHOS) and proteins involved in Fe-S cluster 
biogenesis, local protein synthetic machinery and transport are primarily localised within the 
CM, whilst the IBM is enriched for proteins associated with mitochondrial fusion and related 
with nuclear DNA-encoded protein import (Vogel et al., 2006). 
However, this is not how mitochondria appear in vivo which are often organised into syncytia. 
Mitochondrial ultrastructure is highly variable and depends on the cellular physiological state 
at the time.  
 
 
Chapter 1       Introduction 
9 
F
ig
u
re
 1
- 
1
: 
M
it
o
ch
o
n
d
ri
a
l 
st
ru
ct
u
re
 a
cc
o
rd
in
g
 t
o
 r
e
ce
n
t 
el
e
ct
ro
n
 m
ic
ro
sc
o
p
ic
 o
b
se
r
v
a
ti
o
n
s 
Chapter 1       Introduction 
10 
1.1.2 Mitochondrial biogenesis 
The number of mitochondria within tissues varies greatly, depending on the metabolic demand 
of its cellular populations, and as such mitochondrial biogenesis is tightly regulated so as the 
ATP requirements of the tissue are met. Its primarily regulated by the peroxisome proliferator-
activated receptor γ, coactivator 1α (PGC1-α) and has long being considered to take place 
within the cell nucleus (Jornayvaz and Shulman, 2010).  
1.1.3 Mitochondrial dynamics 
Mitochondria are dynamic organelles and as such rarely appear as single entities. Instead, they 
are usually arranged in networks constantly undergoing fusion and fission allowing for nutrient 
exchange and support between the individual components (Bereiter-Hahn and Voth, 1994; 
Chen and Chan, 2004). The balance between mitochondrial fusion and fission is vital since 
altered fusion/fission rate and/or disturbed fusion/fission machinery have been linked to human 
neurodegenerative disease (Chen and Chan, 2009). Proteins that are involved in mitochondrial 
fusion include mitofusins 1 and 2 (MFN1 and MFN2) and optic atrophy 1 (OPA1), whereas the 
dynamin-1 like protein (DNM1L) is responsible for mitochondrial fission (Liesa et al., 2009). 
Further to fusion and fission, mitochondrial dynamics also comprise mitochondrial autophagic 
degradation, mitophagy (Kim et al., 2007; Twig et al., 2008). Unwanted or damaged organelles 
are selectively targeted via the Pink1-Parkin signalling pathway and removed via lysosomal 
degradation (Clark et al., 2006; Park et al., 2006). 
1.1.4 Neuronal mitochondria  
Neuronal mitochondria are generated in cell bodies and reach the distal parts of an axon via 
motor protein-assisted transport. There are two types of axonal mitochondrial transport, 
anterograde and retrograde. Anterograde transport is promoted via Kinesin motors and involves 
mitochondrial transport towards the axon terminal end of microtubules (Hirokawa and Noda, 
2008). Dyneins on the other hand, facilitate retrograde mitochondrial transport back to the cell 
body (towards the minus-end of microtubules) (Vallee et al., 2004). Mitochondria constantly 
undergo cycles of moving, stopping and restarting. They are capable of moving in both 
directions, whereas specific neuronal and physiological signals promote mitochondrial 
anchoring to particular neuronal sites (Hollenbeck and Saxton, 2005; MacAskill and Kittler, 
2010; Schwarz, 2013; Sheng, 2014).  
Interestingly, recent evidence on the existence of axonal and presynaptic protein synthetic 
machineries suggest that mitochondrial biogenesis does not only take place in neuronal cell 
bodies (Schacher and Wu, 2002; Hillefors et al., 2007; Natera-Naranjo et al., 2010). This is 
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explained by the fact that some peripheral neurons can possess axons that are several 
centimetres long, making it difficult for slow-moving mitochondria to meet the energetic 
demand of distal synapses at any given point. Likewise, Pink1 and Parkin recruitment locally 
by damaged axonal mitochondria suggests that mitophagy may also occur in the axons (Ashrafi 
et al., 2014). Local response to focal damage presents a neuroprotective mechanism that does 
not require retrograde mitochondrial transport.  
1.1.5 Oxidative phosphorylation and ATP synthesis 
ATP synthesis via the oxidative phosphorylation system (OXPHOS) meets approximately 80% 
of the total cellular energetic demand. Intermediate products from the tricarboxylic acid (TCA) 
cycle (also referred to as the citric acid cycle or Kreb’s cycle) donate electrons to the respiratory 
chain, the transfer of which results in ATP generation (Hatefi, 1985; Saraste, 1999). 
The primary step of cellular respiration involves cytoplasmic glycolysis, whereby glucose is 
broken down into pyruvate according to Equation 1- 1 (Berg JM, 2002b): 
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 + 2𝑁𝐴𝐷+ + 2𝐴𝐷𝑃 + 2𝑃𝑖  → 2𝑃𝑦𝑟𝑢𝑣𝑎𝑡𝑒 + 2𝑁𝐴𝐷𝐻 + 2𝐻
+ + 2𝐴𝑇𝑃 + 2𝐻2𝑂  
Equation 1- 1: Glycolysis 
Cytoplasmic pyruvate is then transported into the mitochondrial matrix, within which it 
undergoes decarboxylation in a reaction catalysed by pyruvate dehydrogenase (Equation 1- 2): 
𝑃𝑦𝑟𝑢𝑣𝑎𝑡𝑒 + 𝐶𝑜𝐴 + 𝑁𝐴𝐷+  → 𝐴𝑐𝑒𝑡𝑦𝑙 𝐶𝑜𝐴 + 𝑁𝐴𝐷𝐻 + 𝐻+ +  𝐶𝑂2 
Equation 1- 2: Pyruvate decarboxylation  
Acetyl CoA feeds into the TCA cycle along with NAD+ and FADH. The two substrates are 
reduced into NADH and FADH2, to later become electron carriers, and Acetyl CoA is oxidised 
to CO2. The overall TCA cycle reaction is summarised in Equation 1- 3 (Berg JM, 2002a): 
𝐴𝑐𝑒𝑡𝑦𝑙 𝐶𝑜𝐴 + 3𝑁𝐴𝐷+ + 𝐹𝐴𝐷 + 𝐴𝐷𝑃 + 𝑃𝑖 + 2𝐻2𝑂 
→ 𝐶𝑜𝐴 + 3𝑁𝐴𝐷𝐻 +  𝐹𝐴𝐷𝐻2 + 2𝐻
+ + 𝐴𝑇𝑃 + 𝐶𝑂2 
Equation 1- 3: Outcome of TCA cycle 
The ETC consists of four transmembrane multimeric complexes (complex I-IV) and two mobile 
electron carriers (coenzyme Q and cytochrome c), which along with ATP synthase (complex 
V) comprise the OXPHOS system (Figure 1- 2). Electrons from NADH and FADH2 are donated 
to complexes I and II respectively which in turn transfer the electrons across the chain.  The 
energy released from electron transfer at complexes I, III and IV, is used to pump protons (H+) 
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from the mitochondrial matrix into the intermembrane space creating an electrochemical 
gradient. This gradient drives protons through complex V that facilitates the phosphorylation 
of adenosine diphosphate (ADP) to produce ATP (Figure 1- 2) (Berg JM, 2002c). 
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1.1.5.1 Complex I 
Complex I (NADH: Ubiquinone oxidoreductase) is the largest of the respiratory chain 
complexes with a molecular weight of approximately 1,000kDa. The mammalian mitochondrial 
complex consists of 46 protein subunits, 7 of which are encoded by mitochondrial DNA 
(mtDNA) (Ugalde et al., 2004b). Electron donation to this complex results to the oxidation of 
NADH to NAD+ (by ubiquinone) and to the translocation of four protons into the 
intermembrane space. The reaction is shown below (Equation 1- 4): 
𝑁𝐴𝐷𝐻 + 𝑄 + 5𝐻𝑚𝑎𝑡𝑟𝑖𝑥
+  →  𝑁𝐴𝐷+ + 𝑄𝐻2 + 4𝐻𝑖𝑚𝑠
+  
Equation 1- 4: Complex I reaction  
1.1.5.2 Complex II 
Complex II (succinate dehydrogenase or succinate ubiquinone oxidoreductase) is the smallest 
of all respiratory chain complexes since it is comprised of four protein subunits, solely encoded 
by nuclear DNA. Transfer of electrons across this complex does not drive proton translocation 
into the intermembrane space, though it reduces FAD+ to FADH2 while converting succinate to 
fumarate. The electrons released by the reoxidation of FADH2 to FAD
+ are used to reduce 
ubiquinone to ubiquinol (Equation 1- 5) (Hagerhall, 1997). 
𝑠𝑢𝑐𝑐𝑖𝑛𝑎𝑡𝑒 + 𝑄 → 𝑓𝑢𝑚𝑎𝑟𝑎𝑡𝑒 + 𝑄𝐻2 
Equation 1- 5: Complex II reaction 
1.1.5.3 Complex III 
Complex III (Ubiquinol: cytochrome c oxidoreductase) is composed of 11 protein subunits, one 
of which is mtDNA-encoded (cytochrome b). Complex III utilises the transfer of electrons from 
ubiquinol to cytochrome c, via s process known as the Q cycle, during which two protons are 
pumped into the intermembrane space (Equation 1- 6) (Mitchell, 1976). 
2𝑄𝐻2 + 𝑄 + 2𝐶𝑦𝑡𝑐𝑜𝑥𝑖𝑑𝑖𝑠𝑒𝑑 + 2𝐻𝑚𝑎𝑡𝑟𝑖𝑥
+  → 2𝑄 + 𝑄𝐻2 + 2𝐶𝑦𝑡𝑐𝑟𝑒𝑑𝑢𝑐𝑒𝑑 + 4𝐻𝑖𝑚𝑠
+  
Equation 1- 6: Complex III reaction, the Q cycle 
1.1.5.4 Cytochrome c 
Cytochrome c is a small, nuclear encoded hemoprotein that facilitates the transfer of a single 
electron from complex III to complex IV. It’s function extends beyond respiration, since its 
cytosolic release has been linked to apoptotic cell-death pathways (Huttemann et al., 2011).  
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1.1.5.5 Complex IV 
Complex IV (cytochrome c oxidase) is the terminal enzyme of the ETC which also catalyses 
its rate-limiting reaction. The complex consists of 13 protein subunits, 3 of which are 
mitochondrially encoded, and catalyses the reduction of oxygen (O2) to water (H2O). One 
reduction reaction requires 4 electrons and results in the translocation of 4 protons into the 
intermembrane space (Equation 1- 7) (Huttemann et al., 2011).  
4𝐶𝑦𝑡𝑐𝑟𝑒𝑑𝑢𝑐𝑒𝑑 + 8𝐻𝑚𝑎𝑡𝑟𝑖𝑥
+ +  𝑄2  → 4𝐶𝑦𝑡𝑐𝑜𝑥𝑖𝑑𝑖𝑠𝑒𝑑 + 4𝐻2𝑂 + 4𝐻𝑖𝑚𝑠
+  
Equation 1- 7: Complex IV reaction 
1.1.5.6 Complex V   
Complex V (Fo F1 ATP synthase) employs the electrochemical proton gradient, generated by 
the passage of electrons across the ETC, to drive the phosphorylation of ADP to ATP according 
to Equation 1- 8: 
𝐴𝐷𝑃 + 𝑃𝑖 + 2.7𝐻𝑖𝑚𝑠
+  → 𝐴𝑇𝑃 + 2.7𝐻𝑚𝑎𝑡𝑟𝑖𝑥
+  
Equation 1- 8: ATP synthesis 
The complex contains two domains, the Fo is located in the membrane and the F1 extents into 
the mitochondrial matrix. Proton movement through the Fo domain drives F1 rotation and 
generation of ATP. Eight protons are required for a full 360o rotation of the F1, which produces 
3 molecules of ATP. Thus, the production of one ATP molecule costs 2.7 proton ions 
(Ferguson, 2010; Watt et al., 2010).  
1.1.5.7 Supercomplexes 
Free-floating single respiratory chain complexes within the IMM are believed to co-exist with 
sophisticated supramolecular complexes, termed supercomplexes (Dudkina et al., 2010).  
Evidence for the existence of OXPHOS supercomplexes arises from blue-native PAGE gels 
(Schagger and Pfeiffer, 2000) as well as electron microscopic images that illustrate the presence 
of defined interaction within isolated supercomplexes (Dudkina et al., 2005; Schäfer et al., 
2006). Almost all mammalian complex I and III form stable interactions with four copies of 
complex IV, giving rise to “respirasomes” (Schagger and Pfeiffer, 2000). These can indeed 
respire independently to the rest of the chain in the presence of ubiquinone and cytochrome c 
(Acin-Perez et al., 2008). Remarkably, respirasome activation requires the incorporation of the 
catalytic subunit of complex I (NADH dehydrogenase) to the pre-assembled supercomplex 
(consisted of a complex I scaffold, complex III and IV) (Moreno-Lastres et al., 2012), whereas 
supercomplex formation is likely to be advantageous to the oxidative phosphorylation capacity 
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of the cell (Schagger and Pfeiffer, 2000). The time needed for ETC substrates to travel across 
supercomplexes is decreased, resulting in enhanced catalytic activity of the unit (Schagger and 
Pfeiffer, 2000). Moreover, the demonstration that electron transport chain complexes are 
interconnected could account for combined respiratory chain deficiencies in human 
mitochondrial disease. 
1.1.6 Other mitochondrial functions 
1.1.6.1 Ca2+ signalling and homeostasis 
The mitochondrial membrane potential (~180mV), established by a series of oxidation and 
reduction reactions across the ETC, enables cytoplasmic Ca2+ sequestration and contributes to 
intracellular calcium homeostasis. Cytoplasmic Ca2+ crosses the OMM via the VDAC pore 
(Simamura et al., 2008) and is imported to the mitochondrial matrix via a calcium uniporter 
(MCU) found at the IMM (Kirichok et al., 2004). Within the matrix, Ca2+ functions as a 
signalling molecule serving to regulate cellular communication (Hofer et al., 2000), apoptosis 
(Orrenius et al., 2003), ATP production (Tarasov et al., 2012) and metabolism (Duchen, 2000). 
The importance of mitochondrial calcium buffering within neurons should not be 
underestimated. Elevated cytosolic [Ca2+] drives mitochondrial anchoring to synaptic sites, 
whereas mitochondrial-mediated calcium buffering is key for rapid recovery and therefore 
synaptic transmission preservation in glutamatergic synapses (Billups and Forsythe, 2002). 
Moreover, calcium buffering by mitochondria is central to neuronal polarity and axonal 
differentiation (Mattson and Partin, 1999). Interestingly, synaptic mitochondria appear to have 
a lower threshold for calcium uptake before their membrane potential collapses and their 
function is impaired relative to their non-synaptic counterparts (Yarana et al., 2012), implying 
that the ability of mitochondria to buffer calcium differs across the neuron.  
1.1.6.2 Reactive oxygen species production 
Mitochondrial reactive oxygen species (ROS) have historically being considered to be 
damaging to the cells, though more recent investigations have highlighted their importance in 
cellular physiology, particularly for cell signalling. Complexes I and III possess collectively 10 
sites that are capable of producing superoxide radicals (O2-) and thus mitochondrial ROS (Chen 
et al., 2003; Brand, 2010). Excessive ROS production has been linked to neurodegenerative 
disorders, cancer and ageing, whereas it’s tight regulation facilitates cell differentiation, 
immune cell activation, autophagy and metabolic adaptation (Sena and Chandel, 2012).   
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1.1.6.3 Apoptosis and other cell death mechanisms  
Apoptosis or programmed cell death is the process by which unwanted or damaged cells are 
degraded so that the whole organism can survive. Mitochondria are directly involved in 
apoptotic cell death pathways since intracellular Ca2+ built-up drives pro-apoptotic factors (e.g. 
Bax, Bad) to act on mitochondria. Organelle depolarization and opening of permeability 
transition pore releases cytochrome c that facilitates apoptosome formation via interaction with 
the apoptotic protease activating factor 1 (Apaf-1). Caspase-9 activation and downstream 
signaling cascades eventually lead to cellular death. (Kroemer et al., 1998; Wang and Youle, 
2009).  
Mitochondrial importance in non-apoptotic cell death mechanisms has also been reported and 
includes their involvement in necroptosis, ferroptosis, and caspace-independent cell death 
pathways (Tait et al., 2014; Yang and Stockwell, 2015). Serving as a regulated active type of 
cell death that resembles necrosis (Galluzzi et al., 2011), necroptosis initiation (following DNA 
damage, viral infection and death receptor-ligand binding) leads to necrosome formation 
(containing the receptor-interacting serine/threonine-protein kinase 3 (RIPK3) and the mixed-
lineage kinase domain-like (MLKL) protein) which is then translocated to mitochondrially 
associated endoplasmic reticulum membranes (MAMs) (Chen et al., 2013). Phosphorylation of 
a mitochondrial phosphatase (PGAM5) by RIPK3 drives DNM1L activation followed by 
mitochondrial fission, ROS production and necroptosis (Wang et al., 2012). Mitochondrial 
importance in necroptosis is however controversial since organellar depletion does not affect 
the kinetics or the extent of necroptosis induced by factors other than ROS (Tait et al., 2013). 
Ferroptosis is an iron-dependent form of oxidative cell detah that is genetically, 
morphologically and biochemically unique (Dixon et al., 2012). Two cellular events are 
suggested to be necessary for ferroptosis to occur; one being the disruption of cellular 
antioxidant defences (by chemical compounds like erastin, Sorafenib and p53 and/or following 
ischemia/reperfusion injury) and the other being an increase of intracellular iron (Bogdan et al., 
2015; Yang and Stockwell, 2015). The presence of small mitochondria with increased 
membrane density in cells treated with erastin (Dixon et al., 2012) and the identification of 
VDAC2/3 as direct erastin targets (Yagoda et al., 2007), suggests for mitochondrial 
participation in erastin-induced cell death.   
Mitochondrial outer membrane permeablisation is a shared mechanism between apoptosis and 
caspase-independent cell death pathways (Tait and Green, 2008), which are overall 
biochemically and kinetically distinct. Mitochondria may contribute to caspase-independent 
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cellular death directly, via a loss-of-function mechanism or a combination of the two (Tait et 
al., 2014). Outer membrane permeabilisation leads to intermembrane protein release (e.g 
cytochrome c, apoptosis-inducing factor (AIF), endonuclease G etc) and cellular death 
however, definitive proof that this is indeed the case is lacking (Jones et al., 2003; Bahi et al., 
2006). Instead, mitochondrial permeabilisation is proposed to be crucial for mitochondrial 
function since TIM23 (an inner mitochondrial membrane translocase subunit) (Goemans et al., 
2008) and cytochrome c degradation (following permeabilisation) (Ferraro et al., 2008) 
collectively contribute to respiratory chain (complex I and IV) dysfunction (Lartigue et al., 
2009) and loss of mitochondrial membrane potential. These eventually lead to cellular death. 
Finally, reversal of ATPase function (following mitochondrial permeabilisation) is proposed to 
result in ATP hydrolysis and cellular ATP depletion, thus accelerating caspase-independent cell 
death (Tait et al., 2014). 
1.1.6.4 Iron homeostasis and Fe-S cluster biogenesis 
Mitochondria are central to cellular iron metabolism since the majority of intracellular iron is 
imported into the organelles, via the IMM protein mitoferrin (Shaw et al., 2006). Organellar 
iron is then utilised for haem production and Fe-S cluster biogenesis (Wang and Pantopoulos, 
2011). Fe-S cluster biogenesis is a complex and multi-stage process during which the 
mitochondrial proteins Isu1/2 and Isa1/2 serve as the scaffold for cluster biogenesis and Grx5 
and Abcb7 are involved in cluster maturation (Wang and Pantopoulos, 2011). The primary role 
of Fe-S clusters is to facilitate electron transport, exemplified by the presence of 12 different 
Fe-S clusters in the ETC (Schultz and Chan, 2001), while they are also involved in the sensing 
and regulation of oxidative stress and intra-mitochondrial iron levels (Olsson and Norrby, 2008; 
Yeh et al., 2009). 
1.2 The mitochondrial genome 
Mitochondria contain their own genetic material, mitochondrial DNA (mtDNA) (Nass and 
Nass, 1963), which is a small (16,569bp) and circular double-stranded molecule that resides 
within the mitochondrial matrix. MtDNA is composed of a guanine-rich heavy strand and a 
cytosine-rich light strand, which collectively house the 37 mtDNA genes. The mitochondria 
genome encodes for 13 proteins necessary for the assembly and function of the oxidative 
phosphorylation system, 2 ribosomal RNAs (rRNAs) and 22 transfer RNAs (tRNAs) (Figure 
1- 3) (Anderson et al., 1981). The only non-coding region within mtDNA is known as the 
strand-displacement loop (D-loop), a triple-stranded sequence that serves as the site for heavy 
strand replication and contains elements necessary for mtDNA transcription (Arnberg et al., 
1971; Kasamatsu et al., 1971; Shadel and Clayton, 1997). Unique features of the mitochondria 
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genome include the absence of intronic sequences and scarcity of non-coding regions 
(termination codons created after transcription) within its structure, accounting for the 
compactness of the molecule (Anderson et al., 1981).  
Multiple mtDNA copies (2-10) are present within each mitochondrion (Lee and Wei, 2005) and 
numerous mitochondria are contained within each mammalian cell, thus some cells of the 
human body can have up to 104 mtDNA copies (Lightowlers et al., 1997). Though originally 
believed to be naked and unprotected, mtDNA molecules are packaged into small (~100nm) 
protein-DNA complexes known as nucleoids (Chen and Butow, 2005; Kukat et al., 2011). 
Nucleoids have been reported to contain between 1.4 (Kukat et al., 2011) and 3 (Brown et al., 
2011) mtDNA copies and are highly abundant for the mitochondrial transcription factor A 
(TFAM) (Parisi and Clayton, 1991; Kukat et al., 2011). Other proteins documented to be 
associated with mammalian nucleoids include the mitochondrial DNA helicase - TWINKLE, 
the single-stranded DNA binding protein - mtSSB and the mitochondrial DNA polymerase - 
POLγ (Chen and Butow, 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1       Introduction 
20 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1- 3: The human mitochondrial genome.  
The human mtDNA is a compact, circular double-stranded molecule comprised of a heavy and a light strand. MtDNA 
encodes for 37 genes: 13 polypeptides, 2 rRNAs and 22 tRNAs. The outer (heavy strand) houses 12 of the protein encoding 
genes: 5 complex I subunits (MT- ND1-5), 1 complex III subunit (MT -CYB), 3 complex IV subunits (COX I-III) and 2 
subunits of complex V (ATP 6&8). The ND6 subunit of complex I is transcribed from in the inner light strand, whereas 
tRNA genes are dispersed throughout both stands and interspersed between protein coding regions. The D-loop is the only 
non-coding region within mtDNA and contains the sites for mtDNA transcription (HSP and LSP). The origins for heavy 
(H) and light (L) strand replication (OH and OL) are also shown.  
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1.3 MtDNA transcription and translation 
The three sites of transcription initiation are found within the D-loop: the light strand promoter 
(LSP) and the heavy strand promoters 1 and 2 (HSP1 and HSP2 respectively). The LSP 
transcribes the full length of the light strand (containing mt-ND6 and 8 tRNAs), so does HSP2 
for the heavy strand (12 mitochondrial proteins, 2 rRNAs and 14 tRNAs). On the contrary, 
HSP1 only transcribes 2 tRNAs and both rRNAs of the heavy strand (Figure 1- 3) (Montoya et 
al., 1982; Chang and Clayton, 1984). Once TFAM binds directly upstream of the promoter 
region, the mtDNA undergoes conformational changes that allow the mitochondrial RNA 
polymerase (POLMRT) and mitochondrial transcription factor B1/B2 (TFB1M/TFB2M) to 
access mtDNA and thus initiate the transcription process (Fisher et al., 1987; Dairaghi et al., 
1995). MtDNA is transcribed bi-directionally, producing a polycistronic molecule that will 
subsequently be processed and give rise to mature mRNAs, tRNAs and rRNAs (Rebelo et al., 
2011). Following transcription initiation, the mitochondrial transcription elongation factor 
(TEFM) associates with POLMRT assuring for transcription elongation followed by the 
incorporation of the mitochondrial transcription termination factor (mTERF) and termination 
of the process (Rebelo et al., 2011). There are currently four members of the mTERF family of 
proteins, the function of which might not be restricted to transcription termination but in fact 
also be associated with mtDNA transcription initiation and replication (Roberti et al., 2009). 
Although mammalian mitochondrial translation holds many unique features, it follows the 
canonical initiation, elongation and termination steps (Smits et al., 2010). Mitochondrial 
mRNA translation is performed within mitoribosomes, structures equivalent to nucleolar 
ribosomes that are extremely rich in protein. Mitoribosomes are comprised of a small 28S 
subunit (SSU), a large 39S subunit (LSU) and the 2 mitochondrial rRNAs (12S and 16S) 
(O'Brien, 2003). The translation initiation factors IF2 (Ma and Spremulli, 1995) and IF3 (Koc 
and Spremulli, 2002), the elongation factors mtEFTu (Ling et al., 1997), mtEFTs (Xin et al., 
1995) and mtEFG (Hammarsund et al., 2001) and the release factor RF1 assist the initiation, 
elongation and termination of the translation procedure respectively. An AUA or AUU codon, 
located within the highly compact and uncapped mitochondrial mRNAs, marks the initiation of 
protein synthesis by the 22 mitochondrial tRNAs (contrary to what is suggested by the wobble 
hypothesis) (Barrell et al., 1980). The site of translation termination is marked by the presence 
of an AGG or AGA triplet, in addition to UAA and UAG (Osawa et al., 1992), which is 
recognised by mtRF1α.  
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1.4 MtDNA replication 
MtDNA replication occurs independently of nuclear DNA and of the cell cycle, justifying the 
term “relaxed replication” (Bogenhagen and Clayton, 1977; Birky, 1994). In post-mitotic cells 
mtDNA is turned over in a much slower rate than in actively dividing cells (Wang et al., 1997), 
and there are evidence to suggest that mtDNA synthesis in neurons might take up to 20 hours 
(Calkins and Reddy, 2011). There is an on-going debate as to the exact mechanism(s) that 
account for mtDNA replication, the most popular of which being: the asynchronous or strand-
displacement model and the synchronous model (Holt and Reyes, 2012). According to the 
former, mtDNA replication starts at the origin of heavy strand replication (OH) and processes 
around two-thirds of the mtDNA molecule (synthesizing the leading strand), before initiation 
of lagging strand synthesis starts at the origin of light strand replication (OL) (Kasamatsu and 
Vinograd, 1973; Clayton, 1982).  Later, Holt and colleagues (2000) have identified the presence 
of replication intermediates with differing sensitivities to single-stranded nucleases giving rise 
to the synchronous replication model (Holt et al., 2000). A refined version of the model is 
suggestive of bidirectional mtDNA replication, initiated in more than one regions 
(encompassing MT-CYB, ND5 and ND6) and terminated at the OH (Bowmaker et al., 2003). 
The latest model of mtDNA replication is similar to the strand-displacement model but further 
proposes the incorporation of ribonucleuotides (RNAs) in the lagging strand during leading 
strand synthesis, hence its name: RITOLS (ribonucleotide incorporation throughout the lagging 
strand) (Yang et al., 2002; Yasukawa et al., 2006).  
Although numerous mtDNA replication models have been proposed, few enzymes are currently 
known to be necessary for mtDNA replication. These include: the mtDNA polymerase γ 
(POLG) (Hance et al., 2005), the mitochondrial TWINKLE DNA helicase (Tyynismaa et al., 
2004), the mitochondrial RNA polymerase (POLMRT) (Fuste et al., 2010) and the 
mitochondrial single-stranded binding protein (mt-SSB) (Maier et al., 2001).  
1.5 Mitochondrial genetics 
1.5.1 Maternal inheritance and the bottleneck effect 
MtDNA inheritance does not follow the Mendelian rules; instead mtDNA is strictly inherited 
through the maternal germline (Giles et al., 1980). The mechanisms responsible for paternal 
mtDNA destruction are species-specific and take place both pre- and post-fertilisation (Sato 
and Sato, 2013). Selective proteasomal degradation and autophagy account for paternal mtDNA 
elimination in mammalian (Kaneda et al., 1995; Sutovsky et al., 1999) and nematode fertilised 
eggs (Sato and Sato, 2011) respectively. On the contrary, paternal mtDNA is degraded during 
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spermatogenesis in flies (DeLuca and O'Farrell, 2012), whereas nucleoid density is decreased 
in fish sperm and degraded following fertilisation (Nishimura et al., 2006). However, the 
paternal origin of an inherited deletion in mt-ND2 has been documented providing evidence for 
the only case of human mtDNA inherited from the father (Schwartz and Vissing, 2002).  
Pathogenic mtDNA mutations are therefore transmitted from the mother to her children, though 
there is extensive variability in the number of mutated mtDNA molecules that are passed onto 
the next generation (Taylor and Turnbull, 2005). This genetic variability accounts for 
phenotypic variability amongst patients with the same genetic defect (Chinnery et al., 1997) 
and is attributed to a phenomenon known as genetic bottleneck (Chinnery et al., 2000). There 
is an on-going debate as to the exact mechanism by which the genetic bottleneck occurs, the 
most widely accepted being the rapid replication of mtDNA molecules during embryonic 
development (~200 mtDNA molecules in primordial germ cells, giving rise to oocytes which 
contain ~100,000 copies of mtDNA) (Cree et al., 2008). The level of pathogenic mutations in 
offspring are defined by random genetic drift although specific inheritance patterns for the 
various mtDNA defects exist (Brown et al., 2001). 
1.5.2 MtDNA mutagenesis and repair mechanisms 
Both the compact structure of mtDNA and its close proximity to the ETC render the mtDNA 
susceptible to acquiring defects. The absence of histones (Richter et al., 1988) and the less 
robust mtDNA repair mechanisms (Clayton, 1982) (relative to ones in place for nuclear DNA) 
constitute mtDNA vulnerable to genetic alterations with a 10-fold increased mutation rate 
compared to chromosomal DNA (Brown et al., 1979). Furthermore, the presence of mtDNA 
nucleoids in the vicinity of ROS production sites, occurring during normal OXPHOS 
conditions, has a negative impact on mtDNA integrity.  
MtDNA point mutations, single large-scale or multiple deletions, insertions or duplications can 
occur as a consequence of DNA strand breaks (el-Khamisy and Caldecott, 2007; Kasparek and 
Humphrey, 2011), replication errors or incorporation of modified nucleotides (Kamiya, 2003; 
Boesch et al., 2011). Somatic mtDNA mutations can also be acquired as a result of normal 
ageing whilst ancient genetic variants occur as an adaptive response to differential 
environmental conditions (Wallace, 2010). However, pathogenic nuclear and mtDNA 
mutations associated with adult mitochondrial disease are the focus of this study, detailed 
discussion of which will be provided at the appropriate section.   
Contrary to what was previously believed, the mitochondrial DNA repair pathways are very 
similar to the nuclear ones (Larsen et al., 2005). These include direct reversal (though its 
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function in mammalian mitochondria is yet to be verified) (Yasui et al., 1992), base excision 
repair (Stierum et al., 1999), mismatch repair (Mason et al., 2003) and single-strand break 
repair (Hegde et al., 2012). Mitochondria have also evolved a unique DNA repair mechanism 
according to which damaged mtDNA fractions are degraded and replaced by replicated 
segments of the healthy genome (Gross and Rabinowitz, 1969).  
1.5.3 Heteroplasmy and the threshold effect 
The presence of multiple mtDNA copies within a cell allows for a mixture of wild type and 
mutant mtDNA molecules to co-exist. This significant characteristic of mitochondrial genetics 
is termed heteroplasmy and determines the phenotypic presentation of mitochondrial disease 
(Larsson and Clayton, 1995). Heteroplasmy is expressed as the percentage of mutant mtDNA 
copies within a cell or tissue, whereas a homoplasmic state exists if all the mtDNA molecules 
contained within a cell are identical (either homoplasmic wild type or homoplasmic mutant) 
(Taylor and Turnbull, 2005). 
Random genetic drift controls the levels of pathogenic mutations within a cell via a process 
known as clonal expansion (Elson et al., 2001); that is the selective multiplication of the mutant 
genome during successive mitotic events and eventually the accumulation of high 
heteroplasmic levels in post-mitotic tissues (Weber et al., 1997). However, there exists a critical 
threshold level before a metabolic defect occurs and a clinical phenotype is observed. The value 
that the threshold level occupies is variable and depends on the individual, the tissue metabolic 
requirements and the mutation type. Indeed, the threshold level for mtDNA point mutations 
involving tRNA genes is ~90% (Yoneda et al., 1995), whilst for single large-scale mtDNA 
deletions is ~70-80% (Sciacco et al., 1994). Furthermore, tissue specificity is evident since 
isolated brain mitochondria are thought to have a lower threshold for complex I deficiency 
(compared to heart, muscle, liver and kidney), whilst mitochondria isolated from muscle were 
more vulnerable to complex IV defects (Rossignol et al., 1999).  
1.6 Mitochondrial disease 
There are two sides to every coin and the same is certainly true for mitochondria. The 
respiratory chain serves to provide the cell with the majority (~90%) of its energetic 
requirements and as such defects in the energy production machinery is a common cause of 
inherited disease. Mitochondrial disease encompasses a genetically and phenotypically 
heterogeneous group of disorders that commence due to either primary mtDNA mutations or 
defects in nuclear DNA encoded-genes involved in mtDNA maintenance, respiratory chain 
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assembly and function. Furthermore, mitochondrial disease can arise due to altered 
mitochondrial dynamics, disturbed IMM structure and aberrant mitochondrial protein transport.  
Since the publication of the human mtDNA sequence in 1981 (Anderson et al., 1981) and its 
association with disease in 1988 (Holt et al., 1988; Wallace et al., 1988), over 270 mtDNA 
point mutations have been identified and numerous syndromes are linked to mitochondrial 
dysfunction. The emergence of new technologies enables the identification of nuclear gene 
mutations responsible for respiratory chain deficiencies, expanding the list of nuclear DNA 
genes involved in mitochondrial disease (Taylor et al., 2014). Meanwhile, phenotypic 
heterogeneity is pronounced since distinct syndromes have unique as well as overlapping 
symptoms, constituting clinical diagnosis extremely challenging (McFarland and Turnbull, 
2009). Common disease features might include lactic acidosis, mitochondrial proliferation in 
muscle fibres (ragged-red fibres) and muscular respiratory chain deficiency, though exceptions 
do occur (DiMauro et al., 2006). 
Mitochondrial disorders are much more prevalent than originally anticipated and in fact, the 
frequency of pathogenic mtDNA mutations is likely to be underestimated. Data gathered from 
around the world (England, Finland, Sweden and Australia) suggest that approximately every 
1 in 8,500 individuals (adults and children) are affected by mitochondrial disease (both due to 
mtDNA and nuclear DNA defects) (Chinnery, 2000). According to Schaefer and colleagues 
(2008) every ~1 in 10,000 adults in the North East of England are clinically affected, whereas 
~1 in 6,000 are at risk of developing mitochondrial disease (Schaefer et al., 2008). More 
recently, the estimated prevalence of adult mitochondrial disease in the same region (North East 
of England) was ~1 in 4,300 (Gorman et al., 2015b). 
Mitochondrial disease is progressive (Arpa et al., 2003; Majamaa-Voltti et al., 2006; Coku et 
al., 2010) and valuable work has been performed that allows the prediction of disease 
progression rate (Grady et al., 2014) and the presence of specific system involvement (Grady, 
2013). No treatments are currently available for patients with mitochondrial disease however, 
recent advances in reproductive medicine enable the prevention of mitochondrial disease 
transmission to the next generations (Craven et al., 2010; Craven et al., 2011; Gorman et al., 
2015a).  
1.6.1 Primary mitochondrial DNA disorders in adults  
Primary mtDNA disorders arise due to pathogenic mtDNA defects, including point mutations, 
large-scale deletions, duplications and inversions. MtDNA point mutations involve protein 
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encoding (e.g. ATP6) and rRNA genes but are largely associated with tRNA genes, thus 
affecting respiratory chain protein synthesis. Similarly, mtDNA deletions usually span a 2-10 
kb region and are accompanied by short repeats on the deletion breakpoints, high density of 
which is found within mitochondrial tRNA genes (Schon et al., 1989; Mita et al., 1990; Damas 
et al., 2012). 
Given the high copy number of mtDNA within each cell, every tissue is likely to possess 
defective mtDNA copies explaining the multisystemic nature of mitochondrial disorders and 
the presence of neurological and non-neurological symptoms. Neurological disease is the most 
common feature (McFarland et al., 2010) and symptoms include ataxia, stroke-like episodes, 
myopathy, peripheral neuropathy and deafness. Clinical syndromes with characteristic features 
do exist yet many patients are left undiagnosed (Chinnery et al., 2015).  
1.6.1.1 Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes  
The presence of stroke-like episodes, encephalopathy and elevated lactate is reminiscent for the 
phenotypic manifestation of the mitochondrial encephalomyopathy with lactic-acidosis and 
stroke-like episodes (MELAS) syndrome (Hirano et al., 1992). Originally described by 
Pavlakis (1984), this multisystemic disorder affects normally developed adults who upon 
disease may present with cerebellar ataxia, cardiomyopathy, diabetes mellitus, gastrointestinal 
dysmotility, hearing loss and retinitis pigmentosa (Pavlakis et al., 1984; Hirano et al., 2006; 
Chinnery et al., 2015). Regardless of the numerous neurological deficits, stroke-like episodes 
are the prominent feature of these patients concomitant with headache, nausea and seizures  
(Chinnery et al., 2015; Hirano et al., 2006). Stroke-like episodes predominantly affect posterior 
brain regions (including parietal and occipital lobes) detected as hyperintense lesions upon MRI 
scan, which do not follow the major vascular territories (Ohama et al., 1987; Sue et al., 1998).  
The m.3243A>G point mutation within the MT-TL1 gene (encoding tRNALeu(UUR)) accounts for 
80% of the MELAS cases (Goto et al., 1990), although other less frequent mutations have been 
described. Some of the mutations within tRNA genes include the thymine (T) to cytosine (C) 
transition at position 3271 (m.3271T>C) in MT-TL1 (Goto et al., 1991), m.1642G>A in MT-
TV (tRNAVAL) (Taylor et al., 1996) and m.5814A>G in MT-TC (tRNACys) (Manfredi et al., 
1996). Mutations within protein encoding genes also exist and involve MT-ND1 (Kirby et al., 
2004; Malfatti et al., 2007), MT-ND5 (Santorelli et al., 1997; Corona et al., 2001; Liolitsa et 
al., 2003; McKenzie et al., 2007), MT-CO2 (Tam et al., 2008), MT-CO3 (Manfredi et al., 1995) 
and MT-CYB (De Coo et al., 1999; Emmanuele et al., 2013). Interestingly, not all point 
mutations are unique to MELAS patients since some are also associated with overlapping 
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syndromes, exemplifying the phenotypic heterogeneity of mitochondrial disease (Ruiter et al., 
2006).  
1.6.1.2 Myoclonic epilepsy with ragged-red fibres  
Characteristic features of patients diagnosed with myoclonic epilepsy with ragged-red fibres 
(MERRF) syndrome include progressive myoclonus, epilepsy (focal and generalised), 
cerebellar ataxia and myopathy (Hirano et al., 2006; Chinnery et al., 2015). Peripheral 
neuropathy, bilateral deafness, dementia and muscle weakness are frequently observed, 
whereas optic atrophy, cardiomyopathy, pyramidal signs and lipomatosis may also manifest 
(Hirano and DiMauro, 1996). 
Patients usually present with symptoms in childhood, though adult onset has been reported, 
significantly lowering the life expectancy (Chinnery et al., 2015). The tRNALys gene (MT-TK) 
is considered a mutation hotspot for this syndrome since it houses ~90% of pathogenic 
mutations associated with MERRF, the most frequent of which being the m.8344A>G 
(Shoffner et al., 1990; Hirano et al., 2006). Point mutations in other tRNA genes, whilst rare, 
also exist (MT-TF, MT-TL1, MT-TI and MT-TP) and may also give rise to a differential 
diagnosis (Yoon et al., 1993; Shtilbans et al., 2000; DiMauro S, 2003; Nishigaki et al., 2003; 
Emmanuele et al., 2011). 
1.6.1.3 Kearns-Sayre syndrome 
Serving as the first multisystem mitochondrial disorder to be clinically defined, the Kearns-
Sayre syndrome (KSS) is characterised by ophthalmoplegia and pigmentary retinopathy that 
presents before the age of 20 (Kearns and Sayre, 1958). Patients with KSS have a relatively low 
life expectancy and the majority of them display with short stature, hearing loss, limb weakness 
and cognitive impairment (executive function and visuospatial perception) (Bosbach et al., 
2003). Additional features include cerebellar ataxia, cardiac condition block, elevated 
cerebrospinal fluid protein and proximal myopathy (Maceluch and Niedziela, 2006). 
Genetically, KSS is defined by sporadic large-scale deletions or complex rearrangements of 
mtDNA (Zeviani et al., 1988; Moraes et al., 1989). 
1.6.1.4 Leber’s Hereditary Optic Neuropathy 
Leber’s hereditary optic neuropathy (LHON) predominantly affects young males that lose their 
bilateral central vision sequentially. The vast majority of LHON cases  (over 95%) are due to 
mtDNA point mutations within genes encoding for complex I protein subunits: m.11778G>A 
(MT-ND4), m.3460G>A (MT-ND1) and m.14484T>C (MT-ND6) (Mackey et al., 1996), but 
rare secondary mutations have also been documented (Carelli et al., 2004; Yum et al., 2014). 
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Symptoms develop in a small percentage of homoplasmic mutation carriers (~50% of male and 
~10% of female) implying that epigenetic modification and/or environmental factors are 
important for the clinical manifestation of the disease (Newman, 2002). Moreover, the strong 
disease predilection for males suggests that nuclear X-linked loci control disease phenotypic 
presentation (Bu and Rotter, 1991; Nakamura et al., 1993).  
1.6.1.5 Chronic progressive external ophthalmoplegia  
Chronic progressive external ophthalmoplegia (CPEO) is the most common mitochondrial 
myopathy in adults (Jean-Francois et al., 1997). Dating back from 1867 CPEO is characterized 
by ptosis, ophthalmoparesis and mitochondrial myopathy (Jean-Francois et al., 1997). Proximal 
limb muscle weakness, facial muscle paralysis, early fatigue, exercise intolerance, 
sensorineural hearing loss, axonal neuropathy, ataxia, depression, cataracts and 
cardiomyopathy may also manifest (Cohen and Naviaux, 2010). 
CPEO can be sporadic or familial, a primary or secondary mitochondrial disorder. Single 
mtDNA deletions account for the majority of CPEO cases, whereas mtDNA duplications and 
single nucleotide substitutions in tRNA genes may occur (Holt et al., 1988; Fassati et al., 1994; 
Silvestri et al., 1996; Taylor et al., 1998). Mutations in nuclear genes involved in mtDNA 
maintenance result in secondary mitochondrial disease due to multiple mtDNA deletions 
(Carrozzo et al., 1998; Moslemi et al., 1999). 
1.6.2 Mitochondrial disease in adults due to nuclear defects 
In addition to primary mtDNA mutations, nuclear genetic defects can result in aberrant 
oxidative metabolism and mitochondrial disease. Mutations in genes encoding for respiratory 
chain protein subunits and/or assembly factors directly impair OXPHOS, whereas mtDNA 
integrity is negatively affected by defects in nuclear genes involved in mtDNA maintenance. 
There exists an ever-increasing list of nuclear genetic mutations involved in mitochondrial 
disease whilst multiple alterations in a single gene can account for a plethora of distinct clinical 
syndromes (Lightowlers et al., 2015). Nuclear genes most frequently associated with 
mitochondrial disease will be discussed below. 
1.6.2.1 Polymerase gamma 
Polymerase gamma (POLG) is the sole mtDNA polymerase described to date, mutations in 
which are an important cause of mitochondrial disease (Cohen BH, 2010). Over 160 mutations 
are spread throughout the gene, giving rise to secondary mtDNA alterations (mtDNA depletion 
and deletion) (Fonzo et al., 2003; Tzoulis et al., 2009) and consequent Mendelian inherited 
diseases. A wide spectrum of syndromic diseases are related to POLG mutations, which may 
Chapter 1       Introduction 
29 
have an infantile or adult onset. These include the Alpers-Huttenlocher syndrome (AHS), 
autosomal dominant and recessive PEO and the ataxia neuropathy spectrum (ANS) (Horvath et 
al., 2006). 
AHS usually has a childhood onset and is characterised by severely impaired development 
(psychomotor regression), liver failure, intractable seizures and cortical blindness (Naviaux and 
Nguyen, 2004; Davidzon et al., 2005; Isohanni et al., 2011). Upon magnetic resonance imaging 
(MRI), multiple lesions and severe atrophy are apparent in cortical regions (Saneto et al., 2008; 
Gropman, 2013). Patients with PEO typically present with ptosis and strabismus, consequent 
to progressive weakness of the extraocular eye muscles, and generalised myopathy (Van 
Goethem et al., 2001). Deafness, ataxia, neuropathy, parkinsonism, depression and 
hypogonadism further affect those who acquire the disease due to POLG mutations, giving rise 
to the so called PEO+ phenotypes (Filosto et al., 2003; Mancuso et al., 2004). ANS 
encompasses the previously distinct mitochondrial recessive ataxia syndrome (MIRAS) and 
sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO) (Cohen BH, 2010). 
Further to ataxia and neuropathy (maybe sensory, motor or both), patients with ANS may 
manifest with encephalopathy, myoclonic seizures, blindness and liver dysfunction (Wong et 
al., 2008). 
1.6.2.2 Twinkle 
Twinkle helicase is an important protein of the mtDNA replicative machinery and a constituent 
of mitochondrial nucleoids, present within the matrix. The protein is encoded by the C10orf2 
gene, also known as PEO1, mutations in which result in qualitative (deletions) and quantitative 
(depletions) mtDNA alterations (Spelbrink et al., 2001).  
Large mtDNA deletions are thought to arise due to impaired helicase activity, resulting in adult-
onset PEO or PEO+ phenotypes (Spinazzola and Zeviani, 2005). On the contrary, 
hepatocerebral depletion syndrome and infantile-onset spinocerebellar ataxia (IOSCA) are 
examples of mitochondrial disease due to quantitative mtDNA changes due to C10orf2 
mutations (Hakonen et al., 2007; Sarzi et al., 2007). Infants with hepatocerebral depletion 
syndrome present with elevated lactate, liver enlargement, hypotonia and psychomotor delay. 
Neurological abnormalities are progressive and include ataxia, ophthalmoplegia, nystagmus 
and epilepsy (El-Hattab and Scaglia, 2013). Infants with IOSCA suffer from ataxia, 
ophthalmoplegia, sensory neuropathy, encephalopathy with seizures and muscle hypotonia due 
to mitochondrial depletion in liver and brain (Nikali et al., 2005; Hakonen et al., 2007; Hakonen 
et al., 2008).  
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1.7 Mitochondrial disease and the brain 
Despite the fact that the brain only occupies 2% of our bodies’ mass, it consumes 20% of the 
organisms’ oxygen at rest (Mink et al., 1981), exemplifying the extensive metabolic 
requirements of the tissue. The highly specialised neuronal networks formed in the brain 
facilitate information processing that occurs via synaptic transmission. This process is highly 
dependent on mitochondrial function, constituting mitochondrial biogenesis, transport and 
quality control in neurons vital to neuronal health and brain function. It therefore comes as no 
surprise that the central nervous system (CNS) is vulnerable to mitochondrial respiratory chain 
deficiencies and as such, neurological deficits are one of the most common features of patients 
with mitochondrial disease. 
1.7.1 Brain atrophy 
Primary evidence of CNS abnormalities arise from neuroradiological data as well as 
macroscopic observations upon post-mortem examination. Despite the great variability in the 
phenotypic manifestation of mitochondrial disease, neurodegeneration is a unifying feature 
amongst patients with different disorders and is due to brain atrophy and structural 
abnormalities. Indeed, decreased fresh brain weight (by about ~19%) in 12 patients with 
mitochondrial disease (m.3243A>G, m.8344A>G, m.14709T>C, single large mtDNA deletion 
and POLG) compared to aged-matched controls is due to profound neuronal loss throughout 
the brain (Lax and Jaros, 2012).  
1.7.2 Neuroradiological observations 
Neuroradiological examination of patients with the m.3243A>G and m.8344A>G point 
mutation and of those with mtDNA rearrangements and deletions signifies the presence of 
hyperintense lesions in the brain stem and basal ganglia, whereas white matter and cortical 
changes also exist (Haas and Dietrich, 2004; Saneto et al., 2008; Gropman, 2013). Cerebral 
atrophy is commonly observed in many disease subgroups, though not a specific finding. 
Cerebellar atrophy might serve as the main finding for some patients (Valanne et al., 1998; 
Scaglia et al., 2004; Scaglia et al., 2005), whereas it can be linked to more severe disease in 
others (Sue et al., 1998). Such an example includes the documentation of enlarged fourth 
ventricles in six pedigrees with MELAS (due to the m.3243A>G) predicted to result in 
cerebellar atrophy during disease progression (Sue et al., 1998). 
Neuroimaging findings are variable and often depend on the experimental setting (Magnetic 
resonance imaging, Computerised Tomography scan, diffusion tensor imaging, magnetic 
resonance spectroscopy); they may hint towards signature features for a specific disorder, non-
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specific abnormalities or even demonstrate the occurrence of structurally normal brains (Saneto 
et al., 2008). Such a characteristic feature is the presence of stroke-like cortical lesions in 
posterior brain regions (parieto-occipital region) of patients harbouring the m.3243A>G. 
Lesions affect predominantly grey matter and adjacent white matter areas, while they do not 
conform to the major vascular territories. They may be unilateral or bilateral, they may resolve 
with time or reappear in neighbouring regions upon sequential examination (Haas and Dietrich, 
2004; Gropman, 2013). Neuroradiological imaging of patients with MELAS (due to 
m.3243A>G) performed in 1998 reports mineral deposition (calcification) in the basal ganglia 
as the most common finding, documented in the majority of patients (54%) (Sue et al., 1998).  
Contrary to the specific neuroradiological abnormalities of patients with MELAS, MERRF 
patients present with a variety of neuroimaging changes ranging from white matter lesions, to 
basal ganglia haemorrhage and atrophy of the cerebral cortex and cerebellum (Haas and 
Dietrich, 2004). Moreover, scattered cerebral infarcts are documented in a 39-year-old woman 
(harbouring the m.8344A>G point mutation) who did not present with the classical clinical 
features for MERRF (Tanji et al., 2003).  
A clinicopathological investigation of 26 patients with a combined mitochondrial 
spinocerebellar ataxia and Alpers phenotype due to mutations in POLG (homozygous or 
compound heterozygotes for A467T and W748S) revealed the presence of focal lesions 
involving (with order of frequency) the occipital lobe, deep cerebellar nuclei, the thalamus and 
basal ganglia (Tzoulis et al., 2006). Early onset Alpers syndrome (in childhood) is linked to 
progressive occipital lobe hyperintensities, whilst lesions may resolve and the brain may be 
structurally normal even by the time of death (Saneto et al., 2008).  
White matter changes are the distinctive feature of patients with Mitochondrial 
Neurogastrointestinal Encephalopathy (MNGIE) and KSS syndrome. Termed leukodystrophy, 
these lesions are diffuse sparing the corpus callosum in patients with MNGIE (Nishino et al., 
1999; Labauge et al., 2002) who also present with demyelinated sensory neurons (Hirano et al., 
1994). In patients with KSS, subcortical, basal ganglia, thalamic and brain stem white matter 
lesions are observed, whilst cerebral and cerebellar atrophy are commonly reported (Chu et al., 
1999; Lerman-Sagie et al., 2005). 
1.8 Neuropathological features of mitochondrial disease 
Further to focal lesions detected macroscopically in the brains of patients with mitochondrial 
disease, microscopic neuropathological investigations are indicative of profound neuronal cell 
loss, spongiform degeneration (mainly in the white matter), glial cell proliferation and axonal 
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demyelination (Sparaco et al., 1993). Respiratory chain deficiencies and decreased ETC protein 
expression in vulnerable neuronal, inter-neuronal and vascular cell populations have also been 
documented (Tanji et al., 2001; Betts et al., 2006; Lax et al., 2012b; Lax et al., 2012c; Lax et 
al., 2015). These are usually associated with high heteroplasmic percentages, cellular loss and 
structural abnormalities.  
1.8.1 m.3243A>G 
The presence of pan-necrotic foci is a characteristic feature of patients with MELAS, due to the 
m.3243A>G, associated with neuronal loss, inflammatory response activation and astrocytic 
and capillary proliferation (Sparaco et al., 1993; Sue et al., 1998; Tanahashi et al., 2000; Betts 
et al., 2006). These infarct-like foci are commonly observed in cerebral cortices (bilateral) and 
cerebellum, whilst the basal ganglia, the thalamus, the brain stem and subcortical white matter 
may also be affected (Sparaco et al., 1993; Sue et al., 1998; Betts et al., 2006; Lax et al., 2012c). 
Calcium deposition constitutes the second most frequent lesion in patients with MELAS, 
whereas cortical vacuolation (spongiform degeneration) is observed in the cerebrum and spinal 
cord (lateral and posterior columns (Sparaco et al., 1993). 
Vascular abnormalities include vessel wall calcification reported in globus pallidus, basal 
ganglia and thalamus (Sue et al., 1998; Tanahashi et al., 2000), decreased immunoreactivity 
against mtDNA-encoded respiratory chain subunits (Sparaco et al., 2003) and COX-deficient 
blood vessels with high heteroplasmic percentages in various brain regions (Betts et al., 2006; 
Lax et al., 2012c). COX-deficiency is not only observed in association with lesions since it’s 
particularly prominent in meningeal, cortical and white matter vessel walls (Betts et al., 2006; 
Lax et al., 2012c). Thinning of the smooth muscle and endothelial cell layers in the cerebellum 
is indicative of vascular cell loss, whilst plasma protein (fibrinogen and IgG) extravasation 
(Tanji et al., 2001; Lax et al., 2012c) and decreased tight junction protein expression (Lax et 
al., 2012c) are reminiscent of blood-brain barrier (BBB) permeability problem. According to 
electron microscopic observations, enlarged mitochondria are aggregated within the smooth 
muscle and endothelial cell layer of cerebral and cerebellar arterioles and small arteries (Ohama 
et al., 1987; Mizukami et al., 1992; Tanahashi et al., 2000). Likewise, mitochondrial 
proliferation in choroid plexus epithelial cells is documented and accompanied by COXII 
immunodeficiency (Ohama and Ikuta, 1987; Tanji et al., 2001). 
Generalised cerebellar atrophy is observed, whilst the extent of neurodegeneration in the olivo-
cerebellar pathway varies and involves inferior olivary, Purkinje cell and dentate nucleus 
neurons (Sparaco et al., 1993; Tanahashi et al., 2000; Lax et al., 2012b). Preserved neurons 
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contain high percentage of mutant mtDNA species and have severely decreased respiratory 
chain protein expression (complex I and IV) (Lax et al., 2012b; Chrysostomou et al., 2015). 
Selective deficiency in mtDNA-encoded respiratory chain protein subunits (COXII and 
ATPase8) are documented in 2 patients harbouring the m.3243A>G point mutation (Sparaco et 
al., 2003). Swollen Purkinje cell axons (“torpedoes”) and thickened dendritic trees (cacti) are 
documented (Mori et al., 2000; Tanahashi et al., 2000; Betts et al., 2006; Lax et al., 2012b) and 
the latter is usually associated with increased mitochondrial density upon light (Lax et al., 
2012b) and electron (Tanahashi et al., 2000) microscopic observations. Moreover, grumose 
degeneration around dentate nucleus neurons (Tanahashi et al., 2000) and decreased 
synaptophysin immunoreactivity at the region (Lax et al., 2012b) suggests altered synaptic 
input (probably inhibitory) to the dentate nucleus. Indeed, complex I protein expression defects 
detected in GABAergic presynaptic terminals contacting dentate nucleus neurons combined 
with inhibitory synapse loss denote aberrant inhibitory neurotransmission to the region 
(Chrysostomou et al., 2015). Intracerebellar synaptic remodelling is proposed since enlarged 
residual inhibitory synapses may represent means to compensate for synaptic loss 
(Chrysostomou et al., 2015). 
Profound inhibitory interneuronal loss is documented in occipital, temporal and frontal cortices 
of four patients with MELAS, accompanied by severe complex I protein expression deficiencies 
and high heteroplasmic percentages (79%) in residual interneurons. This is in accordance with 
near homoplasmic (92%) mutation load percentages detected in various brain regions of an 
autopsy case (Betts et al., 2006).  
1.8.2 m.8344A>G 
Selective neurodegeneration within the cerebellum, brain stem and spinal cord is characteristic 
of patients harbouring the m.8344A>G point mutation (Sparaco et al., 1993). The cerebellar 
dentate nucleus neurons and Purkinje cells, the inferior olivary neurons within the brain stem 
and cells in Clarke’s nucleus of the spinal cord are preferentially lost, whereas cytoplasmic 
eosinophilia, neuronal atrophy and astrocytic proliferation is apparent in affected areas 
(Sparaco et al., 1993; Zhou et al., 1997; Lax et al., 2012b). Heteroplasmic levels for the 
m.8344A>G point mutation in individual neurons do not necessarily correlate with percentage 
cell loss (Zhou et al., 1997; Lax et al., 2012b) and axonal demyelination in cerebellar peduncles 
and posterior spinocerebellar tracts is likely consequent to neuronal/axonal degeneration 
(Sparaco et al., 1993; Lax et al., 2012b).  
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Preserved neurons have combined complex I and IV protein expression deficiencies (Lax et al., 
2012b), contrary to selective decrease in COXII protein expression in the frontal cortex, 
cerebellum and medulla documented during autopsy (Sparaco et al., 1995). Abnormal 
intracerebellar microcircuitry is suggested following the documentation of structurally 
abnormal Purkinje cell axons (spheroids), degenerative Purkinje cell presynaptic terminals 
(grumose degeneration) and decreased synaptophysin immunoreactivity (mainly involving the 
dentate nucleus) (Sparaco et al., 1993; Lax et al., 2012b). This notion is strengthened by 
observations made by Chrysostomou and colleagues who report complex I deficiency in 
Purkinje cell presynaptic terminals, associated with inhibitory synapse loss from the dentate 
nucleus (Chrysostomou et al., 2015).   
Additional to neuronal populations, GABAergic interneuronal density is severely decreased in 
the occipital, temporal and frontal lobe (Lax et al., 2015). Near homoplasmic percentages for 
the mutated mtDNA species is detected on homogenised tissue, whilst surviving interneurons 
have combined respiratory chain protein expression deficiencies involving complex I and IV 
(Lax et al., 2015). 
Necrotic foci detected in MERRF are accompanied by vascular proliferation, whilst respiratory 
chain deficiency, high heteroplasmy (86%) and cellular loss have been detected in cerebellar 
blood vessels (Lax et al., 2012c). Moreover, Purkinje cell and dentate nucleus neurons 
immunoreactive against plasma proteins and decreased tight junction protein expression 
suggests BBB leakage (Lax et al., 2012c).  
1.8.3 MtDNA rearrangements and deletions 
The most frequent neuropathological manifestation in patients with KSS is spongy degeneration 
in the cerebrum, cerebellum and spinal cord, although grey matter changes have been observed 
in the brain stem (Oldfors et al., 1990; Sparaco et al., 1993; Lax et al., 2012b). Axonal 
demyelination is related to spongiform degeneration since its most frequently detected in 
cerebral and cerebellar white matter (Sparaco et al., 1993). Lax and colleagues (2012) attribute 
demyelination to oligodendrocyte dysfunction since loss of myelin associated glycoprotein 
from the dentate nucleus is accompanied by high mtDNA deletion levels, glial depletion and 
respiratory chain protein expression deficiencies (Lax et al., 2012a).  
Extensive neurodegeneration and gliosis is detected in brain stem and the cerebellum, most 
commonly affecting the substantia nigra, the red, vestibular and oculomotor nuclei as well as 
cerebellar Purkinje cells and dentate nuclei neurons (Oldfors et al., 1990; Sparaco et al., 1993; 
Tanji et al., 1999; Lax et al., 2012b). Cactus-like Purkinje cell dendrites (Tanji et al., 1999; Lax 
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et al., 2012b), axonal swellings (torpedoes) proximal and distal to Purkinje cell bodies (Lax et 
al., 2012b) and decreased axonal density in the white matter (Tanji et al., 1999) are reminiscent 
of neuronal structural disorganisation and likely altered intracerebellar signalling. Indeed, 
synaptophysin immunoreactivity to the dentate nucleus is scarce and Purkinje cell terminal 
arborisations are swollen (Tanji et al., 1999). Structurally abnormal mitochondria (enlarged 
with disturbed cristae organisation) have been detected in the Purkinje cells of a single case 
(Adachi et al., 1973), whereas residual Purkinje cell and dentate nuclei neurons have marked 
complex I and IV protein expression deficiencies (Lax et al., 2012b). 
GABAergic interneuron loss has recently been documented in the occipital and (to a lesser 
extent) temporal cortex of a KSS patient accompanied by severe complex I and IV protein 
expression deficiencies detected upon quadruple immunofluorescence (Lax et al., 2015). COX-
deficient interneurons and blood vessels in these regions have also been reported (Lax et al., 
2015).  
Vascular proliferation is evident in various brain regions, whereas iron and calcium deposition 
is found within and around capillary and arterial walls (Sparaco et al., 1993; Tanji et al., 1999). 
Moreover, fibronectin extravasation in the cerebral cortex provides evidence towards BBB 
breakdown (Oldfors et al., 1990), though no fibrinogen or IgG extravasation was detected by 
Lax and colleagues (Lax et al., 2012c). Remarkably, decreased COX II immunoreactivity in 
the epithelial cells of the choroid plexus and high levels of deleted (Δ) mtDNA species implies 
that the threshold for impaired mtDNA translation has been exceeded (Tanji et al., 2001).  
1.8.4 Leber’s hereditary optic neuropathy 
Degeneration of the ganglion cell layer and optic nerve along with relative preservation of the 
rest of the retina constitutes the typical pathological finding in patients with LHON (Kwittken 
and Barest, 1958; de Gottrau et al., 1992; Kerrison et al., 1995; Sadun et al., 2000). Marked 
axonal depletion in the optic nerve has been observed in association with demyelination of the 
spinal cord and peripheral nerves (Kwittken and Barest, 1958) and gliosis within the optic nerve 
(Kermode et al., 1989; Smith et al., 1990; Kerrison et al., 1995) and spinal cord (Kwittken and 
Barest, 1958). Lateral geniculate body loss suggests for transneuronal degeneration (Kwittken 
and Barest, 1958), whereas calcium deposition is detected on preserved swollen retinal ganglion 
cells which contain swollen mitochondria (Kerrison et al., 1995).   
1.8.5 Mitochondrial disease associated with Polymerase γ mutations  
Originally described by Cottrell and colleagues, neuropathological changes in a patient with 
multiple mtDNA deletions involved selective neuronal degeneration, axonal demyelination, 
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diffuse astrocytosis and a mosaic pattern of neuronal COX deficiency (Cottrell et al., 2000). 
Astrogliosis was pronounced in superficial occipital cortex and hippocampal layers depleted of 
neurons (CA1-4), in the dorsal columns of the spinal cord and in the white matter of the 
cerebellum, basal ganglia, thalamus and hypothalamus. Extensive neurodegeneration is 
reported in pyramidal cell layers of the hippocampus (CA1-4), the substantia nigra of the 
midbrain, the inferior olivary nucleus of the medulla and the Purkinje cells and dentate nucleus 
of the cerebellum. Degenerative changes are also detected in the dorsal root and paraspinal 
sympathetic ganglia, whereas myelin pallor in the inferior olivary nucleus, the cerebellar white 
matter and the cervical spinal cord suggest axonal demyelination.  Neuronal respiratory chain 
deficiency is detected throughout the brain, though variable, and does not necessarily correlate 
with the extent of neuropathological changes (Cottrell et al., 2000).  
Considerable substantia nigra neuronal loss has also been documented in association with Lewy 
body pathology, high mtDNA deletion levels, COX deficiency (Betts-Henderson et al., 2009) 
and severely decreased complex I and IV protein expression in remaining neurons (Reeve et 
al., 2013). Betts and colleagues further document gracile nucleus, Purkinje cell and dentate 
nucleus neurodegeneration and cervical spinal cord axonal demyelination in accordance with 
neuropathological features of mitochondrial disease (Betts-Henderson et al., 2009).  
Tzoulis and colleagues have described the neuropathological changes observed in patients with 
POLG-related encephalopathy (Alpers syndrome and spinocerebellar ataxia) (Tzoulis et al., 
2006; Tzoulis et al., 2010; Tzoulis et al., 2014). Cerebral cortical lesions detected upon 
neuroradiological examination were associated with extensive neurodegeneration, cortical 
vacuolation, astrocytic proliferation and microglia activation (Tzoulis et al., 2010). Vacuolation 
and eosinophilic necrosis was also detected in the thalamus, where neuronal loss appeared more 
selective compared to the cortex. The cerebellar cortex (Purkinje cell layer) suffered neuronal 
loss, gliosis and eosinophilic necrosis, which was also detected in the dentate nucleus.  
A sequential study performed by the same group reports the presence of acute focal lesions in 
the neocortex, hippocampus, thalamus and cerebellar cortex, all associated with selective 
neuronal loss, eosinophilic necrosis, neuropil vacuolation, astrocytosis and microglia activation 
(Tzoulis et al., 2014). Stroke-like cortical lesions detected on MRI correlated with the lesions 
documented on post-mortem tissue. The thalamus, substantia nigra and dentate-olivary and 
dentatorubral systems suffered severe neuronal loss and gliosis, whereas more selective 
changes were observed in the spinal cord. Interestingly, complex I protein expression defects 
were more severe in regions with chronic changes and higher neuronal density (compared to 
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regions with acute focal lesions), where complex IV deficiency also occurred to a lesser extent. 
The most severe electron transport chain protein expression deficiencies were detected in the 
substantia nigra, red, olivary and pontine nuclei (Tzoulis et al., 2014).  
Similarly, Lax and co-workers report the presence of cerebellar microinfarcts and associated 
astrogliosis in patients with heterozygous POLG mutations (Lax et al., 2012b). Marked 
neuronal loss in the dentate nucleus correlates with massive outflow tract demyelination, though 
neurodegeneration across the olivo-cerebellar pathway does not relate to the low heteroplasmic 
levels for mtDNA deletion detected (Lax et al., 2012b). More recently, profound inhibitory 
interneuron loss has been detected in the occipital, temporal and frontal cortices with associated 
complex I and IV (to a lesser extent) protein expression deficiencies in preserved GABAergic 
interneurons (Lax et al., 2015). 
Neurophysiological examination of 11 patients with compound heterozygous changes in POLG 
confirmed sensory neuropathy (usually in association with motor neuropathy) due to dorsal root 
ganglion abnormalities. Neuropathological examination revealed extensive neurodegeneration 
in the dorsal root ganglia, axonal and myelin loss in posterior spinal funiculus. Mitochondrial 
density and complex IV protein expression was intact in posterior horn neurons of the spinal 
cord, whereas complex I protein expression was severely decreased. On the contrary, altered 
mitochondrial mass, defective oxidative metabolism (COX-deficiency), decreased respiratory 
chain protein expression and mtDNA deletion and depletion is documented in dorsal root 
ganglia (Lax et al., 2012d). 
1.9 Animal and cell culture models of mitochondrial disease 
Examining human post-mortem brain tissue and characterising the biochemical defects and 
neuropathological features of patients with mitochondrial disease is important since it 
strengthens our understanding of the consequences of mitochondrial dysfunction in a biological 
system. However, this only provides the chance to document chronic, end-stage disease changes 
without providing any information as to the molecular pathways and mechanisms responsible 
for initiation and progression of the neurodegenerative process. Animal models and cell culture 
systems that successfully recapitulate the human disease are therefore an invaluable tool for 
exploring mechanisms of neurodegeneration and choosing appropriate drug targets.  
Skin fibroblasts extracted from patients with mitochondrial disease are routinely employed in 
order to investigate the pathophysiological changes in different tissues as a consequence of 
disease. Fibroblast reprogramming, into induced pluripotent stem cells (iPSCs), may alter the 
heteroplasmic levels for any given mtDNA mutation (Hamalainen et al., 2013; Kodaira et al., 
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2015) however it provides the opportunity to model specific mitochondrial disorders (Kodaira 
et al., 2015) and screen potential therapeutic compounds (Breuer et al., 2013). High mutation 
load for the m.3243A>G point mutation in iPSCs (Kodaira et al., 2015), differentiated neurons 
and teratomas (Hamalainen et al., 2013) was demonstrated to selectively impair complex I 
activity, in accordance with observations in tissue from MELAS patients. Interestingly, 
complex I-positive mitochondria were clustered around neuronal cell bodies and were 
eliminated by mitophagy with time (Hamalainen et al., 2013). Likewise, aberrant complex I 
activity was detected in fibroblasts extracted from patients with Leigh syndrome, due to Ndufs4 
mutations, accompanied by complex III deficiencies and subassembled complex I and IV units 
(Scacco et al., 2003; Ugalde et al., 2004a). Moreover, altered mitochondrial morphology, 
membrane potential, calcium signalling and ROS production levels demonstrate organellar 
vulnerability to damaging factors (Valsecchi et al., 2013).  
Further to neurons differentiated from patient iPSCs, mouse embryonic stem cells engineered 
to express pathogenic mtDNA mutations were exploited in order to establish the impact of 
mitochondrial dysfunction on neuronal morphology and health (Kirby et al., 2009; Abramov et 
al., 2010; Trevelyan et al., 2010). Trans-mitochondrial cybrids with severe complex I (~10% 
residual activity) and mild complex IV (40% residual activity) defects were able to successfully 
differentiate into neurons and form functional synaptic connections (Kirby et al., 2009). 
However, cybrids harbouring severe respiratory chain defects had decreased neuronal 
differentiation capacity (Kirby et al., 2009) and increased membrane potential upon  neuronal 
maturation (Abramov et al., 2010). Increased ROS production rate (Abramov et al., 2010) and 
altered Ca2+ handling following repetitive stimulation (Trevelyan et al., 2010) in both neuronal 
cell lines suggests that more than one mechanisms are likely to collectively contribute to 
neurodegeneration observed in patients with mitochondrial disease.  
An ever-increasing number of mouse models have been developed in an attempt to mimic 
mitochondrial disease, both in terms of pathophysiology and neuropathology. Pioneering work 
from Sligh (2000) and Inoue (2000) involved the introduction of pathogenic mtDNA molecules 
into embryonic stem cells (Sligh et al., 2000) or fertilised embryos (Inoue et al., 2000), 
achieving the transmission of pathogenic mutations (Sligh et al., 2000) and deletions (Inoue et 
al., 2000) into successive generations. A similar approach to directly manipulate mtDNA 
involved the introduction of severe complex I (MT-ND6) and mild complex IV (MT-COXI) 
mutations into the female germline, though severe defects were selected against during 
oogenesis (Fan et al., 2008). 
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Alternatively, manipulation of nuclear DNA-encoded genes involved in mtDNA maintenance 
has proved to be an effective method for altering mtDNA integrity. Examples include the 
“deletor” and the “mutator” mouse due to mutations in Twinkle (Tyynismaa et al., 2005) and 
POLG (Trifunovic et al., 2004) respectively. Accumulation of multiple mtDNA deletions in the 
deletor mouse induces the muscle features of patients with PEO. Respiratory chain deficiency 
has mainly been detected in muscle and hippocampus, though low percentage of COX-deficient 
neurons exists in the cerebellum, olfactory bulbs, substantia nigra and hypothalamus 
(Tyynismaa et al., 2005). In contrast, the mutator mouse demonstrates an accelerated ageing 
phenotype with weight and hair loss, kyphosis, osteoporosis, anaemia, reduced fertility and 
cardiomegaly (Trifunovic et al., 2004). Accumulation of mtDNA mutations with time results 
in extensive respiratory chain deficiencies without elevated ROS production (Trifunovic et al., 
2005). 
Recent technologies allow inactivation of genes in selective tissues or cell types providing the 
opportunity to replicate the features of specific mitochondrial disorders. Such an example is the 
inactivation of Ndufs4 from Purkinje cells and glia in an effort to simulate Leigh syndrome 
(Quintana et al., 2010). Spongiform degeneration, astrogliosis and vascular proliferation in the 
cerebellum constitute the main neuropathological findings, accompanied by abnormal 
mitochondrial structure within presynaptic terminals contacting Purkinje cell bodies (Quintana 
et al., 2010).  Phenotypic manifestations of these mice recapitulate those of Leigh syndrome 
including ataxia, failure to thrive, motor dysfunction and premature death (Quintana et al., 
2010). However, no basal ganglion pathology is detected, contrary to observations in patients 
with the disease, highlighting the need for interpreting the results with caution.  
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1.10 Aims and Objectives 
How do synapses and microvessels contribute to neurodegeneration due to mitochondrial 
disease? 
Cerebellar ataxia is the most common neurological deficit of patients with mitochondrial 
disease. Neuropathological observations include pronounced neuronal degeneration, 
documented in association with synaptic disturbances and likely consequent altered 
intracerebellar circuitry. The relatively simple and well-studied cerebellar microcircuitry will 
be used in this thesis to answer the following questions: 
 Is synaptic pathology a primary event in neurodegeneration or consequent to the 
degenerative process? 
 Is there any evidence for structural synaptic abnormalities and/or respiratory chain 
deficiency in Purkinje cell presynaptic terminals contacting dentate nucleus neurons? 
 How do presynaptic abnormalities relate to postsynaptic neuronal deficiency and loss? 
Extensive neurodegeneration and pan-necrotic foci are also detected in association with stroke-
like cortical lesions. These are prominent but not restricted to patients with MELAS syndrome. 
The brain microvasculature will be examined in this thesis to answer the following questions: 
 Is there any evidence of respiratory chain protein expression deficiency in arterioles 
and capillaries of posterior cortical regions? 
 How do neuropathological observations relate to clinical and neuroradiological data 
for these patients?
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Chapter 2 Materials and methods 
2.1 Equipment and consumables 
2.1.1 Equipment 
2100 Antigen Retriever      Aptum Biologics 
3510 benchtop pH meter      Jenway 
AxioCam ICc1       Carl Zeiss microscopy 
AxioCam MRc       Carl Zeiss microscopy 
AxioCam MRm       Carl Zeiss microscopy 
ChemiDoc™ Imaging System     Bio-Rad 
Eppendorf Centrifuge 5418      Eppendorf 
Veriti® 96-Well Thermal Cycler     Life Technologies 
Horizontal gel electrophoresis tank     Peqlab 
IKA Magnetic stirrer hotplate RCT basic    Fisher Scientific 
MP-250V power supply      Cleaver Scientific 
OHAUS adventurer® balance     OHAUS 
Nikon A1R scanning confocal system    Nikon 
Olympus microscope BHX54      Olympus 
PALM MicroBeam Observer 21     Carl Zeiss microscopy 
Pyromark Q24 workstation      Qiagen 
Zeiss Axio Imager M1      Carl Zeiss microscopy 
2.1.2 Software 
ZEN imaging software      Carl Zeiss microscopy 
Volocity® 3D image analysis and deconvolution software (v.6.1) PerkinElmer 
IMARIS scientific 3D/4D Image processing & analysis software Bitplane 
ImageLab software (v.4.1)      Bio-Rad 
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PALM RoboSoftware       Carl Zeiss microscopy 
StereoInvestigator software      MBF Bioscience 
2.1.3 Consumables 
0.2ml Thin-Walled PCR Tubes      Thermo Scientific 
0.5ml PCR Tubes       Thermo Scientific 
1.5ml Eppendorf Tubes       Thermo Scientific 
2ml Eppendorf tubes       Biogene 
96-well plate Semi-Skirted with Raised Rim    Starlabs 
AdhesiveCap 200 clear (D) PCR Tubes (0.2ml)   Zeiss 
Aerosol resistant Pipette tips      Starlabs 
Coverslips (22x20, 22x32mm, 22x40mm, 22x50mm) VWR International 
Charged adhesion slides (26x76x1.0-1.2mm)   CellPath 
ErgoOne® Single-channel Pipettes (P1000, P200, P20, P10) Starlabs 
Gel extraction Kit       Qiagen 
HiQA Mega converslips (37x58mm)     CellPath 
HiQA Supa Mega coverslips (50x64mm)    CellPath 
HISTOBOND® + supa mega slides (75.2 x 50.4 x 1mm)  CellPath 
ProLong® Gold Antifade Mountant      Life Technologies 
PyroMark Gold Q24 Reagents     Qiagen 
SuperFrost™ Plus Adhesion slides (38x75x1mm)   ThermoScientific 
 
2.2 Solutions and chemicals 
2.2.1 Solutions 
Solutions and buffers were prepared in Nanopure (18 Mega Ohms activity) water and 
subsequently autoclaved.  
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1% Acid-alcohol solution     500ml Ethanol 
        5ml HCL 
3% Hydrogen Peroxide     485ml dH2O 
        15ml Hydrogen peroxide 
3% Sudan Black B      0.3g of Sudan black B 
        100ml of 70% ethanol 
Acetate Buffer pH 4.5      13.5ml Acetic acid 
        23.5g Sodium acetate 
        2L dH2O   
Cresyl fast violet (CFV) staining solution   500ml Acetate Buffer pH 4.5 
        500ml dH2O 
        50ml CFV  
DNA Loading Buffer      0.25% (w/v) Bromophenol Blue
        0.25% (w/v) Xylene Cyanol 
        30% (v/v) Glycerol 
Electrophoresis Buffer (1l)     100ml 10x TAE  
        900ml Nanopure water 
50μl 0.5M TrisHCL pH 8.5     30.275g Trisma base  
500ml dH2O 
Scott’s tab water      2g Sodium bicarbonate 
        20g Magnesium sulphate 
        1L tap water 
Single cell Lysis Buffer (500μl)    250μl 1% Tween 20  
        50μl 0.5M TrisHCL pH 8.5 
195μl dH2O    
5μl proteinase K 
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Phosphate Buffered Saline pH 7.4    0.276g NaH2PO4*H2O 
        1.136g Na2HPO4 
        8.5g NaCl 
        1L dH2O 
Tris-Buffered Saline pH7.4      1.2g Trisma base 
17g NaCl  
2L dH20  
Tris-Buffered Saline – Tween pH7.4    1.2g Trisma base 
17g NaCl  
2L dH20  
1ml Tween 20 
10mM Tri-sodium citrate pH6.0     2.941g tri-sodium citrate  
1L dH20 
1mM EDTA pH8       0.416g EDTA  
1L dH20  
2.2.2 Chemicals  
2.2.2.1 Antibodies 
Anti-Synaptophysin       DAKO 
Anti-GAD65/67       Sigma-Aldrich 
Anti-Gephyrin        BD Biosciences 
Anti-Calbindin       Swant 
Anti-pan-AMPA       Millipore 
Anti-VGLUT1       NeuroMab 
Anti-GLUT1        Thermo Scientific 
Anti-α-SMA        Abcam 
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Anti-VDAC1        Abcam 
Anti-NDUFB8       Abcam 
Anti-NDUFA13       Abcam 
Anti-COX I        Abcam 
Anti-COX IV        Abcam 
Alexa Fluor®405       Life technologies 
Alexa Fluor®488       Life technologies 
Alexa Fluor®546       Life technologies 
Alexa Fluor®647       Life technologies 
Biotin-XX        Life technologies 
Streptavidin, Alexa Fluor® 647 conjugate    Life technologies 
Biotin-SP        Jackson ImmunoResearch 
Rhodamine Red™-X       Jackson ImmunoResearch 
 
2.2.2.2 Histological reagents 
Acetic acid        VWR 
Anti‐Mouse/Rabbit PolyVue HRP Labe    Diagnostic BioSystems 
Cresyl violet acetate       Sigma    
3, 3’ Diaminobenzidine Tetrahydrochloride    Sigma 
Di-Sodium hydrogen orthophosphate anhydrous   VWR 
DPX™        Merck 
Ethanol        Fischer Scientific 
Ethylenediaminetetraacetic Acid, Disodium Salt, Dihydrate  Affymetrix 
Histoclear™        National Diagnostics 
30% w/v Hydrogen Peroxide      Sigma 
Mayers Haematoxylin       TCS Biosciences Ltd 
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Normal goat serum       Sigma 
Paraformaldehyde solution 4% in PBS    Santa Cruz Biotechnology 
Polymer Penetration Enhancer     Diagnostic BioSystems 
Sodium acetate       VWR 
Sodium chloride       Sigma 
Sodium dihydrogen orthophosphate 1-hydrate   VWR 
Sudan Black B (Noir Soudan)     RAL diagnostics  
Tri-sodium citrate       VWR 
Trizma base        Sigma 
Tween 20        Sigma 
 
2.2.2.3 Molecular Biology reagents 
Agarose MP        Roche 
AmpliTaq GOLD® DNA polymerase    Life Technologies 
10X AmpliTaq Gold® PCR Buffer     Life Technologies 
Buffer QX1        Qiagen 
Buffer PE        Qiagen 
Deoxynucleotide Triphosphates     Rovalab 
Diethylpyrocarbonate (DEPC) -treated water   Life Technologies  
GelRed nucleic acid stain      Biotium 
GO Taq Hot Start DNA Polymerase     Promega 
Hyperladder IV       Bioline 
La Taq DNA polymerase      Takara 
Proteinase K        Invitrogen 
PyroMark Annealing buffer      Qiagen 
PyroMark Binding buffer      Qiagen 
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PyroMark Gold Q24 Reagents (5 x 24)    Qiagen 
PyroMark Wash buffer (x10)      Qiagen 
Quick-load 1kb DNA ladder      BioLabs 
Streptavidin sepharoseTM high performance beads    GE Healthcare 
Tris-HCl        Sigma 
 
2.3 Central nervous system samples 
2.3.1 Patient cohort 
Central nervous system (CNS) tissue from thirteen adult patients was obtained from the 
Newcastle Brain Tissue Resource (NBTR). All patients included in this study were clinically 
and genetically diagnosed with mitochondrial disease and received regular clinical assessments 
using the validated Newcastle Mitochondrial Disease Adult rating Scale (NMDAS) (Schaefer 
et al., 2006). Patients and their families provided informed consent to donate their tissue for 
research purposes and ethical approval for this study was gained from Newcastle and North 
Tyneside Local Research Ethics Committee (LREC 2002/205). A summary of the clinical, 
genetic and neuropathological details of patients is provided in Table 2- 1 (patient numbering 
is the same throughtout the thesis for consistency).  
Upon patient death, NBTR pathologists remove the whole brain for dissection. Half of the 
cerebral hemisphere (left hemisphere) is snap frozen and stored at -80oC for molecular genetic 
investigation, whilst the other half (right hemisphere) is fixed in 10% formalin and embedded 
in paraffin wax.  
Frozen tissue was cut at 15µm-thick sections using a cryostat (-12oC) and mounted on 
SuperFrost glass slides. Frozen sections were left to air dry before stored at -80oC until required.  
Formalin–fixed Paraffin-Embedded (FFPE) tissue was cut using a microtome at either 20µm 
or 5µm-thick sections and mounted on SuperFrost glass slides. Fixed tissue was then incubated 
at 37oC for 3-5 days in order to ensure tissue adhesion onto the slide and was then stored at 4oC 
until required. 
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2.3.2 Control tissue 
To determine the extent of neuropathological changes in patients with mitochondrial disease, 
neurologically normal age-matched controls are used. Frozen control tissue was obtained from 
the NBTR, whereas FFPE brain sections were obtained from the NBTR and the MRC Sudden 
Death Brain and Tissue Bank, Edinburgh. The neuropathological details of controls are 
summarised in Table 2- 2.
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1 ND – not determined 
Type 
 
Age 
(years) 
 
Sex 
 
Length 
of 
fixation 
(weeks) 
 
Post-
mortem 
delay 
(hours) 
 
Cause of death 
 
Source 
 
Control 1 69 Female 6 16 Gastric cancer NBTR 
Control 2 68 Male 8 54 Bowel cancer NBTR 
Control 3 78 Female 5 23 metastatic oesophageal carcinoma NBTR 
Control 4 74 Female 13 67 Lung cancer NBTR 
Control 5 55 Male 14 41 Liver cancer NBTR 
Control 6 74 Female 9 53 Heart failure and lung cancer NBTR 
Control 7 70 Male 11 72 Metastatic prostate cancer NBTR 
Control 8  73 Male 7 25 ND1 NBTR 
Control 9 78 Female 8 34 
Metastatic cancer - primary origin 
unknown (probably ovarian) 
NBTR 
Control 10 45 Male 13 13 ND NBTR 
Control 11 48 Male 1 72 Coronary artery atherosclerosis Edinburgh 
Control 12 48 Male 1 46 Coronary artery atherosclerosis Edinburgh 
Control 13 61 Male 1 61 ND Edinburgh 
Control 14 48 Male 1 43 
Coronary artery thrombosis and 
atherosclerosis 
Edinburgh 
Control 15 25 Male 1 53 ND Edinburgh 
Control 16 44 Male 1 83 
Complications of 
bronchopneumonia and coronary 
artery atherosclerosis 
Edinburgh 
Control 17 43 Male 1 96 
Coronary artery thrombosis and 
atherosclerosis 
Edinburgh 
Control 18 74 Female 1 41 Pulmonary thromboembolism Edinburgh 
Control 19 70 Male 1 ND 
Hypertensive and ischaemic heart 
disease, Type 2 diabetes and Fatty 
degeneration of the liver 
Edinburgh 
Control 20 52 Male 1 52 
Ischaemic heart disease, Coronary 
artery atherosclerosis and Type 2 
Diabetes Mellitus 
Edinburgh 
Control 21 71 Female 1 41 
Ischaemic and hypertensive heart 
disease 
Edinburgh 
Control 22 75 Male 1 78 
Ischaemic heart disease and 
Coronary artery atherosclerosis 
Edinburgh 
Control 23 51 Male 1 71 
Ischaemic heart disease and 
Coronary artery atherosclerosis 
Edinburgh 
Control 24 41 Female 1 50 Unascertained Edinburgh 
Control 25 33 Male 1 47 
Ischaemic heart disease and 
Coronary artery atherosclerosis 
Edinburgh 
Control 26 68 Male 1 96 
Complications of familial amyloid 
polyneuropathy 
Edinburgh 
Table 2- 2: Neuropathological details of controls included in this study 
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2.4 Two-dimensional neuronal density 
In order to assess the degree of neuronal loss in the cerebellum of patients with mitochondrial 
disease, 20µm-thick FFPE sections from patients and controls were subjected to a two-
dimensional neuronal density protocol previously described (Lax et al., 2012). In summary: 
2.4.1 Cresyl Fast Violet (CFV) stain  
Dewaxed and rehydrated sections (see section 2.6) were fixed in 1% acid alcohol solution for 
5 minutes and rinsed 3-4 times in distilled water. Following this, sections were incubated in 
pre-warmed CFV staining solution for 10-15 minutes at 60oC and were then left to cool for 5 
minutes at room temperature in staining solution. A final wash in distilled water for 1 minute 
was followed by dehydration in a graded ethanol series (70%, 95% and 100%) and mounting 
on DPX™ (Merck).   
2.4.2 Quantification of Purkinje cell and dentate nucleus neuronal populations 
For Purkinje cell neuronal count, the cerebellar cortex was identified at x10 magnification and 
the boundaries of the Purkinje cell layer were outlined to give distinct lobular areas (Figure 2- 
1) using the closed contour function of the StereoInvestigator software. Cells with a visible 
nucleolus and a clear cytoplasm were counted in each lobular area at x40 magnification using 
the Meander scan. Purkinje cell density for each lobule was deviated after dividing the number 
of identified neurons by the lobule’s area (number of neurons per mm2 lobular area) and overall 
Pukrinje cell density was evaluated after pooling together the data for each lobule.  
Similarly, the dentate nucleus (DN) grey matter ribbon was identified at x2.5 magnification and 
was divided into quadrants according to Su and colleagues (Su et al., 2000) (Figure 2- 1). Cells 
that fulfilled the criteria of a visible nucleolus and a clear cytoplasm were counted for each 
quadrant at x100 magnification using the Meander scan. Dentate nucleus neuronal cell densities 
for each quadrant were calculated after dividing the number of identified neurons by the 
quandrant’s area (number of neurons per mm2 quadrant area), whereas the overall dentate 
nucleus neuronal cell density deviated after combing the data for each quadrant. 
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2.5 Dual cytochrome c oxidase (COX)/ Succinate dehydrogenase (SDH) stain 
Frozen brain tissue sections mounted on SuperFrost glass slides (15μm thick) were left to air-
dry for one hour before being subjected to a dual COX/SDH histochemical protocol. COX 
medium was prepared by adding 200μl of cytochrome c stock solution (500μM cytochrome c 
in 0.2M phosphate buffer, pH 7.0) to 800μl of 3,3’diaminobenzidine tetrahydrochloride (DAB) 
stock solution (5mM DAB in 0.2M phosphate buffer, pH 7.0) with 20μg.ml-1 catalase. Each 
section was incubated with 200μl of the COX solution for 50 minutes at 37oC. Following 
incubation, sections were washed in phosphate-buffered saline (PBS) (3x5 minutes). SDH 
medium was prepared by adding 800μl NitroBlue tetrazolium (NBT) stock solution (1.5mM 
NBT in 0.2M phosphate buffer pH 7.0) to 100μl sodium succinate stock solution (1.3M sodium 
succinate in 0.2M phosphate buffer pH 7.0), 100μl phenazine methosulphate (PMS) stock 
solution (2mM PMS in 0.2M phosphate buffer pH 7.0) and 10μl sodium azide stock solution 
(100mM sodium azide in 0.2M phosphate buffer pH 7.0). Sections were incubated with the 
SDH solution (200μl on each section) for 45 minutes at 37oC. Tissue sections were washed in 
PBS (3x5 minutes), dehydrated through graded ethanol series (70%, 95% and 2x 100%), cleared 
in two changes of Histoclear™ (National Diagnostics, Charlotte, NC) and mounted in DPX™ 
(Merck).  
2.6 Immunohistochemical staining 
FFPE (5µm) cerebellar tissue sections mounted on SuperFrost glass slides were dewaxed by 
placing in a 60ºC oven for 20 minutes and rehydrated by immersion in Histoclear™ (x2) 
(National Diagnostics, Charlotte, NC) and  graded ethanol series (2x100%, 95% and 70%) for 
5 minutes. Following a thorough wash under distilled water, heat mediated antigen retrieval 
was performed. This involved immersing the sections in 1mmol Ethylenediaminetetraacetic 
Acid (EDTA) (pH 8.0) and pressure cooking for 40 minutes or microwaving in boiling Tri-
sodium citrate (10mM; pH 6.0) for 10 minutes and cooling, depending on the antibody used. 
Endogenous peroxidase activity was blocked by incubating in 3% Hydrogen peroxide (Sigma) 
solution for 30 minutes at room temperature (RT). Sections were washed (3x5 minutes) with 
tris-Buffered saline-Tween (TBST) followed by incubation in the appropriate primary antibody 
dilution (Table 2- 3) for 1 hour at RT. The sections were washed with TBST (3x5 minutes) and 
a Polymer Penetration Enhancer (Diagnostic BioSystems) was applied for 30 minutes, followed 
by further washes (TBST; 3x5 minutes) and incubation with an Anti‐Mouse/Rabbit PolyVue 
horseradish peroxidase (HRP) (Diagnostic BioSystems) for 30 minutes, all at RT. Antibody 
binding to the epitope of interest was detected after incubation with 3, 3’-diaminobenzidine 
(DAB) (Sigma-Aldrich) for 5 minutes at RT. Sections were then washed in running water and 
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counterstained with Mayer’s haematoxylin for 10 minutes. “Blueing” of the nuclei was 
achieved after incubating in Scott’s tab water for 1 minute and dehydration was achieved by 
immersing the sections in  70%, 95%, 2x100% ethanol and 2x Histoclear™ (National 
Diagnostics, Charlotte, NC) for 5 minutes. Finally, coverslips are mounted on to tissue sections 
using DPX™ (Merck).    
2.7 Immunofluorescent staining 
2.7.1 FFPE tissue 
Using a microtome 5µm-thick FFPE CNS tissue sections were mounted on SuperFrost glass 
slides and subjected to immunofluorescent staining to allow for co-localisation studies. Sections 
were dewaxed by placing in a 60ºC oven for 20 minutes and rehydrated by immersion in 
Histoclear (National Diagnostics, Charlotte, NC) and graded ethanol series (100% to 70%). 
Antigen retrieval was performed using the 2100 retriever unit (Electron Microscopy Sciences©, 
Hatfield) by immersing sections in 1mmol EDTA (pH 8) and pressure cooking for 40 minutes. 
Sections were blocked in 1 or 10% normal goat serum (NGS) (Sigma) (depending on the 
antibody used) for 1 hour at RT and incubated in primary antibodies (Table 2- 3) at the optimal 
dilution overnight at 4oC. Mouse monoclonal and rabbit polyclonal primary antibodies were 
applied to the sections at the appropriate dilution and for the appropriate time depending on the 
experimental protocol (details of these are given in Chapter 3 of this thesis). Following 
incubation with primary antibodies, sections were washed with 10mM PBS (3x5 minutes) and 
subjected to incubation with a biotinylated secondary antibody (when necessary). Quadruple 
immunofluorescent labelling involved tissue incubation with secondary anti-mouse, anti-rabbit 
or streptavidin-conjugated antibodies coupled with Alexa Fluor 405, 488, 546 and 647 (Life 
Technologies). The signal-to-noise ratio was increased by quenching autofluorescence with 3% 
Sudan Black b solution for 10 minutes. Sections were then washed in distilled water and 
mounted in Prolong Gold (Life Technologies). All the primary and secondary antibodies used 
for this study are listed in Table 2- 3. 
Immunofluorescence was performed on positive controls (all antibodies), no-primary-antibody 
(NPA) and no-secondary-antibody (NSA) controls for each of the four fluorophores to allow 
background correction and cross-reactivity checks respectively. All patient and control samples 
were stained under the same conditions and slides were kept at -20C until required.  
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2.7.2 Frozen tissue 
Frozen cerebellar tissue sections (15µm) were air-dried for 1.5 hours at RT before being fixed 
in 4% Paraformaldehyde (PFA) (Santa Cruz Biotechnology) for 10 minutes. Washes with 
10mM Tris-buffered saline (TBS) (2x2 minutes and 1x10 minutes) were followed by section 
blocking with 10% NGS for 30 minutes at RT and primary antibody incubation overnight at 
4oC (Table 2- 3). Following TBS washes (3x5 minutes) a biotinylated secondary antibody 
(Table 2- 3) was applied for 30 minutes at RT. Double immunofluorescence was achieved after 
incubating the sections with secondary streptavidin-conjugated and anti-goat antibodies 
coupled with Rhodamine Red-X  and Alexa Fluor 488 respectively (Table 2- 3) for 2 hours at 
4oC.  Tissue auto-fluorescence was blocked by incubating with 3% Sudan Black b solution for 
3 minutes. 
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Primary antibody Epitope Host and isotype Source
Catalog 
No.
Antigen retrieval
Synaptophysin presynaptic vesicles
Mouse monoclonal - 
IgG1
DAKO M0776
Microwaving in Tri-sodium citrate 
(10mM) pH6 for 10 minutes
Glutamic acid 
decarboxylase 65/67
GABAergic neurons - 
GAD67 and Inhibitory 
axonal terminals -
GAD 65
Rabbit polyclonal - 
IgG
Sigma-Aldrich G5163
Microwaving in Tri-sodium citrate 
(100mM) pH6 for 10 minutes
Primary antibody Epitope Host and isotype Source
Catalog 
No.
Antigen retrieval
Synaptophysin      
(SY-38)*
presynaptic vesicles
Mouse monoclonal - 
IgG1
DAKO M0776
EDTA (1mM); 2100 antigen 
retriever
Gephyrin
Inhibitory 
postsynaptic 
compartments
Mouse monoclonal - 
IgG1
BD Biosciences 610585
EDTA (1mM); 2100 antigen 
retriever
Calbindin D-28k
Calcium binding 
protein; Calbindin-
expressing neurons
Mouse monoclonal - 
IgG1
Swant CB300
EDTA (1mM); 2100 antigen 
retriever
Glucose transporter 1 
(GLUT-1)
Endothelial cell layer
Rabbit polyclonal - 
IgG
Thermo Scientific PA1-21041
EDTA (1mM); 2100 antigen 
retriever
Alpha- Smooth 
muscle actin (SMA)
Smooth muscle layer
Rabbit polyclonal - 
IgG
Abcam ab5694
EDTA (1mM); 2100 antigen 
retriever
Complex I        
subunit NDUFA13
NDUFA13
Mouse monoclonal - 
IgG2b
Abcam ab110240
EDTA (1mM); 2100 antigen 
retriever
Complex I        
subunit NDUFB8
NDUFB8
Mouse monoclonal - 
IgG1
Abcam ab110242
EDTA (1mM); 2100 antigen 
retriever
Complex IV     
subunit IV
COX4+COX4L2
Mouse monoclonal - 
IgG2a
Abcam ab110261
EDTA (1mM); 2100 antigen 
retriever
Complex IV      
subunit I
COX1
Mouse monoclonal - 
IgG2a
Abcam ab14705
EDTA (1mM); 2100 antigen 
retriever
Voltage-dependent 
anion channel 1 
(VDAC1)
Outer mitochondrial 
membrane protein 
(VDAC1/porin)
Mouse monoclonal - 
IgG2b
Abcam ab14734
EDTA (1mM); 2100 antigen 
retriever
Vesicular glutamate 
transporter 1 
(VGLUT1)
Neurotransmitter 
transporter
Mouse monoclonal – 
IgG1
NeuroMab 73-066
EDTA (1mM); 2100 antigen 
retriever
Pan-AMPA receptor 
(GluR1-4)
Glutamate receptors
Mouse monoclonal – 
IgG2bk
Millipore MABN832
EDTA (1mM); 2100 antigen 
retriever
Rabbit polyclonal - 
IgG
Sigma-Aldrich G5163
EDTA (1mM); 2100 antigen 
retriever
Glutamic acid 
decarboxylase 65/67 
(GAD 65/67)*
Immunohistochemistry
Immunofluorescence
GABAergic neurons 
(GAD67) and 
inhibitory axonal 
terminals (GAD 65)
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Table 2- 3: Primary and secondary antibodies used in this study.  
* Indicates antibodies used for frozen tissue immunofluorescence. 
 
Secondary antibody Target Host Source
Catalog 
No.
Antigen retrieval
Biotin-XX* Mouse IgG1 (γ1) Goat Life technologies A10519 N/A
Biotin-SP Mouse IgG1 (γ1) Goat
Jackson 
ImmunoResearch
115-065-
205
N/A
HRP-conjugated Mouse IgG1 (γ1) Goat Life technologies A10551 N/A
Alexa Fluor® 647 
Tyramide
HRP N/A Life technologies T2095 N/A
Streptavidin, Alexa 
Fluor® 647 
Conjugate
Biotin N/A Life technologies S32357 N/A
Alexa Fluor® 405 Rabbit IgG (H+L) Goat Life technologies A31556 N/A
Alexa Fluor® 488 Mouse IgG2b (γ2b) Goat Life technologies A2114 N/A
Alexa Fluor® 488* Rabbit IgG (H+L) Goat Life technologies A11008 N/A
Alexa Fluor® 488 Mouse IgG2a (γ2a) Goat Life technologies A21131 N/A
Alexa Fluor® 546 Mouse IgG2a (γ2a) Goat Life technologies A21133 N/A
Alexa Fluor® 546 Mouse IgG2b (γ2b) Goat Life technologies A21143 N/A
Rhodamine Red™-
XD26:I34 (RRX) 
Streptavidin*
Biotin N/A
Jackson 
ImmunoResearch
016-290-
084
N/A
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2.8 Microscopic and image analysis techniques 
2.8.1 Point-scanning confocal microscopy 
Immunofluorescently stained FFPE brain sections from patients and controls were imaged 
using an A1R confocal system (Nikon). The system is equipped with a fully motorised inverted 
point scanning confocal microscope (Nikon), four spectrally unmixed lasers (405nm, 488nm, 
561nm and 647nm), six different objectives (air or oil) and the NIS-Elements software (v4.2) 
(Nikon). Specific neuronal and sub-neuronal compartments and vascular cell populations were 
easily detected using an immersion oil x60 objective with numerical aperture 1.4 and working 
distance 0.13cm. Regions of interest were identified, a Step-by-step Nikon A1 Piezo Z scanner 
and Nikon TI-S-EJOY (Nikon) defined the z dimensions (top and bottom limits) of each region 
on the software surface. The depth of the tissue was then automatically calculated and the 
appropriate number of z stacks was captured at x180 magnification (x60 objective and x3 
electronic zoom) according to the recommended microscope settings: Pixel size: 0.14μm, z-
step size: 0.175μm, optical resolution: 0.13μm and optical sectioning 0.54μm. The resonant 
scanning mode was chosen that facilitated fast scanning at high resolution (512x512 frames). 
Laser settings for each experiment were chosen by adjusting the photomultiplier tube gain 
(HV), laser power and offset functions on the software work surface.  Tissue from 
neurologically normal controls was chosen for setting up the lasers, making sure that the 
intensity profiles for each channel would fall within the normal range (avoiding under- or over-
exposure of samples).  All the patient and control samples were imaged under the same laser 
settings; while laser stability and day-to-day variation was tested using FocalCheck™ 
Fluorescence Microscope Test slides (Molecular Probes™, Invitrogen).  
2.8.2 Three-dimensional analysis software 
Z stacking and confocal microscopy produced three-dimensional (3D) images (sampled on x- 
y- and z-planes) and enabled the investigation of respiratory chain protein expression within 
fine structures, for example, synapses. Two three-dimensional software packages were used 
throughout the study, each with certain advantages over the other. Volocity® 3D image analysis 
and deconvolution software (v.6.1.1, PerkinElmer) was used for image deconvolution and 
generation of protocols that allowed for respiratory chain protein expression quantification in 
neuronal cell bodies, dendrites, presynaptic terminals and vascular cell populations. For 
quantification of dendritic length extension and isolation of presynaptic terminals directly 
opposed to postsynaptic sites the IMARIS scientific 3D/4D Image processing & analysis 
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software (Bitplane) was used. All the patient and control images were processed using the same 
software and experimental protocols depending on the research question at the time.  
2.9 Molecular techniques 
2.9.1 Isolation of different neuronal sub-compartments 
In order to dissect out individual neurons and synapses,  15µm-thick frozen cerebellar sections 
were mounted on SuperFrost glass slides and subjected to double immunofluorescence (as 
described above) followed by laser capture microdissection (Zeiss PALM microdissection 
system).  Immunofluorescently stained sections were left to air dry for 1 hour in the dark before 
tissue was cut and collected into sterile 0.2ml AdhesiveCap PCR tubes (Zeiss).   
Purkinje cells were identified at x40 magnification by diffuse GAD-65/67 staining.  Twenty 
randomly selected neuronal cell bodies were then isolated using the “close cut and AUTO-
LPC” function of the PALM RoboSoftware into separate PCR tubes.  
Areas of co-localisation between GAD-65/67 and SY-38 at the periphery of dentate nucleus 
neurons indicated the presence of GABAergic presynaptic terminals at x63 magnification. 
Given the small size of presynaptic terminals, ≥3 inhibitory axonal terminals per dentate 
nucleus neuron were isolated into separate PCR tubes. The “centreRoboLPC” function was 
employed to isolate three terminals from twenty randomly selected dentate nucleus neurons.   
2.9.2 DNA extraction 
Isolated tissue captured onto the adhesive caps was later subjected to centrifugation (14 000rpm 
for 10 minutes) into 10 µl of cell lysis buffer (50mM Tris-HCL pH 8.5, 1% Tween-20, 20mg/ml 
proteinase K and nanopure water) (Taylor et al., 2003). Samples were lysed after incubation at 
55oC overnight followed by 10 minute incubation at 95oC for proteinase K inactivation.  
2.9.3 Polymerase chain reaction (PCR) for pyrosequencing 
Cell lysates were used as template DNA to establish the m.3243A>G or m.8344A>G mutation 
load in Purkinje cells and presynaptic terminals from patients harbouring the m.3243A>G or 
m.8344A>G mutations respectively.  1µl of the Purkinje cell and 2µl of the synaptic lysate were 
subjected to two rounds of PCR amplification in order to have enough DNA for 
pyrosequencing. All the samples were run in triplicate. PCR reactions were set up in a sterile 
UV hood and were implemented in 25µl volumes.  
2.9.3.1 M.3243A>G point mutation 
To define the levels of m.3243A>G mutation load, a forward biotinylated and a reverse primer 
(Primer sequences and positions are summarised in Table 2- 8) amplified a 210bp PCR 
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fragment that spanned the m.3243 mutation site. The PCR mastermix consisted of 11.8µl 
DEPC-treated water (Life Technologies), 5µl, 5x GoTaq Flexi Buffer (Promega, UK), 2µl 
MgCl2 (Promega, UK), 2.5µl 10x dNTPs (Rovalab), 2.5µl primers (10μM) (forward and 
reverse) and 0.2µl Go Taq Hot Start DNA polymerase (Promega, UK). The PCR conditions on 
the Thermal cycler (Life Technologies) were as follows (Table 2- 4): 
Process Temperature Time Cycles 
Initial 
Denaturation 
95oC 10 minutes 1 
Denaturation 95oC 30 seconds 
30 
Primer 
annealing 
62oC 30 seconds 
Extension 72oC 30 seconds 
Final Extension 72oC 10 minutes 1 
Hold 4oC ∞  
Table 2- 4: PCR conditions for the m.3243A>G point mutation assay. 
2.9.3.2 M.8344A>G point mutation 
 The m.8344A>G assay involved the use of a biotinylated forward and a reverse primer (Table 
2- 8) that generated a 147bp fragment spanning the mutation site.  The mastermix for the 
specific PCR amplification reaction was made up of 10.8µl DEPC-treated water (Life 
Technologies), 5µl, 5x reaction buffer (Promega, UK), 3µl MgCl2 (Promega, UK), 2.5µl 10x 
dNTPs (Rovalab), 2.5µl primers (10μM)  (forward and reverse) and 0.2µl Go Taq Hot Start 
DNA polymerase (Promega, UK).  The Thermal cycler conditions for this assay are summarised 
below (Table 2- 5):   
 
 
 
 
 
 
 
1µl of known heteroplasmy (74% and 33% for m.3243A>G; 81% and 20% for m.8344A>G) 
and wild-type (WT) human homogenate DNA and mastermix were run alongside the lysates 
and were employed as positive and negative controls respectively.   
Process Temperature Time Cycles 
Initial 
Denaturation 
95oC 10 minutes 1 
Denaturation 94oC 30 seconds 
30 
Primer 
annealing 
62oC 30 seconds 
Extension 72oC 30 seconds 
Final Extension 72oC 10 minutes 1 
Hold 4oC ∞ 
 
Table 2- 5: PCR conditions for the m.8344A>G point mutation assay. 
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2.9.4 PCR amplification for known heteroplasmy DNA stock generation 
For the generation of mtDNA stocks with known heteroplasmy levels, 1μl of homogenate DNA 
was subjected to a two-stage PCR amplification protocol with an intermediate gel extraction 
step. The primary PCR reaction involved the use of a forward and a reverse primer (Primer Pair 
B; Table 2- 8) in order to amplify mitochondrial DNA and generate a ̴ 2.5kb fragment that span 
the mutation site. The reaction was implemented in 50μl volumes using a mastermix that 
consisted of 33.5μl of DEPC-treated water (Life Technologies), 5μl 1x LA PCR buffer (Mg 2+) 
(Takara Bio Inc), 8μl 10x dNTPs (Rovalab), 2μl primers  (10μM) (forward and reverse) and 
0.5μl LA Taq DNA polymerase (Takara Bio Inc). The PCR conditions were as follow (Table 
2- 6): 
Process Temperature Time Cycles 
Initial 
Denaturation 
94oC 30 seconds 1 
Denaturation 94oC 30 seconds 
35 
Primer 
annealing 
58oC 30 seconds 
Extension 68oC 11 minutes 
Final Extension 72oC 10 minutes 1 
Hold 4oC ∞  
Table 2- 6: Thermal cycler conditions for the first round of DNA amplification. 
 
Following gel extraction (see section 2.9.5), the purified DNA fragments were used as template 
DNA to generate a 568bp product spanning the mutation site. PCR reactions were performed 
at 25μl volumes using a mastermix that consisted of 14.87μl DEPC-treated water (Life 
Technologies), 2.5μl 10x AmpliTaq Gold PCR buffer (150mM Tris-HCL, pH 8.0, 500mM 
KCl), 2.5μl 10x dNTPs (Rovalab), 2μl 25μM MgCl2, 2μl primers (10μM) (Primer Pair 6; Table 
2- 8) and 0.13μl AmpliTaq Gold Hot Start DNA polymerase (Applied Biosystems). Thermal 
cycler conditions are listed in Table 2- 7. 
 
 
 
Process Temperature Time Cycles 
Initial 
Denaturation 
95oC 10 minutes 1 
Denaturation 94oC 45 seconds 
35 
Primer 
annealing 
58oC 45 seconds 
Extension 68oC 45 seconds 
Final Extension 72oC 8 minutes 1 
Hold 4oC ∞  
Table 2- 7: Thermal cycler conditions for the second round of DNA amplification. 
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2.9.5 Gel electrophoresis 
Two different concentrations of agarose gel were prepared depending on the size of the PCR 
products to be resolved; 1.5% (W/V) for PCR pyrosequencing products and 1% (W/V) for PCR 
products used to generate stocks of known heteroplasmy DNA. Gels contained GelRed (4μl per 
100ml) that intercalated with DNA to allow for visualisation under UV light and were loaded 
with either Quick-load 1kb DNA ladder (BioLabs) or 100bp Hyperladder IV (Bioline). 5μl of 
each PCR product was mixed with 1μl loading dye (0.25% (w/v) bromophenol blue, 0.25% 
(w/v) xylene cyanol, 30% (v/v) glycerol) and were loaded on to the gels.  Gels were submerged 
in 1xTAE buffer (0.8mM Tris acetate, 0.02mM EDTA, 0.4μg/ml Ethidium Bromide) and 
electrophoresis was performed at 75V for 45 minutes to allow separation and sizing of the PCR 
products. A ChemiDoc Imaging System (Bio-Rad) was used to visualise and take digital images 
of the gel. An example of a 1.5% gel loaded with Purkinje cell and synaptic products is shown 
in Figure 2- 2.
Figure 2- 2: A 1.5% gel loaded with DNA extracted from Purkinje cell bodies and synapses (in 
triplicate) alongside with homogenate WT and known heteroplasmy DNA.   
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2.9.6 Gel extraction and DNA fragment purification 
Following the first PCR amplification step of known heteroplasmy mtDNA, the products were 
loaded on to a 1% agarose gel and were electrophoresed to allow adequate separation and sizing 
of the PCR products. Bands of the appropriate size were excised into 1.5ml Eppendorf tubes 
and were subjected to DNA extraction using a QIAEX II gel extraction kit (Qiagen) per 
manufacturer’s instructions.  
2.9.7 Pyrosequencing to define levels of mutated mtDNA 
The final PCR amplification products were used to define the levels of mutated mtDNA in 
Purkinje cells and presynaptic terminals of patients harbouring the m.3243A>G and 
m.8344A>G point mutations. Depending on the intensity of the bands on the agarose gel, 10µl 
or 20µl of PCR product were combined with 28µl or 18µl of DEPC-treated water (Life 
Technologies), 40µl PyroMark binding buffer (Qiagen), and 2µl Streptavidin sepharose™ high 
performance beads (GE Healthcare) to give 80µl volumes of the binding solution. The samples 
were agitated for 10 minutes to promote DNA binding to the beads and were then transferred 
to the PyroMark Q24 workstation (Qiagen). A hedgehog (Qiagen), attached to a dry vacuum 
pump (Welch), was used to drive the samples through 70% Ethanol (5 seconds), denaturation 
solution (0.2M NaOH) (5 seconds) and 1x PyroMark wash buffer (Qiagen) (10 seconds). The 
vacuum pump was then turned off and the hedgehog was held at an angle before immersing it 
into a 25µl sequencing solution in a 24 well pyrosequencing plate to release the beads. The 
sequencing solution consisted of 24.25µl PyroMark annealing buffer (Qiagen) and 0.75µl 
pyrosequencing primer specific to either the m.3243A>G or the m.8344A>G assay (Table 2.4). 
DNA denaturation of the samples and annealing of the pyrosequencing primer required heating 
at 80oC for 2 minutes and cooling at room temperature for 5 minutes minimum. The PyroMark 
Q25 cartridge (Qiagen) was then loaded with the appropriate volumes of PyroMark Gold Q24 
reagents (Qiagen), enzyme mix (DNA polymerase, ATP sulfurylase, luciferase and apyrase), 
substrate mix (adenosine 5’ phosphosulfate and luciferin) and dNTPS, suggested by the 
PyroMark Q24 software (Qiagen). The m.3243A>G or m.8344A>G assay was selected on the 
PyroMark Q24 platform (Qiagen) with each plate containing Purkinje cell samples, presynaptic 
terminal samples, WT and known heteroplasmy DNA. Once the pyrosequencing run was 
finished, results were uploaded on to and analysed using the allele quantification application of 
the PyroMark Q24 software (Qiagen). If the mutation load for WT and known heteroplasmy 
samples was within 4% of the expected value, the heteroplasmy levels for the samples to be 
tested were averaged amongst the triplicates.  
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Chapter 3 Optimisation of a quadruple immunofluorescence assay to 
quantify respiratory chain subunit expression in human brain tissues 
3.1 Introduction 
3.1.1 Detection and quantification of respiratory chain deficiency 
The electron transport chain (ETC), composed of four complexes and two mobile electron 
carriers, is located in the inner mitochondrial membrane and along with complex V (ATP 
synthase), constitutes a vital part of the oxidative phosphorylation system responsible for ATP 
production in mitochondria (Hatefi, 1985). Of the respiratory chain complexes, complexes I 
and IV are most frequently deficient in patients with primary mitochondrial disease (DiMauro 
and Schon, 2003; Swalwell et al., 2011), hence many studies focus on studying the enzymatic 
activity and/or protein expression levels of the different complex subunits. 
In order to assay the enzymatic activities of the mitochondrial respiratory chain, two approaches 
can be used, one which relies on fresh tissues to measure enzyme activities using 
spectrophotometry (Kirby et al., 2007) and the other on sequential cytochrome c oxidase 
(COX)/succinate dehydrogenase (SDH) histochemistry performed on frozen tissue sections 
(Old and Johnson, 1989). COX/SDH histochemistry was originally developed to measure the 
enzymatic activity of complex IV (COX) relative to complex II (SDH) at the single cell level 
in human skeletal muscle (Old and Johnson, 1989) and was employed to determine the level of 
COX-deficiency in muscle fibres of patients with mitochondrial myopathy (Sciacco et al., 
1994). Complex II (SDH) consists entirely of nuclear DNA-encoded subunits, and its activity 
gives some indication of mitochondrial mass. COX on the other hand has both nuclear and 
mitochondrial DNA-encoded subunits (Chinnery et al., 2008), making this respiratory chain 
complex vulnerable to mitochondrial DNA defects and therefore deficiency. Hence, COX/SDH 
histochemistry in skeletal muscle has traditionally been used as means for the clinical diagnosis 
of patients with mitochondrial disease.  
Since similar histochemical assays are not available for complex I, measuring the enzymatic 
activity for this respiratory chain complex is not feasible on a single cell level (Grünewald et 
al., 2014). Instead, enzymatic activity is quantified spectrophotometrically using homogenised 
tissue, and protein expression is evaluated through immunohistochemistry (IHC) using 
monoclonal antibodies and chromogens to visualise the protein of interest.  
Employing the techniques mentioned above, enzymatic activity can only be reliably detected 
in homogenate tissues using spectrophotometry or by COX/SDH histochemistry; while protein 
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expression can be measured by presence or absence of DAB staining (IHC). The current 
methods do not account for mitochondrial mass and are dependent on the subjective 
interpretation of the pattern of staining. Hence, any mild or intermediate changes in respiratory 
chain protein expression may be overlooked.  
Patients with mitochondrial disease have been extensively documented to be affected with a 
wide spectrum of neurological deficits (McFarland et al., 2010), whilst research demonstrates 
the far-reaching signs for structural and functional neuronal abnormalities in the brains of 
patients with mitochondrial disease. Taking into careful consideration the urgent need for 
understanding the mechanisms that account for neuronal loss in mitochondrial disease 
combined with the short comings of current protein expression quantification techniques, one 
realises the necessity for developing a quantitative multiple immunofluorescent protocol that 
would enable the simultaneous exploration of neuronal network organisation and respiratory 
chain protein expression.  
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3.2 Aims 
The major aim of this study was to develop a quantitative immunofluorescent method to allow 
precise detection of multiple proteins of interest, including mitochondrial respiratory chain 
subunits within specific neuronal subtypes, synapses and blood vessels. More specifically I 
aimed to: 
1. Optimise a quadruple immunofluorescent technique that would allow the simultaneous 
detection of neuronal cell bodies, inhibitory synapses and mitochondrial populations 
within these.  
2. Distinguish the mitochondria found in neuronal cell bodies from those located within 
presynaptic terminals, which would enable the precise and reliable quantification of key 
respiratory chain protein subunits within each neuronal sub-compartment.  
3.3 Samples 
3.3.1 Cerebellar tissue samples 
FFPE cerebellar tissue sections (5μm thick) from ten cognitively-normal controls were 
employed to develop an immunofluorescent protocol for respiratory chain protein expression 
investigation in neuronal and sub-neuronal compartments. Tissue sections were obtained from 
the NBTR and the MRC Sudden Death Brain and Tissue Bank, Edinburgh. Neuropathological 
details of controls included in this study are summarised in Table 3- 1.  
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3.4  Methodological approach 
3.4.1 Immunohistochemistry for synaptic and mitochondrial protein expression  
Neuropathological studies conducted on patients with mitochondrial disease suggest an 
intrinsic vulnerability of cerebellar Purkinje cells to mitochondrial defects and highlight their 
central importance to the development of cerebellar ataxia. Extensive neuronal loss is 
accompanied with respiratory chain protein deficiencies in remaining cells, whilst the synaptic 
connections between Purkinje cells and dentate nucleus neurons can appear abnormal (Tanji et 
al., 1999; Lax et al., 2012). These features highlight the need to study the intra-cerebellar 
circuitry in greater detail, including the investigation of structural synaptic characteristics and 
respiratory chain protein expression within these.  
For the purpose of this study 5μm-thick FFPE control cerebellar tissue sections were subjected 
to immunohistochemical staining according to the protocol described in section 2.6. The general 
presynaptic marker synaptophysin and the GABA-specific neuronal and axonal terminal 
marker GAD-65/67 were employed in order to study the amount, the distribution and the 
structural characteristics of synapses to the dentate nucleus. As revealed in Figure 3- 1, 
synaptophysin immunoreactivity indicates synaptic connections on Purkinje cell bodies and 
dendrites in the Purkinje cell layer and highlights the presence of glomeruli in the granule cell 
layer of the cerebellar cortex. At the dentate nucleus, synaptophysin is abundantly expressed 
with punctate staining surrounding large glutamatergic (GADnL) and smaller 
GABAergic/glycinergic (GAD +) neurons. GAD-65/67 is diffusely expressed in Purkinje cells 
due to their inhibitory (GABAergic) nature, outlining neuronal bodies and dendrites at the 
molecular layer (Figure 3- 2). The protein is also widely expressed at the boundaries and in 
some circumstances at the cell body of dentate nucleus neurons. When at the periphery of 
neurons, GAD immunoreactivity indicates the presence of inhibitory presynaptic terminals 
contacting dentate nucleus neurons, while cytoplasmic GAD stain is reminiscent of the presence 
of local GABAergic neurons (Uusisaari and Knöpfel, 2013) (Figure 3- 2).  
Mitochondrial presence and distribution within neurons was examined following 
immunohistochemical staining against the outer mitochondrial membrane protein porin. As 
demonstrated in Figure 3- 3 (top panel) neurons contain a high density of mitochondria that are 
localised both within neuronal cell bodies and their neuritic processes. Similarly, a monoclonal 
antibody against NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8 (NDUFB8) 
was used to examine complex I protein expression in neurons and was indicative of cells with 
intact (black arrow), decreased (white asterisk) or absence (black asterisk) (compatible with 
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complex I deficiency) of complex I expression (Figure 3- 3) (middle panel). Furthermore, COX 
subunit protein expression was studied using chromogen stain against cytochrome c oxidase 
subunit 1 (COX1) (Figure 3- 3) (bottom panel).  Some neurons were exhibitive of normal COX1 
protein levels (black arrow) while others had decreased protein expression (white asterisk).     
Despite the fact that synaptic proteins follow the expected pattern of expression and 
mitochondrial proteins indicate changes in protein expression levels, there are a number of 
factors that render chromogen immunohistochemistry and brightfield microscopy unsuitable 
for the type of analysis I am interested in performing. The pronounced levels of synaptic protein 
expression in the dentate nucleus neuropil makes single synapse identification challenging and 
often impossible (Figure 3- 1 and Figure 3- 2), while immunohistochemical staining for 
mitochondrial protein expression only enables the subjective identification of neurons which 
are intact, intermediate or negative for the protein of interest. Moreover, protein expression 
quantification using indirect immunohistochemistry is not reliable since the protein signal is 
amplified in a non-linear fashion, establishing the relationship between protein presence and 
signal inaccurate (Gustashaw et al., 2010). Chromogen immunohistochemistry is also 
restrictive since it only enables a single marker to be studied at a time. Hence, a direct 
comparison between synaptophysin and GAD expression, the potential use of synaptic and 
mitochondrial protein expression markers on the same tissue section or investigation of 
respiratory chain protein subunit loss relative to mitochondrial mass would not be feasible. 
Finally, two-dimensional brightfield microscopy does not provide the possibility to examine 
synaptic structural characteristics since synaptic size measurements cannot be derived from 2D 
datasets.  
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Figure 3- 3: Mitochondrial protein expression using immunohistochemical staining in control cortex.  
Top panel: Neuronal mitochondria are detected using the outer mitochondrial membrane protein porin/VDAC1 
as a mass marker. Cell bodies and processes (black arrows) contain high density of organelles, demonstrated by 
high DAB immunoreactivity. Middle panel: NDUFB8 is employed as a marker for complex I expression, 
highlighting intact (black arrow), decreased (white asterisk) and absence of immunoreactivity (black asterisk), 
compatible with complex I deficiency in neurons. Bottom panel: Complex IV subunit protein expression 
employing COX1 immunohistochemistry is denotive of neurons with normal (black arrow) and decreased (white 
asterisk) protein levels. Scale bar: 20μm 
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3.4.2 Optimal immunofluorescent staining conditions 
Bearing the drawbacks of chromogen immunohistochemistry into consideration, I have decided 
to optimise an immunofluorescence technique in order to investigate respiratory chain protein 
expression in different cellular populations and sub-cellular compartments (neuronal cell bodies 
and inhibitory presynaptic terminals here). 5μm-thick FFPE cerebellar tissue sections from 
neurologically normal controls were subjected to a standard immunofluorescent staining 
protocol as previously described (see section 2.7.1).  
I have decided to use mouse monoclonal antibodies against cytochrome c oxidase subunit 4 
(anti-COX4 (+4L2)) and NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 
(anti-NDUFA13) for mitochondrial identification and complex I protein expression 
investigation respectively. A mouse monoclonal antibody against the presynaptic protein 
synaptophysin (anti-SY-38) was employed for the identification of presynaptic terminals and a 
rabbit polyclonal antibody directed against Glutamic acid decarboxylase (anti-GAD-65/67) was 
used to mark GABAergic neurons and axonal terminals. The original choice of mitochondrial 
markers was based on pragmatic reasons. Since the majority of antibodies employed were raised 
in mice (Table 3- 2), different antibody isotypes should have been combined to avoid cross-
reactivity and unspecificity. COX4 is a nuclear DNA-encoded subunit of COX that was 
previously shown to be preserved in patients with mitochondrial disease (Lax et al., 2012), 
hence justifying its use as a mitochondrial mass marker. Moreover, NDUFA13 served as a 
marker for complex I deficiency since protein expression deficiencies were previously detected 
in our patients (Lax et al., 2012). 
Different antigen retrieval solutions were employed including Tri-sodium citrate (10mM) and 
EDTA (1mM), whereas different retrieval methods involved microwaving for 10 minutes and 
pressure cooking for 40 minutes. Likewise, serial dilutions of each of the antibodies were tested 
before the optimal working dilution for each was selected.   
The optimal staining conditions (summarised in Table 3- 2) were decided for each of the four 
markers based on the strength, the sub-cellular distribution and the specificity of protein 
expression. As shown in Figure 3- 4, both COX4 and NDUFA13 demonstrate punctate staining 
throughout cortical grey matter and high protein expression in control neurons (white arrows) 
indicative of densely packed neuronal mitochondria with preserved complex I protein subunit. 
Furthermore, synaptophysin is widely expressed in grey matter areas with each punctum 
representing a single axonal terminal, whereas GAD-65/67 stains the neuronal cytoplasm of 
GABAergic neurons (white arrow) and inhibitory presynaptic terminals in the cortex (punctate 
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staining throughout grey matter) (Figure 3- 4). Once single antibody immunofluorescence was 
optimised, double, triple and quadruple immunofluorescent staining followed so as to verify 
that antibody immunoreactivity was similarly strong and specific. Indeed, COX4 co-localised 
with NDUFA13 in neuronal cell bodies and processes, demonstrative of mitochondria with 
intact complex I protein expression (double IF) (Figure 3- 5). Synaptophysin (SY-38) 
expression was prominent around neurons, reminiscent of synaptic terminal presence, while 
GAD-65/67 was punctate and co-existed with SY-38 on the periphery of neurons suggestive of 
GABAergic presynaptic terminal convergence.     
Furthermore, antibody specificity and fluorescent channel crosstalk was tested after including 
no-primary-antibody (NPA) controls to the study. As verified in Figure 3- 6, each antibody is 
specific to the targeted protein since omitting  primary antibody incubation (one antibody 
omitted at a time) but still incubating the sections with all the secondary antibodies 
demonstrates an absence of immunoreactivity in the channel to be tested.  
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Table 3- 2: The optimal working conditions for each of the primary and secondary antibodies used for 
immunofluorescence 
Primary antibody Isotype Source
Catalogue 
No.
Antigen 
retrieval
Optimal 
dilution
Optimal 
incubation 
conditions
Synaptophysin (SY-38)
Mouse 
monoclonal - 
IgG1
DAKO M0776
EDTA (1mM); 
2100 antigen 
retriever
1 in 50 O/N at 4
o
C
Complex I subunit NDUFA13
Mouse 
monoclonal - 
IgG2b
Abcam ab110240
EDTA (1mM); 
2100 antigen 
retriever
1 in 100 O/N at 4
o
C
Complex IV subunit IV
Mouse 
monoclonal - 
IgG2a
Abcam ab110261
EDTA (1mM); 
2100 antigen 
retriever
1 in 200 O/N at 4
o
C
Secondary antibody Isotype Source
Catalogue 
No.
Antigen 
retrieval
Optimal 
dilution
Optimal 
incubation 
conditions
Biotin-XX
Goat Anti-Mouse 
IgG1 (γ1)
Life 
technologies
A10519 N/A 1 in 100
30 
minutes, 
RT
Streptavidin, Alexa Fluor® 647 
Conjugate
N/A
Life 
technologies
S32357 N/A 1 in 100
30 
minutes, 
RT
Alexa Fluor® 405
Goat Anti-Rabbit 
IgG (H+L)
Life 
technologies
A31556 N/A 1 in 100
30 
minutes, 
RT
Alexa Fluor® 488
Goat Anti-Mouse 
IgG2b (γ2b)
Life 
technologies
A2114 N/A 1 in 100 1 hour, RT
Alexa Fluor® 546
Goat Anti-Mouse 
IgG2a (γ2a)
Life 
technologies
A21133 N/A 1 in 100
30 
minutes, 
RT
Glutamic acid decarboxylase 
65/67 (GAD 65/67)
Rabbit 
polyclonal - IgG
Sigma-
Aldrich
G5163
EDTA (1mM); 
2100 antigen 
retriever
1 in 800 O/N at 4
o
C
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Figure 3- 4: Optimised single immunofluorescence against mitochondrial and synaptic protein markers of 
interest.  
COX4 is employed as a mitochondrial mass marker and demonstrates punctate staining in grey matter neuropil and 
neurons (white arrow). Similarly, the complex I protein expression marker NDUFA13 is punctate in cortical grey 
matter and is enriched neurons, indicative of complex I intact cells. Synaptophysin (SY-38) is reminiscent of axonal 
terminal convergence and GAD-65/67 stains for inhibitory neurons (white arrows) and GABAergic synaptic 
terminals. Scale bar: 20μm. 
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Figure 3- 6: NPA controls for cross-reactivity and assay specificity checks.  
Control A: Section stained with all four markers is demonstrative of positive staining in all channels. Omission of 
GAD-65/67 (Control B), SY-38 (Control C), COX4 (Control D) or NDUFA13 (Control E) is accompanied by 
absence of signal in the corresponding channel. Scale bar: 10μm 
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3.4.3 Autofluorescence and Sudan Black b treatment 
Tissue autofluorescence is a natural phenomenon which occurs either due to the intrinsic 
properties of the tissue under investigation or is induced during tissue processing (Baschong et 
al., 2001). Nevertheless, autofluorescence is an important restricting factor when it comes to 
immunofluorescence analysis since it may mask true fluorescence or may be mistaken for the 
fluorescent label (Del Castillo et al., 1989; Noonberg et al., 1992; Viegas et al., 2007). 
Amongst the reagents frequently used to eliminate tissue autofluorescence is Sudan Black b 
(SB) (Baschong et al., 2001) thus I have performed immunofluorescence with (+) or without (-
) SB treatment to test for the this reagent’s effectiveness in removing background signal and 
tissue autofluorescence. Control FFPE sections (5µm thick) were subjected to a standard 
immunofluorescent protocol (section 2.7.1), according to the previously optimised staining 
conditions, and included positive and NPA controls. Unspecific “staining” observed mainly in 
the NDUFA13 channel is removed after SB application for 10 minutes, whereas fluorescence 
emitted in NPA control sections is eliminated following reagent application (Figure 3- 7).  
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Figure 3- 7: The importance of Sudan Black b treatment in removing background and increasing 
signal-to-noise ratio.  
Scale bar: 10μm. SB-Sudan Black, NPA – no primary antibody 
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3.4.4 Respiratory chain protein expression in neuronal cell bodies and presynaptic 
terminals 
Purkinje cells utilise the inhibitory neurotransmitter GABA to suppress neurons of the deep 
cerebellar nuclei (Uusisaari and De Schutter, 2011), projecting inhibitory synapses mainly 
around neuronal cell bodies (axosomatic synapses). GAD-65/67 was uniformly and highly 
expressed in GABAergic neuronal cell bodies (GAD67) and inhibitory presynaptic terminals 
(GAD65) (Figure 3- 8) , in accordance to the anticipated subcellular distribution of the two 
enzymatic isoforms (Kaufman et al., 1991). Synaptophysin demonstrated strong and punctate 
staining surrounding neuronal cell bodies, representing presynaptic terminals. These terminals 
were suggestive of a mixture of excitatory and inhibitory synapses since only a portion of those 
co-localised with GAD65 (Figure 3- 8).  
COX4 was expressed strongly and abundantly, with each individual puncta indicating the 
presence of a potentially small network of mitochondria (Figure 3- 8). Though a nuclear DNA-
encoded subunit of complex I, NDUFA13 has been demonstrated to be necessary for complex 
assembly and stability (Angebault et al., 2015). Hence, by using NDUFA13 in combination 
with COX4 we can determine the relative loss of this complex I subunit.  
Similar to Purkinje cell bodies, GAD-65/67 is expressed in different neuronal compartments of 
dentate nucleus neurons. When expressed in the neuronal cytoplasm, GAD67 is suggestive of 
Glutamic acid decarboxylase synthesis and hence of inhibitory local neuron presence (Uusisaari 
and Knöpfel, 2013). When expressed around the neuronal cell body, GAD65 potentially 
represents the occurrence of GABAergic Purkinje cell axonal terminals. To verify the existence 
of presynaptic terminals, synaptophysin immunoreactivity was taken into consideration. Areas 
of co-localisation between SY-38 and GAD-65/67 around the dentate nucleus neuronal soma 
are indicative of GABAergic axonal terminal divergence (Figure 3- 9). COX4 protein 
expression is strong throughout the dentate nucleus grey matter ribbon and within inhibitory 
presynaptic terminals, the same was true for the NDUFA13 subunit of complex I (Figure 3- 9). 
The majority of synapses demonstrated a single COX4-positive punctum, likely to be 
reminiscent of a small mitochondrial network (microscopic resolution does not allow for 
identification of single mitochondria), co-existing with NDUFA13. 
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3.4.5 Confocal microscopy 
An A1R confocal system (Nikon) was employed since it presented with significant advantages 
over other, conventional microscopic systems. The inverted point scanning confocal 
microscope enabled three-dimensional image sampling, while the four spectrally unmixed 
lasers (405nm, 488nm, 561nm and 647nm) allowed high resolution, multi-channel images to 
be acquired. Moreover, confocal laser scanning microscopy eliminates out-of-focus light 
interference, thus generates images specific to the plane of view. 
 Areas of interest (neurons or blood vessels) were identified using the microscope eyepiece at 
x60 magnification whilst the depth of the tissue was specified using a Step-by-step Nikon A1 
Piezo Z scanner on the software surface (NIS-Elements, v4.2). Z-stacks were captured at x180 
magnification (x60 objective plus x3 digital zoom) and according to the recommended 
microscope settings: Pixel size: 0.14μm, z-step size: 0.175μm, optical resolution: 0.13μm and 
optical sectioning 0.54μm. Further to image acquisition, quadruple fluorescent beads 
(TetraSpeck™ Fluorescent Microsphere Standards; Invitrogen) were imaged in order to 
measure the system’s Point Spread Function (PSF).  
3.4.6 Image processing 
Since the data set acquired is three-dimensional, the appropriate 3D analysis software and 
analysis protocol is required in order to benefit from the advantages provided by laser scanning 
confocal microscopy. The Nikon files (.nd2) generated by the NIS-Elements software were 
imported into various different software, amongst which were the Volocity® 3D image analysis 
and deconvolution software (v.6.1.1, PerkinElmer) and IMARIS scientific 3D/4D Image 
processing & analysis software (Bitplane). Different analysis approaches were undertaken 
before the one that generated the desired output was selected.  
For studying respiratory chain protein expression in Purkinje cell bodies and inhibitory 
presynaptic terminals to dentate nucleus neurons, z stacks were initially cropped and 
deconvolved using the freehand tool and the “iterative restoration” function of the Volocity 
software respectively. Image cropping helped analyse single neurons, whereas deconvolution 
facilitated light re-assignment back to its original point source giving rise to crisper images 
(Sarder and Nehorai, 2006) (Figure 3- 10). Thus, identifying distinct synaptic terminals would 
be feasible and distinguishing somatic from synaptic mitochondria would be possible.  
Purkinje cell bodies were manually selected as “regions of interest”, whereas GABAergic 
synapses were identified as areas of SY-38  and GAD-65/67 co-localisation. Mitochondrial 
objects within each neuronal sub-compartment were then detected, using the deconvolved 
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COX4 channel as a reference and the “automatic threshold” function, and were employed to 
acquire intensity measurements for COX4 and NDUFA13 protein expression (Figure 3- 11).  
Furthermore, three-dimensional reconstruction of structures was made plausible since all 
images were sampled in x-, y- and z-planes.  As demonstrated in Figure 3- 11 and Video 3-1, 
fluorescent staining can be substituted by artificial surfaces and fine sub-neuronal 
compartments like synapses can be modelled. 
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3.4.7 Quantification of respiratory chain protein expression and Z scoring  
Once the mean optical density (OD) measurements for COX4 and NDUFA13 
immunofluorescence were acquired using the Volocity® software (PerkinElmer), data were 
initially analysed manually. The (NDUFA13)OD/(COX4)OD  ratio was used to calculate the 
amount of NDUFA13 protein expression relative to mitochondrial presence (COX4 employed 
as a mitochondrial mass marker).  
Later, the SAS (v.9.3) (Cary, NC) statistical software package was employed to generate z score 
values for each protein of interest, indicative of the degree of protein expression deviation from 
control values. Data normalisation and transformation was performed automatically, so was the 
estimation of regression parameters and standard error values. 
For each area of interest (Purkinje cell body or GABAergic presynaptic terminal) the measured 
OD values of COX4 and NDUFA13 immunofluorescence were background corrected. Since 
the data were not normally distributed, the background-corrected values were then log 
transformed to allow for data normalisation (yielding COX4T and NDUFA13T). The 
distribution for COX4T and the regression of NDUFA13T against COX4T were plotted and 
were used to estimate the mean and standard error (from the COX4T distribution) as well as 
the regression parameters and the standard error of the estimate (from the regression of 
NDUFA13T against COX4T). For each Purkinje cell or presynaptic terminal the z score for 
COX4 levels was calculated, while the z score for NDUFA13 levels deviated from the linear 
regression based on the level of COX4. Furthermore, areas of interest were classified based on 
standard deviation (SD) limits (for COX4 and NDUFA13: normal if -2< z <2SD, low if z <-
2SD, deficient if z <-3SD and very deficient if z <-4SD). 
For example, quantification of control inhibitory presynaptic terminals (however many 
synapses were detected around twenty randomly selected dentate nucleus neurons) 
demonstrates high protein expression levels for COX4 and NDUFA13 (Figure 3- 12). Indeed, 
statistical analysis and z scoring for the levels of COX4 and NDUFA13 indicated normal 
protein expression (-2< z <2SD) (Table 3- 3), consistent with a very low percentage of 
GABAergic axonal terminals that were low or deficient for either of the two proteins (Table 3- 
3).  
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Figure 3- 12: Boxplots for the standard deviation limits of COX4 and NDUFA13 protein 
expression in control GABAergic presynaptic terminals.  
The majority of inhibitory synapses have normal levels of COX4 (A) and NDUFA13 (B) protein 
expression, with few data points  above or below the normal ±2 SD limits. Blue boxplots: controls 
grouped; Purple boxplots: individual control samples. Each data point represents protein expression 
in a single GABAergic presynaptic terminal. 
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3.5 Discussion 
The severe neurological impairments affecting patients with mitochondrial disease highlight 
the need for developing a reliable, precise and reproducible quantitative immunofluorescent 
protocol that would facilitate the investigation of mitochondrial protein expression in the central 
nervous system. The increasing body of evidence for cerebellar vulnerability to mitochondrial 
dysfunction (Tanji et al., 1999; Hakonen et al., 2008; Lax et al., 2012) and the well-known 
structural and functional organisation of the cerebellum, enable its use as a tool for protocol 
development. 
Changes in mitochondrial proteins have previously been studied using conventional 
histochemical (COX/SDH) and immunohistochemical techniques. Despite the fact that 
COX/SDH histochemistry is an invaluable tool for identifying cells that are clearly deficient 
for COX (Ross, 2011), it relies on the subjective decision for the presence, absence or low 
immunoreactivity of DAB and does not allow subtle changes in protein activity to be detected. 
Similarly, indirect immunohistochemistry is semi quantitative, lacks correction for 
mitochondrial mass and requires a number of post-capture processing steps for it to serve as a 
reliable quantitative method (Taylor and Levenson, 2006; Nguyen, 2013). Furthermore, 
immunohistochemistry is restrictive in the number of proteins that can be examined per section, 
constituting the simultaneous investigation of several proteins impossible.  
Here I report the development of an accurate, quadruple immunofluorescent technique that 
relies on the densitometric quantification of fluorescence to determine protein expression 
levels. The intra-cerebellar circuitry and more specifically the Purkinje cell-dentate nucleus 
inhibitory synapse is employed as an example for establishing a method that allows respiratory 
chain protein expression investigation in neuronal and sub-neuronal compartments. Strong and 
punctate staining of the inhibitory neuronal and presynaptic terminal marker GAD-65/67 and 
the general synaptic marker SY-38 enables the detection of GABAergic neurons and inhibitory 
axonal terminals, whereas the abundant immunoreactivity of antibodies against NDUFA13 and 
COX4 facilitates the examination of complex I protein expression relative to mitochondrial 
mass. Moreover, laser scanning confocal microscopy and three-dimensional analysis software 
enable the detection of synaptic mitochondria and inhibitory presynaptic terminal 
reconstruction. Hence, a single cerebellar tissue section can be employed to simultaneously 
examine complex I protein expression in the Purkinje cell soma and its inhibitory presynaptic 
terminals and to further quantify the number and the size of synaptic connections established 
between Purkinje cells and dentate nucleus neurons.   
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The technique is specific in that there is absence of antibody cross-reactivity thus channel 
densitometry only reflects the extent of protein expression investigated at the time. The use of 
a similar quadruple immunofluorescent technique for the investigation of respiratory chain 
protein expression in dopaminergic midbrain neurons further verifies the reliability and 
reproducibility of the assay (Grünewald et al., 2014).  
3.5.1 Future work 
Given the evidence for cerebellar dysfunction and the extensive neuronal and synaptic 
abnormalities in patients with mitochondrial disease (Tanji et al., 1999; Lax et al., 2012), there 
needs to be an in depth study of the respiratory chain deficiencies in neuronal and sub-neuronal 
compartments and further a quantitative assessment of the type and nature of synaptic changes. 
Investigating the extent of respiratory chain protein deficiencies and of structural synaptic 
abnormalities and associating the observed neuropathological changes with the patients’ 
clinical phenotype is likely to provide further insights into disease mechanisms and explain for 
the progression of ataxia.  
Indeed, future work involves the employment of this quantitative quadruple immunofluorescent 
technique for the establishment of neuronal cell body and synaptic respiratory chain protein 
deficiencies and for the characterisation of synaptic morphological changes.  
3.6 Conclusion 
For the purposes of this study I have developed a quadruple immunofluorescent technique that 
serves as an objective, quantitative, reliable and reproducible alternative to the previously used 
histochemical and immunohistochemical methods. Simultaneous assessment of expression 
levels of four different proteins is made possible, while precise spatial distribution and 
morphological characterisation of synaptic terminals is possible. The method is versatile and 
can be adjusted to incorporate different markers depending on the research question at the time, 
hence serving as a valuable tool for quantifying the degree of protein expression changes in 
post-mortem brain tissue.
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Chapter 4 Cerebellar ataxia in patients with mitochondrial disease 
Part 1: Synaptic terminal pathology in the cerebellum of ataxic patients 
4.1 Introduction 
4.1.1 Cerebellar structure  
The cerebellum is crucial for muscle tone and motor movement coordination, critically defined 
by the fine harmonisation between ascending sensory and descending motor signals (Holmes, 
1939; Chambers and Sprague, 1955; Cooper, 1958). The structure is also important for 
cognition (Parsons and Fox, 1997; Thach and Thach, 1997), whilst recent studies on cerebellar 
dysfunction were exhibitive of its importance in language, working memory and decision-
making skills (Martin, 2002).  
The cerebellum is located on the posterior part of the brain, dorsal to the medulla and pons 
when viewed on a sagittal plane. The structure’s complex organisation drives its anatomic, 
phylogenetic and functional compartmentalisation. The cerebellum is divided into three sagittal 
zones (Martin, 2002; Apps and Garwicz, 2005) and further into ten lobules (I-X) (Voogd and 
Glickstein, 1998). Functionally, the cerebellum is organised into the spinocerebellum, the 
vestibulocerebellum and the pontocerebellum (cerebrocerebellum), which, as the names 
suggest receive, input from the spinal cord, the vestibular system and the cerebral cortex 
respectively (Rajakumar, 2013).  
The cortex, the medullary core of white matter and the deep cerebellar nuclei make up the basic 
cerebellar structure. The cortex is subdivided into three stratums – the molecular, Purkinje cell 
and granule cell layer- and contains two neuronal and three interneuronal populations. Cortical 
interneurons include the inhibitory stellate and basket cells, which reside within the molecular 
cell layer, and the inhibitory Golgi cells found at the granule cell layer. The excitatory granule 
cells constitute the most abundant neuronal subtype of the granule cell layer (and of the brain 
as a whole), whilst the inhibitory Purkinje cells form a distinct “neuronal ribbon” interjected 
between the granule and molecular cell layers (Martin, 2002). Furthermore, there are three types 
of deep cerebellar nuclei (DCN), the dentate, the fastigial and the interposed nucleus, which 
contain different neuronal/interneuronal populations with distinct electrophysiological 
capacities (Uusisaari and Knöpfel, 2013; Cohen, 2014).  
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4.1.2 Cerebellar connectivity 
Afferent signals to the cerebellum arrive from the inferior olive (IO), the brain stem and spinal 
cord. Excitatory climbing fibres (CF) project their axons from the IO and synapse onto Purkinje 
cells, evoking “complex spike” formation (Voogd and Glickstein, 1998; Apps and Garwicz, 
2005), and onto DCN neurons. Mossy fibres (MF), originating from the brain stem and spinal 
cord, indirectly excite Purkinje cells (via granule cell parallel fibres) (Voogd and Glickstein, 
1998; Apps and Garwicz, 2005; Rajakumar, 2013) and neurons of the DCN. Cerebellar 
efferents include DCN projections onto brainstem nuclei, the red nucleus of the midbrain and 
– via the thalamus – to premotor and primary motor cortices (Rajakumar, 2013). A summary 
of the intra- and extracerebellar circuitry is presented in Figure 4- 1.  
The Purkinje cell-dentate nucleus neuronal synapse is the main component of intracerebellar 
circuitry, since Purkinje cells are the sole output neurons from the cerebellar cortex, projecting 
their synapses onto deep cerebellar nuclei (Uusisaari and De Schutter, 2011). Synaptic 
communication between the two neuronal populations is established via the inhibitory 
neurotransmitter γ-aminobutyric acid (GABA). The majority of Purkinje cell axonal terminals 
form connections on the dentate nucleus neuronal soma (cell body), giving rise to axosomatic 
synapses, with some synapses also being formed on neuronal dendrites or axons (axodendritic 
and axoaxonic synapses respectively).  
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Figure 4- 1: A summary of the intra- and extracerebellar circuitry.  
The cerebellum receives efferents from the inferior olive, the brain stem and the spinal cord. Climbing fibres 
arise from the inferior olive, project onto and excite Purkinje cells (located in the cerebellar cortex) and deep 
cerebellar nuclei (DCN). Mossy fibres, originating from precerebellar nuclei (brainstem and spinal cord), 
project their excitatory presynaptic terminals onto DCN and indirectly excite Purkinje cells (via granule cells). 
Intracerebellar connectivity is established via the inhibitory Purkinje cell-dentate nucleus neuronal synapse. 
GABAergic Purkinje cells contact DCN (principally dentate nucleus neurons), which form local feedback and 
global signal transduction networks by projecting their axons to the brainstem, red nucleus, premotor and 
primary motor cortices.  
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4.1.3 Cerebellar ataxia 
“Lack of order” and inability to coordinate voluntary movement broadly defines ataxia. 
Amongst the pioneers in recognising and characterising the condition were Babinski (1899) and 
Holmes (1939) who introduced the terms “asynergy” (Babinski, 1899) and “delayed initiation” 
of voluntary movements (Holmes, 1939) to describe this pathological state. Damage to or 
dysfunction of the cerebellum or of its input/output pathways result in cerebellar ataxia 
(Marsden and Harris, 2011), with associated symptoms including dyssynergia, dysmetria, 
tremor, dysdiadochokinesia, asthenia and hypotonia, balance and gait dysfunction as well as 
dysarthria and oculomotor deficits (Klockgether, 2000).  
Cerebellar dysfunction and altered intra- and extra-cerebellar connectivity is the pathological 
hallmark of many inherited ataxias including Spinocerebellar and Friedreich’s ataxia (Scherzed 
et al., 2012; Koeppen et al., 2013). Proteins involved in hereditary forms of ataxia are associated 
with mitochondria and in fact, mitochondrial dysfunction is involved in the 
neuropathological/neurodegenerative profiles of Spinocerebellar (Das et al., 2010; Sykora et 
al., 2011), spastic (Girard et al., 2012) and Friedreich’s ataxia (Gonzalez-Cabo and Palau, 
2013). 
The intrinsic vulnerability of the cerebellum to mitochondrial dysfunction can be explained by 
its remarkably high neuronal density. Although it only occupies 10% of the brain’s volume, the 
cerebellum contains 50% of the brain’s total neuronal population (Knierim, 1997). Neural 
computation models for the estimation of energy required for signalling on principle cerebellar 
cells – Purkinje cells – estimates that  ̴10 11 molecules of ATP are required per second (Howarth 
et al., 2010). Surprisingly, the increased density and the excitatory nature of another cerebellar 
neuronal cell type –granule cells – implies that these cells outrank Purkinje neurons in terms of 
their energetic requirements (Howarth et al., 2010). Thus, a considerable amount of energy is 
necessary to maintain cerebellar neuron function, assuring for the structural and functional 
preservation of the region (Knierim, 1997). 
4.1.4 Mitochondrial disease and cerebellar ataxia 
Bearing in mind the frequent involvement of mitochondria in the pathogenesis of several 
hereditary ataxias (Das et al., 2010; Sykora et al., 2011; Girard et al., 2012; Gonzalez-Cabo 
and Palau, 2013), it comes as no surprise that patients with mitochondrial disease are frequently 
and severely affected by cerebellar ataxia. The increased metabolic demand of the CNS 
combined with the importance of mitochondria in providing the cells with the energy they 
require, explains the severe neurological impairments of patients with mitochondrial disease. 
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Despite the plethora of neurological deficits, including sensorineural deafness, cognitive 
decline and stroke-like episodes (McFarland et al., 2010), cerebellar ataxia is the most 
frequently presenting symptom. In fact, approximately 70% of the patients recruited to the UK 
MRC Mitochondrial Disease Patient cohort are affected by ataxia which is progressive and  
very disabling (Lax et al., 2012; Nesbitt et al., 2013).  
The recently developed and validated Newcastle Mitochondrial Disease Adult rating Scale 
(NMDAS) is routinely employed by neurologists in order to assess patient progression and 
decide on personalised patient care (Schaefer et al., 2006). According to the NMDAS scale for 
cerebellar ataxia, patients are scored with 0-5. A score of zero indicates an absence of 
phenotype, whereas 5 is given to patients that are severely impaired and as such become 
wheelchair-dependent. The highly heterogenic and multisystemic nature of mitochondrial 
disorders implies that cerebellar ataxia affects patients with different genetic diagnoses to a 
currently unpredicted extent. Valuable work has been performed into understanding the 
progression of ataxia in patients with the m.3243A>G point mutation, suggesting that patient 
age and urine heteroplasmy levels can collectively help predict the severity of the ataxic 
phenotype. However, there is more left to do before we can confidently predict patients’ 
progression (Grady, 2013).  
Cerebellar abnormalities are routinely detected though neuroradiological imaging (Lax and 
Jaros, 2012). Patients with the Kearns-Sayre syndrome (KSS) demonstrate an atypical 
cerebellar structure (upon neuropathological examination) (Barkovich et al., 1993), with 
Purkinje cell loss from the cerebellar cortex (Tanji et al., 1999), spongiform deterioration of the 
white matter (Oldfors et al., 1990; Tanji et al., 1999) and decreased synaptic input to the dentate 
nuclei microscopically detected (Tanji et al., 1999). Cerebellar ataxia is a prominent feature of 
patients with the myoclonus epilepsy with ragged-red fibres (MERRF) syndrome (Austin et al., 
1998; McFarland et al., 2002). Patient brains have atrophic pons, cerebellar hemispheres and 
middle and superior cerebellar peduncles (Ito et al., 2008). Neuropathologically, cerebellar 
lesions are pronounced (Fukuhara, 1991) whilst neuronal loss affects the inferior cerebellar 
cortex (Lax et al., 2012). Similarly, enlarged fourth ventricles in patients with mitochondrial 
encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), due to the m.3243A>G 
point mutation, are reminiscent of the presence of cerebellar atrophy (Sue et al., 1998). MELAS 
patients present with severe cerebellar neuropathological abnormalities, some of which include 
neuronal loss, axon demyelination and microinfarct presence (Lax et al., 2012). Generalized 
pontocerebellar atrophy is evident in patients with the neurogenic weakness, ataxia and retinitis 
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pigmentosa (NARP) syndrome (Renard and Labauge, 2012). Ataxia also affects patients with 
secondary mitochondrial disease, due to mutations in mtDNA maintenance genes. Autosomal 
recessive polymerase γ (POLG) gene mutations have been associated with cerebellar ataxia 
(Van Goethem et al., 2004; Tzoulis et al., 2006), whereas neuronal loss in both the midbrain 
and the cerebellum of a patient suffering from multiple mtDNA deletions, due to recessive 
POLG mutations, were also detected (Betts-Henderson et al., 2009).  
4.1.5 Synaptic plasticity and mitochondria 
The highly sophisticated neuronal structure ensures the formation of dynamic and functional 
networks with extensive energetic demands which can render neurons vulnerable to fluctuations 
in mitochondrial function. Specific neuronal sub-compartments, including synapses, are more 
metabolically active than others accounting for the increased mitochondrial density in these 
regions (Hollenbeck and Saxton, 2005). As a matter of fact, synaptic mitochondrial function 
goes beyond energy production, ensuring structural integrity and functional maintenance of the 
synaptic compartment. A summary of synaptic mitochondrial function is provided in Figure 4- 
2. 
More specifically, signal transduction and synaptic transmission requires most of the ATP 
produced in the brain as demonstrated from studies on rat cerebral (Attwell and Laughlin, 2001) 
and human cortices (Lennie, 2003). Cortical regions enriched with neurons, and high synaptic 
density, consume considerable amounts of energy (Harris et al., 2012), whereas ATP supplied 
by mitochondria is required by both axonal terminals and neuronal dendrites (pre- and post-
synaptic compartments respectively) for synaptic transmission to take place.  
Action potential initiation at the presynapse requires ionic flux balance, regulated by 
mitochondrial-generated ATP which ensures for fine tuning of ionic pumps (Attwell and 
Laughlin, 2001). Additionally, synaptic activity was demonstrated to “drive” synaptic 
mitochondrial density (Brodin et al., 1999), whereas ATP supply from mitochondria is needed 
for synaptic vesicle transport (Verstreken et al., 2005), exocytosis and recycling (Rowland et 
al., 2000; Perkins et al., 2010). Post-synaptically, the energy required for reversal of ionic 
gradients created following excitation (Harris et al., 2012), and to a much lesser extent 
following inhibition (Howarth et al., 2010), is provide by mitochondria.  
Further to ATP production, calcium buffering by mitochondria is essential for the establishment 
of neuronal polarity and thus for axonal differentiation (Mattson and Partin, 1999). Also, 
maintenance of synaptic transmission capacity following  tetanic stimulation in glutamatergic 
synapses is achieved thanks to mitochondrial calcium buffering that ensures for rapid recovery 
Chapter 4                                               Cerebellar ataxia in patients with mitochondria disease 
103 
 
(Billups and Forsythe, 2002). Moreover, studies performed on hippocampal neuronal cultures 
(Kang et al., 2008), hippocampal slices (Levy et al., 2003) and crayfish neuromuscular 
junctions (Tang and Zucker, 1997) are demonstrative of the importance of mitochondrial 
calcium buffering in synaptic plasticity.  
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Figure 4- 2: Synaptic mitochondrial functions. 
Mitochondria are enriched at synaptic sites (axonal terminals and neuronal dendrites), where their 
function is crucial for synaptic transmission. At the presynaptic terminal, mitochondrial generated 
ATP is used to drive synaptic vesicle transport, release and endocytosis (synaptic vesicle recycling), 
regulate ionic fluxes necessary for action potential propagation (via fuelling ATPases) and motor-
protein assisted organelle transport to/from the synapse. Postsynaptic mitochondria are essential for 
synaptic transmission preservation since mitochondrial ATP production and calcium buffering 
capacities are key for reversing ionic gradients generated following transmitter release and uptake. 
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4.1.6 Evidence of synaptic pathology in mitochondrial disease 
Generalised neurodegeneration observed in post-mortem brain samples from patients with 
mitochondrial disease is accompanied by structural abnormalities, specific to neuronal sub-
compartments. The synaptic terminal connections linking the Purkinje cells to dentate nucleus 
neurons within the cerebellum have been the centre of attention, since these efferents constitute 
the main component of the intracerebellar circuitry (Uusisaari and De Schutter, 2011). 
Detailed neuropathological studies performed by Lax and colleagues (2012) demonstrated 
decreased Purkinje cell efferent density to the dentate nucleus of patients carrying the 
m.3243A>G and m.8344A>G point mutations, despite Purkinje cell number preservation in the 
cerebellar cortex (Lax et al., 2012). Moreover, “ghost synapses” were present in the dentate 
nucleus of a patient harbouring the m.14709T>C point mutation, which consisted of large 
presynaptic structures (detected following synaptophysin immunoreactivity) in the absence of 
postsynaptic dentate nucleus neurons (Lax et al., 2012).  Likewise, Tanji and co-workers (1999) 
employed synaptophysin and Calbindin immunohistochemistry in KSS patients to demonstrate 
the decrease in axonal terminal density and the existence of sparse and swollen Purkinje cell 
terminals to the dentate nucleus respectively (Tanji et al., 1999).  
Changes in the number and structural characteristics of Purkinje cell presynaptic terminals were 
followed by abnormalities in neuronal dendrites and regions proximal to Purkinje cell bodies. 
Main observations include swollen axons, known as “Torpedoes”, and thick dendritic trees 
which are extensively arborized (Lax et al., 2012).  
The importance of mitochondrial presence and function in synaptic structural integrity and 
functional preservation is also demonstrated through the use of genetic modification techniques 
and cell culture/animal models. Mitochondrial localisation in dendritic protrusions following 
repetitive excitation favour the formation of new spines, whereas altered mitochondrial 
dynamics, via disturbed fusion/fission balance, results in decreased mitochondrial density in 
dendrites and decline in dendritic spine number (Li et al., 2004). Moreover, disturbed Optic 
Atrophy 1 (OPA1) gene expression in mice is indicative of a link between mitochondrial 
dynamics, mitochondrial localisation and synaptic density. 10-15 month old mice heterozygous 
for OPA1 (a mitochondrial fusion protein) were demonstrative of mitochondrial fragmentation 
with retraction back to the soma and a consequent decrease in retinal ganglion cell synaptic 
density (Williams et al., 2012). Finally, mutations of the mitochondrial fission protein 
Dynamin-related protein1 (Drp1) results in mitochondrial absence from the synapse in fly 
models (Drosophila melanogaster). In spite of maintained basal synaptic function under resting 
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conditions, flies are unable to transduce neuronal signals after high (10Hz) electrical current 
application (Verstreken et al., 2005).   
4.1.7 Synaptic protein expression 
Bearing in mind Purkinje cell vulnerability to mitochondrial dysfunction, the importance of 
deep cerebellar nuclei in controlling cognition, emotion and language and mitochondrial 
significance in maintaining synaptic structure and function, I have decided to investigate 
dentate nucleus neuronal innervation with a focus on the Purkinje cell-dentate nucleus neural 
synapse.  
GABA synthesis requires the enzymatic activity of Glutamic acid decarboxylase (GAD) that 
acts to convert L-glutamate into the inhibitory neurotransmitter (Erlander and Tobin, 1991). 
GAD exists in two isoforms, GAD65 and GAD67, which are encoded by two distinct genes 
and have differential neuronal distributions (Erlander et al., 1991). The 67kDa isoform 
(GAD67) is expressed throughout the neuronal cell, while the 65kDa isoform (GAD65) is 
specific to presynaptic terminals (Kaufman et al., 1991).  
One of the key presynaptic proteins is synaptophysin, the most abundant (by mass) glycoprotein 
(Takamori et al., 2006) that surrounds SVs (Jahn et al., 1985). Synaptophysin is equally present 
in glutamate- and GABA-containing SVs (Takamori et al., 2000a; Takamori et al., 2000b) and 
has been demonstrated to control SV endocytosis following neurotransmitter release (Kwon 
and Chapman, 2011). Hence, synaptophysin is useful for determining the presence of a 
presynaptic terminal, regardless of the nature of the synaptic connection (excitatory or 
inhibitory). 
Taking into consideration the expected neuronal distribution for GAD-65/67 and 
synaptophysin, these two markers can be used in conjunction in order to closely investigate the 
cerebellar microcircuitry. GAD67 will enable the detection of inhibitory Purkinje cell bodies 
within the cerebellar cortex, while areas of co-localisation between GAD65 and synaptophysin 
could be indicative for the presence of Purkinje cell efferents onto dentate nucleus neurons.   
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4.2 Aims of the study 
Notwithstanding the clinical relevance of the cerebellum to mitochondrial disease and the 
previous detailed neuropathological studies in patients with mitochondrial disease, the presence 
and extent of respiratory chain defects in and the morphological characteristics of synapses 
have never been the point of focus. Hence, this study aims to answer the following questions: 
1. Is there evidence of mitochondrial dysfunction in Purkinje cell synapses?  
2. If so, does synaptic mitochondrial dysfunction have any effects on synaptic 
morphology and/or density? 
3. Could these changes represent a primary event in neuronal degeneration? I.e. is 
mitochondrial disease a synaptopathy? 
 I will achieve these by combining a validated quantitative immunofluorescent technique with 
sophisticated molecular biology methods to evaluate the distribution of respiratory chain 
deficiencies and assess the degree of synaptic and dendritic morphological abnormalities. The 
frequent involvement of the cerebellum in mitochondrial disease and the simplistic architecture 
of the intracerebellar circuitry provide the possibility to employ the Purkinje cell-dentate 
nucleus synapse as a tool to gain more mechanistic insights into cerebellar ataxia and to further 
understand the importance of synapses in neurodegeneration due to mitochondrial disease. 
4.3 Methodology 
4.3.1 Cerebellar tissue samples 
This study involves the neuropathological investigation of twelve adult patients who have been 
clinically and genetically diagnosed with mitochondrial disease.  The patients were routinely 
assessed by neurologists using the validated  Newcastle Mitochondrial Disease Adult Scale 
(NMDAS) (Schaefer et al., 2006), while the scores for cerebellar ataxia confirm that all patients 
included in this study  were ataxic. Patient clinical and neuropathological details are 
summarised in Table 4- 1. 
Ten cognitively normal controls that were matched for age and post-mortem interval (PMI) 
with patients were included in the study (Age: Mann Whitney U test, p value =0.3390; PMI: 
Mann Whitney U test, p value =0.7667). Patient and control tissue characteristics are 
summarised in Table 4- 2.  
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Type 
Age 
(years) 
Sex 
Length of 
fixation 
(weeks) 
Post-mortem 
delay (hours) 
Cause of death Source 
Control 2 68 Male 8 54 Bowel cancer NBTR 
Control 3 78 Female 5 23 
metastatic oesophageal 
carcinoma 
NBTR 
Control 4 74 Female 13 67 Lung cancer NBTR 
Control 9 78 Female 8 34 
Metastatic cancer - 
primary origin unknown 
(probably ovarian) 
NBTR 
Control 11 48 Male 1 72 
Coronary artery 
atherosclerosis 
Edinburgh 
Control 12 48 Male 1 46 
Coronary artery 
atherosclerosis 
Edinburgh 
Control 13 61 Male 1 61 ND Edinburgh 
Control 14 48 Male 1 43 
Coronary artery 
thrombosis and 
atherosclerosis 
Edinburgh 
Control 15 25 Male 1 53 ND Edinburgh 
Control 16 44 Male 1 83 
Complications of 
bronchopneumonia and 
coronary artery 
atherosclerosis 
Edinburgh 
Patient 1 36 Female 1 42 Cardiac arrest NBTR 
Patient 2 60 Female 6 10 Multi-organ failure NBTR 
Patient 3 30 Male 10 69 Mitochondrial disease NBTR 
Patient 4 45 Female 8 43 Mitochondrial disease NBTR 
Patient 5 20 Male 6 187 
Aspiration, pneumonia 
and MELAS 
NBTR 
Patient 6 57 Male 50 36 Cardiac failure NBTR 
Patient 7 42 Male 8 59 Respiratory failure NBTR 
Patient 8 58 Male 6 66 Mitochondrial disease NBTR 
Patient 9 59 Female 4 67 Mitochondrial disease NBTR 
Patient 10 79 Female 8 85 Mitochondrial disease NBTR 
Patient 11 55 Male 7 112 Mitochondrial disease NBTR 
Patient 13 55 Male 17 10 Mitochondrial disease NBTR 
Table 4- 2: Characteristics of control and patient post-mortem tissue included in this study. 
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4.3.2 Immunofluorescence  
Various different immunofluorescent experiments were performed depending on the research 
question at the time, though all protocols employed were slightly modified versions of the 
previously developed immunofluorescent technique (Chapter 3 of this thesis and section 2.7.1). 
For evaluating complex I protein expression in Purkinje cells bodies and axonal terminals, 5μm-
thick FFPE cerebellar tissue sections were immunofluorescently stained according to the 
protocol described in Chapter 3 of this thesis (section 3.4) (see Table 2- 3 for primary and 
secondary antibody combination). Triple immunofluorescence was used to study complex I 
protein expression in Purkinje cell dendrites and involved the use of primary and secondary 
antibodies included in Table 4- 3.  
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Table 4- 3: Primary and secondary antibodies used in this study along with their optimal working 
conditions. 
Primary antibodies
Host and 
isotype
Source
Catalogue 
No.
Antigen retrieval
Optimal 
dilution
Optimal 
incubation 
conditions
Calbindin (D-28k)
Mouse 
monoclonal - 
IgG1
Swant CB300
EDTA (1mM); 
2100 antigen 
retriever
1 in 1000 O/N at 4
o
C
Complex I                 
subunit NDUFA13
Mouse 
monoclonal - 
IgG2b
Abcam ab110240
EDTA (1mM); 
2100 antigen 
retriever
1 in 100 O/N at 4
o
C
Complex IV              
subunit IV
Mouse 
monoclonal – 
IgG2a
Abcam ab110261
EDTA (1mM; 2100 
antigen retriever)
1 in 200 O/N at 4
o
C
Secondary antibodies
Host and 
epitope
Source
Catalogue 
No.
Antigen retrieval
Optimal 
dilution
Optimal 
incubation 
conditions
Alexa Fluor® 647
Goat Anti-
Mouse IgG1 
(γ1)
Life 
technologies
A21240 N/A 1 in 100 1 hour, RT
Alexa Fluor® 488
Goat Anti-
Mouse IgG2b 
(γ2b)
Life 
technologies
A21141 N/A 1 in 100 1 hour, RT
Alexa Fluor® 546
Goat Anti-
Mouse IgG2a 
(γ2a)
Life 
technologies
A21133 N/A 1 in 100 1 hour, RT
Triple immunofluorescence
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4.3.3 Confocal microscopy and image processing 
Immunofluorescently stained sections were imaged using an inverted point scanning confocal 
microscope (Nikon A1R) as described earlier (section 2.8.1 and 3.4.5). Z stacks were acquired 
for twenty randomly selected neurons - according to the recommended microscope settings - 
and were employed for image analysis.  
Respiratory chain protein expression quantification in neuronal cell bodies involved outlining 
and defining the soma as a “ROI”. Purkinje cell neuronal dendrites were identified due to their 
calbindin immunoreactivity and were manually cropped, whereas GABAergic synapses were 
identified as the regions of co-localisation between GAD-65/67 and SY-38 around dentate 
nucleus neuronal cell bodies. Once the neuronal sub-compartment of interest was manually or 
automatically selected, mitochondria were identified within each using COX4 as a reference 
channel (and the “automatic threshold” function). Mitochondrial “objects” within each sub-
neuronal compartment were employed to acquire the fluorescence intensity measurements for 
different respiratory chain proteins (COX4 and NDUFA13). All intensity measurements were 
performed using Volocity® (PerkinElmer). 
Synaptic terminal density quantification was performed using both Volocity® and IMARIS 
software. Volocity® facilitated image cropping and deconvolution (section 3.4.6), whereas 
IMARIS was employed for surface reconstruction. GAD- and SY-positive puncta were 
substituted by surfaces mimicking the pattern of staining and GABAergic synapses were 
detected when both surfaces were present. The number of inhibitory presynaptic terminals 
detected was normalised to cell circumference (per μm circumference).  
Due to limited tissue availability, dendritic length extension was investigated in thin tissue 
sections (5 μm-thick) that were subjected to triple immunofluorescence (Table 4 – 3). Confocal 
images were manually cropped using Volocity® and z stacks of individual Purkinje cells were 
later imported into IMARIS software (Bitplane). The Filament tracer module enabled the 
creation of a continuous surface that resembled neuronal dendrites through the use of an 
“Autopath” algorithm. The Calbindin channel (Alexa Fluor 647) was employed as the source, 
while the filament start- and end-points were manually added. However, this technique holds 
significant drawbacks which are discussed below (see section 4.5).  
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4.3.4 Defining the levels of mutated mtDNA in neuronal cell bodies and presynaptic 
terminals 
15μm-thick frozen cerebellar tissue sections mounted on SuperFrost glass slides were employed 
to determine mtDNA heteroplasmic levels in Purkinje cell bodies and axonal terminals. 
Sections were initially subjected to a double immunofluorescent protocol (for details see section 
2.7.1 and Table 2- 3) and were then employed for single neuronal and synaptic isolation as 
described in section 2.9.1. DNA was extracted from the isolated tissue as previously described 
(section 2.9.2) and was amplified using the appropriate primers depending on the type of point 
mutation (section 2.9.3 and Table 2- 8). The levels of mutated over wild-type mtDNA were 
determined through pyrosequencing as described in section 2.9.7.  
4.3.5 Statistical analyses 
The mean optical density (OD) values for NDUFA13 and COX4 immunofluorescence were 
employed to calculate the z score values for respiratory chain protein expression in different 
neuronal sub-compartments using SAS 9.3 (Cary, NC). Each area was categorised according to 
the standard deviation limits for NDUFA13 protein expression as being normal, low, deficient 
or very deficient. A detailed description on data analysis is provided in Chapter 3 of this thesis 
(section 3.4.7).   
Z score differences between sub-neuronal compartments or patients with different genetic 
diagnoses were assessed using two-sample (for parametric data) or Mann-Whitney U (for 
nonparametric data) tests. Paired nonparametric data were tested using the Wilcoxon Signed-
Rank test, whilst associations between continuous variables were evaluated using Spearman’s 
rank correlation. All statistical testing was performed in Minitab®. 
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4.4 Results 
4.4.1 Complex I deficiency in Purkinje cells and inhibitory presynaptic terminals 
Control Purkinje cells had high expression of COX4 and NDUFA13 (Figure 4- 3), indicating 
that control neuronal cell bodies had an abundance of mitochondria that were intact for complex 
I protein expression. Although patient Purkinje cells were enriched for mitochondria, in 
agreement to the comparable levels between control and patient COX4 protein expression (two 
sample t-test, p value =0.323), NDUFA13 expression was variably decreased in the majority of 
cells (Figure 4- 3). Protein expression quantification verified variable NDUFA13 expression 
and helped define the exact protein expression levels (Figure 4- 4). Some of the patients 
carrying the m.3243A>G point mutation (Patient 1, 3 and 5) and a patient with recessive POLG 
mutations (Patient 11) contained Purkinje cells deficient for complex I (NDUFA13z < -3SDs), 
whilst patients 4 (m.3243A>G), 6 (m.3243A>G) and 7 (m.8344A>G) had milder changes in 
NDUFA13 expression consistent with low protein expression levels (NDUFA13z < -2SDs) 
(Figure 4- 4) (Table 4- 4). Patients harbouring the m.3243A>G point mutation had more severe 
complex I defects relative to patients with other genetic defects (m.8344A>G, m.14709T>C 
and recessive POLG) (Mann Whitney U test, p value= 0.0306). The derived z score values for 
NDUFA13 expression were not affected by either PMI (Spearman’s rho= -0.242, p value= 
0.449) or fixation time (rho= -0.035, p=0.913) (Spearman’s rank correlation). The correlations 
for PMI are displayed in Appendix A.
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Similarly, inhibitory presynaptic terminals present around control dentate nucleus neurons 
contained mitochondria with normal levels of NDUFA13 protein expression (NDUFA13z = 
0.0562SDs) (Figure 4- 5). Patient GABAergic synapses had similar COX4 expression to that 
of control terminals (two sample t-test, p= 0.620) nevertheless, NDUFA13 expression was 
variably different. Inhibitory presynaptic terminals that belonged to patients had mild (Patient 
1, m.3243A>G), intermediate (Patient 7, m.8344A>G) or severe (Patient 11, POLG) decreases 
in NDUFA13 expression (Figure 4- 5). Z score analysis for NDUFA13 expression 
demonstrated that all patients possessed a mixture of normal, low, deficient or very deficient 
synapses (Figure 4- 6) (Table 4- 4). In contrast to Purkinje cell bodies, synaptic NDUFA13 
protein expression was similar between patients with the m.3243A>G point mutation and others 
when genetic defects were grouped (m.8344A>G, m.14709T>G and recessive POLG) (Mann 
Whitney U test, p value= 0.6889). Neither PMI (rho= -0.126, p value= 0.696) (Appendix A) 
nor fixation length (rho= -0.007, p value= 0.983) affected the z score values for NDUFA13 
expression in inhibitory presynaptic terminals (Spearman’s rank correlation).  
Interestingly, NDUFA13 expression in synapses was negatively related to the NMDAS scores 
for cerebellar ataxia such that patients with higher NMDAS scores, indicative of more severe 
ataxia, possessed synapses with lower NDUFA13 z scores, consistent with more complex I 
deficiency (rho= -0.60, p value= 0.0493). Likewise, synaptic complex I protein expression is 
inversely related to the percentage of dentate nucleus neuronal loss. That is patients with lower 
synaptic complex I protein expression, indicative of more complex I deficiency, had more 
dentate nucleus neuronal loss (rho= -0.92, p= 0.0013) (Spearman’s rank correlation). 
NDUFA13 expression is variable in Purkinje cells and GABAergic synapses among patients 
with different genetic diagnoses. Patients harbouring the m.3243A>G point mutation have more 
pronounced complex I deficiency in Purkinje cell bodies compared to presynaptic terminals. 
On the contrary, patients with other genetic defects (m.8344A>G, m.14709T>C and recessive 
POLG) possess Purkinje cells that are less deficient relative to synapses (Table 4- 4). Following 
statistical analysis, there is a significant difference between the two patient groups (Mann 
Whitney U test for the difference between Purkinje cell and synaptic deficiency, p value= 
0.0051). When taking into account the patient group as a whole, there is no difference in 
complex I expression levels between neuronal cell bodies and axonal terminals (Wilcoxon 
Signed-Rank test of differences, p= 0.666). 
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4.4.2 Heteroplasmic levels of mtDNA in neuronal cell bodies and synapses 
Defining the levels of mutated over wild type mtDNA in Purkinje cell bodies and presynaptic 
terminals of patients with the m.3243A>G and m.8344A>G point mutation indicated high 
heteroplasmic levels in both neuronal compartments (Figure 4- 7). Some synaptic values were 
near homoplasmic (Patient 1, 2 and 3; m.3243A>G), whilst the levels of mutated mtDNA are 
comparable between the two neuronal sub-compartments (Wilcoxon Signed-Rank test of 
differences, p=1) (Figure 4- 7). 
The levels of heteroplasmic mtDNA levels in Purkinje cell bodies and inhibitory presynaptic 
terminals are not related to NDUFA13 z score values for complex I deficiency in the 
corresponding sub-neuronal compartments (Purkinje cell bodies: rho= -0.6, p value= 0.285; 
Presynaptic terminals:  rho= -0.3, p value= 0.624) (Spearman’s rank correlation).
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4.4.3 Remodelling of GABAergic input to the dentate nucleus                                
Quadruple immunofluorescence and confocal microscopy facilitated the numerical and 
structural investigation of GABAergic pre- and postsynaptic compartments found on the 
periphery and proximal dendrites of dentate nucleus neurons. Evaluating the number of 
inhibitory presynaptic terminals revealed decreased Purkinje cell efferent density around 
dentate nucleus neurons in the majority of patients (Patients 1, 2, 4, 5, 7, 9-11), though the 
derived z score values were within the normal ±2 SD limits (Figure 4- 8). Decreased inhibitory 
synapse density is in agreement with Purkinje cell loss previously documented for these patients 
(Table 4- 1) (Lax et al., 2012) and indeed, there is a significant negative relationship between 
the percentage of Purkinje cell loss and the number of synapses detected (rho= -0.74, p value= 
0.02) (Spearman’s rank correlation). Moreover, patients 3 (m.3243A>G), 8 (m.8344A>G) and 
13 (m.14709T>C) demonstrated maintained synaptic and preserved Purkinje cell numbers 
(Figure 4- 8) (Table 4- 1).  
Remarkably, residual synapses were enlarged since synaptic number and size (volume – μm3) 
were negative correlated (rho= -0.615, p value= 0.037). The volume of inhibitory presynaptic 
terminals is displayed in Appendix B. Synaptic number counts were not affected by PMI 
(rho=0.522, p value=0.082) (Appendix A) or fixation time (rho=0.011, p value= 0.980) nor was 
synaptic volume (PMI: rho= -0.595, p value= 0.120 (Appendix A); Fixation length: rho=-0.688, 
p value=0.059) (Spearman’s rank correlation). 
Chapter 4                                               Cerebellar ataxia in patients with mitochondria disease 
 
125 
 
 
F
ig
u
re
 4
- 
8
: 
Z
 s
co
re
s 
fo
r 
th
e 
n
u
m
b
er
 o
f 
G
A
B
A
er
g
ic
 p
re
sy
n
a
p
ti
c 
te
r
m
in
a
ls
 s
u
rr
o
u
n
d
in
g
 d
en
ta
te
 n
u
cl
eu
s 
n
e
u
ro
n
s.
  
M
o
st
 p
at
ie
n
ts
 (
8
 o
u
t 
o
f 
1
2
) 
h
ad
 d
ec
re
as
ed
 P
u
rk
in
je
 c
el
l 
ef
fe
re
n
t 
d
en
si
ty
 c
o
m
p
ar
ed
 t
o
 c
o
n
tr
o
ls
, 
th
e 
st
a
n
d
ar
d
 d
ev
ia
ti
o
n
 l
im
it
s 
fo
r 
th
e 
n
u
m
b
er
s 
o
f 
in
h
ib
it
o
ry
 s
y
n
ap
se
s 
fa
ll
 w
it
h
in
 t
h
e
 n
o
rm
al
 l
im
it
s 
th
o
u
g
h
. 
E
ac
h
 d
at
a 
p
o
in
t 
re
fl
ec
ts
 t
h
e 
n
u
m
b
er
 o
f 
sy
n
ap
se
s 
d
et
ec
te
d
 a
ro
u
n
d
 a
 s
in
g
le
 d
en
ta
te
 
n
u
cl
e
u
s 
n
e
u
ro
n
 (
n
=
2
0
).
 
Chapter 4                                               Cerebellar ataxia in patients with mitochondria disease 
 
126 
 
4.4.4 Complex I deficiency in Purkinje cell dendrites 
The expression of NDUDFA13 and COX4 proteins was assessed in calbindin immunoreactive 
Purkinje cell dendritic trees extending in the molecular cell layer of the cerebellar cortex using 
triple immunofluorescence. As with other neuronal sub-compartments, control neuronal 
dendrites contained a high density of mitochondria with intact complex I protein expression 
(Figure 4- 9). COX4 was a reliable marker for mitochondrial abundance since protein 
expression in neuronal dendrites did not show any difference between controls and patients 
(two sample t-test, p value= 0.232), however NDUFA13 protein expression was variably 
decreased in line with complex I deficiency. 
As shown in Figure 4- 9, there were patients whose dendrites completely lack NDUFA13 
immunoreactivity (Patient 4, m.3243A>G), in others NDUFA13 expression was considerably 
lower relative to COX4 expression (Patient 7, m.8344A>G), while there were also patients 
which possessed dendrites with preserved complex I expression (Patient 10, POLG). In 
agreement with observations made on neuronal cell bodies and GABAergic axonal terminals, 
there is a great extent of intra- and inter-patient variability in dendritic NDUFA13 protein 
expression (Figure 4- 10). A patient may contain cells whose dendrites have normal levels of 
the protein (2 <NDUFA13z< -2SDs) and cells whose dendrites are deficient for complex I 
(NDUFA13z< -4SDs) (e.g. Patient 6, m.3243A>G), whilst patients with the same genetic defect 
might have very different dendritic complex I expression levels (Patient 7 vs. Patient 8, 
m.8344A>G) (Figure 4- 10). Patients with the m.3243A>G point mutation (Patients 1-6) 
generally demonstrate lower z score values for NDUFA13 in neuronal dendrites (Figure 4- 10), 
compatible with the increased percentage for dendrites that are low, deficient or very deficient 
for NDUFA13 when these are quantified (Table 4- 5).  
Indeed, dendritic complex I deficiency is more pronounced in patients with the m.3243A>G 
mutation compared to other patients when genetic defects are grouped (m.8344A>G, 
m.14709T>C and POLG) (two sample t-test, p value= 0.018). Furthermore, the level of 
complex I deficiency in Purkinje cell dendrites is comparable to that of Purkinje cell bodies 
(Wilcoxon Signed-Rank test of differences, p= 0.290). Z score values for NDUFA13 protein 
expression in neuronal dendrites were not affected by the length of formalin fixation (rho= -
0.298, p value= 0.347) or by post-mortem interval (rho= -0.018, p value= 0.957) (Spearman’s 
rank correlation) (Appendix A). 
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4.4.5 Calbindin immunoreactivity and dendritic extension 
As demonstrated in Figure 4- 11, the patient neuronal dendrites are equally as expanded as 
control dendrites, since all the patient z score values for dendritic length lie within the normal 
±2SD limits. Likewise, Calbindin expression is normal in all patients (2 <Calbindinz< -2SDs) 
though some patient median z score values are decreased relative to controls (Figure 4- 12). 
Dendritic extension was not affected by fixation length (rho= 0.340, p value= 0.279) or by PMI 
(rho= -0.567, p value= 0.054) (Appendix A), neither were Calbindin z score values (Fixation 
length: rho= 0.362, p value= 0.248; PMI: rho= 0.060, p value= 0.854 (Appendix A)).  
Interestingly, there is a significant positive relationship between the z score values for Calbindin 
expression and dendritic extension (rho= 0.604, p value= 0.024), suggesting that the patients 
possessing the longest dendrites are the ones with increased Calbindin expression (Spearman’s 
rank correlation). Surprisingly, Calbindin expression is significantly positively related to 
NMDAS scores for cerebellar ataxia implying that patients with higher scores, thus more severe 
ataxia, have high Calbindin immunoreactivity (rho= 0.627, p value= 0.039) (Spearman’s rank 
correlation).   
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4.5  Discussion 
Cerebellar ataxia is a common neurological deficit and an important cause of disability in 
patients with mitochondrial disease (Tzoulis et al., 2006; Hudson et al., 2008; McFarland et al., 
2010). The exact underlying mechanisms that account for the genesis and progression of this 
condition remain largely unknown, though valuable neuropathological studies performed in the 
past reveal Purkinje cell vulnerability to mitochondrial dysfunction (Tanji et al., 1999; Sparaco 
et al., 2003; Hakonen et al., 2008; Lax et al., 2012). The importance of mitochondrial function 
on synaptic transmission combined with the significance of the Purkinje cell-dentate nucleus 
synapse in establishing intracerebellar communication and extracerebellar information 
processing, place the inhibitory Purkinje cell synapses onto dentate nucleus neurons at the 
centre of attention. In this study, I have used a previously developed quantitative quadruple 
immunofluorescent technique (see Chapter 3) to assess the degree of complex I deficiency in 
Purkinje cell bodies, dendrites and inhibitory presynaptic terminals of twelve patients with 
mitochondrial disease. Moreover, I have quantified the density and the size of GABAergic 
synapses to the dentate nucleus in an attempt to gain further insights into the impact of 
mitochondrial dysfunction onto the synapse. Finally, I have examined the level of Purkinje cell 
dendritic tree arborisation and the expression of a Ca2+-binding protein in order to assess the 
presence of neurodegenerative signs.  
I demonstrate that Purkinje cell bodies, dendrites and GABAergic presynaptic terminals to the 
dentate nucleus have decreased NDUFA13 protein expression levels in patients relative to 
controls. Complex I deficiency in Purkinje cell bodies and neuronal dendrites is more prominent 
in patients harbouring the m.3243A>G point mutation, consistent with studies performed in 
skeletal muscle of patients with m.3243A>G point mutations and demonstrate low complex I 
activity and low complex I subunit protein expression (Moraes et al., 1992; Petruzzella et al., 
1994; Koga et al., 2000). On the contrary, complex I protein expression in Purkinje cell 
presynaptic terminals is similar amongst patients with different genetic diagnoses. The length 
of formalin fixation and post-mortem interval do not affect the levels of complex I protein 
expression in any of the neuronal subtypes or sub-neuronal compartments studied, implying 
that the observed changes are due to disease mechanisms. 
There is considerable intra- and inter-patient variability across all neuronal sub-compartments 
investigated, exemplifying the phenotypic heterogeneity of mitochondrial disease (Moggio et 
al., 2014). Generally, the degree of complex I expression is similar between Purkinje cell pre-
/post-synaptic compartments (presynaptic terminals and dendrites respectively) and Purkinje 
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cell bodies. Likewise, molecular genetic investigation of patients with mtDNA point mutations 
(m.3243A<G and m.8344A>G) shows that mutated mtDNA heteroplasmic levels are similar 
between Purkinje cell bodies and inhibitory presynaptic terminals, though mutated mtDNA 
levels do not correlate with complex I protein expression in either of the two neuronal 
compartments.   
Mitochondrial turnover takes place in neuronal cell bodies, via a process known as mitophagy, 
and assures the recycling of damaged organelles (Cai et al., 2012). The high metabolic profile 
of a synapse implies that there needs to be a constant removal (via retrograde transport) of 
dysfunctional mitochondria and supply of newly-synthesised organelles to the region in order 
to maintain the balance between energy demand and supply (MacAskill and Kittler, 2010; 
Sheng, 2014). Similar complex I expression levels and mtDNA heteroplasmic percentages 
between synaptic and somatic neuronal compartments implies that deficient mitochondria are 
not efficiently removed from the synapse for degradation and/or that mitochondrial degradation 
mechanisms are impaired. Mitochondrial transport mechanisms to/from the synapse could 
therefore be malfunctional in mitochondrial disease, consistent with evidence for impaired 
neuronal transport in other neurodegenerative disorders (Chevalier-Larsen and Holzbaur, 2006; 
Morfini et al., 2009; Kanaan et al., 2013). Moreover, evidence for dysfunctional mitochondrial 
autophagic mechanisms (mitophagy) has been documented for common neurodegenerative 
disorders (Ghavami et al., 2014), hinting towards their use as  therapeutic targets (Santos et al., 
2011). 
Remarkably, NDUFA13 protein expression in GABAergic presynaptic terminals is related to 
cerebellar ataxia suggesting that synaptic complex I deficiency might be important in 
mitochondrial disease pathogenesis. This would be compatible with other neurodegenerative 
disorders according to which, synaptic disturbances have a central role in disease initiation and 
progression (Marcello et al., 2012; Picconi et al., 2012). Induction and/or overexpression of a 
cold-shock protein (RBM3) prevents synapse loss and reverses cognitive deficits in 
neurodegenerative mouse models, suggesting that synaptic pathology is likely to be reversible 
and highlighting the potential use of synapses as a therapeutic drug target (Peretti et al., 2015). 
Synaptic activity drives local ATP requirements which are met by mitochondrial-generated 
energy (Rangaraju et al., 2014). ATP generated by mitochondria fuels synaptic vesicle 
transport, docking, exocytosis and recycling, thus directly affects synaptic transmission 
(Rowland et al., 2000; Perkins et al., 2010).  Mitochondrial function is also key in maintaining 
ionic gradient balance in pre- and post-synaptic terminals, allowing for the initiation of action 
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potentials and recovery following depolarisation respectively (Billups and Forsythe, 2002). 
Furthermore, the importance of mitochondrial respiratory chain function in synaptic oxygen 
consumption and energetic availability have been demonstrated in rat synaptosomal (Telford et 
al., 2009) and extracted mitochondrial preparations (Davey et al., 1998). Complex I deficiency 
in the inhibitory presynaptic terminals of patients with mitochondrial disease is therefore likely 
to have adverse effects for synaptic function.  
Three-dimensional reconstruction of inhibitory synapses to the dentate nucleus enabled the 
investigation of synaptic number and size (in volume). Interestingly, the majority of patient 
Purkinje cells appear to have lost some of their inhibitory contacts to the dentate nucleus, while 
the volume of remaining ones is increased. This change can be suggestive of a compensatory 
mechanism that takes place to maintain the total synaptic contact area of dentate nucleus 
neurons, thus increasing the size of residual synapses in case of loss. Likewise, a model 
proposed by Scheff and Price (2003) suggests that at the early stages of Alzheimer’s disease 
denervated neurons release signals that drive the formation of new synapses or enlargement of 
remaining ones in order to keep the total synaptic contact area stable (Scheff and Price, 2003).  
Additional to inhibitory presynaptic terminals to the dentate nucleus, Purkinje cell dendrites 
and axons have previously been demonstrated to be structurally different in patients with 
mitochondrial disease. Purkinje cell axons proximal to neuronal cell bodies are swollen, giving 
rise to “Torpedoes”, whereas Purkinje cell trees are thicker (forming “cactus-like” structures) 
and more extended  (Tanji et al., 1999; Lax et al., 2012). Quantification of dendritic tree 
extension in this study demonstrates that patient Purkinje cell dendrites are equally as extended 
as control ones, contrary to what is commonly accepted for mitochondrial disease. It here has 
to be noted that quantification of dendritic length using thin tissue sections is not optimum since 
it only allows tissue sub-sampling and relies on the orientation that the tissue has been cut. 
Thus, it is likely that the results obtained from this study are not entirely reflective of Purkinje 
cell dendritic expansion in the cerebellum as a whole and instead only provide information for 
the region sampled. Alternatively, the use of thicker tissue sections (250μm -500μm) combined 
with recently developed methods that allow tissue clearing and neuronal structure preservation 
(e.g. CLARITY) would be more informative with regards to Purkinje cell dendritic arborisation 
(Chung and Deisseroth, 2013).  
Cognition and motor coordination have been demonstrated to be regulated by a calcium-binding 
and buffering protein, Caldindin-D28k. Deletions (Barski et al., 2003) or null mutations 
(Airaksinen et al., 1997) of the protein result in altered fast calcium transients accompanied by 
Chapter 4                                               Cerebellar ataxia in patients with mitochondria disease 
 
136 
 
permanent motor coordination disturbances and ataxia. The protein is suggested to have a 
neuroprotective role from Ca2+ overload (Heizmann and Braun, 1992) and excitotoxicity 
(Iacopino et al., 1992) and decreased protein expression levels have been linked to the 
pathogenesis of many neurodegenerative conditions (Heizmann and Braun, 1992) and aging 
(Iacopino and Christakos, 1990). Elevated calbindin protein expression levels in patients with 
higher NMDAS scores for cerebellar ataxia detected in this study might be reflective of a 
protective mechanism taking place in patients with more severe ataxia. Mitochondrial 
dysfunction in patient Purkinje cells is highly likely to negatively affect the calcium buffering 
capacity of the organelles, further to their capability for ATP production, thus elevation in 
Calbindin expression acts to protect the remaining neurons from calcium overload and 
excitotoxicity. Interestingly, a positive relationship between calbindin expression and dendritic 
extension is detected implying that extra burden (cytosolic Ca2+) to already deficient 
mitochondria may negatively affect dendritic arborisation and thus, synaptic contact. 
4.5.1 Future work 
The importance of the cerebellum in motor coordination and cognition, the frequent 
presentation of cerebellar ataxia in patients with mitochondrial disease and the extensive 
neurodegeneration in the olivo-cerebellar pathway of patients, highlight the need for 
understanding the mechanisms responsible for the initiation and progression of the neuronal 
loss process. Despite the documentation of respiratory chain protein deficiencies in neuronal 
cell bodies, dendrites and presynaptic terminals and the demonstration of structural synaptic 
changes, it is still unclear whether synaptic pathology contributes to neuronal loss. 
The use of a reliable, transgenic mouse model that replicates human mitochondrial disease 
would help determine the sequence and timescale of events that lead to neuronal degeneration. 
Behavioural mouse testing in parallel with quantitative immunofluorescence against respiratory 
chain and synaptic proteins will help understand whether mitochondrial dysfunction at the 
synapse is the one to drive synaptic loss and further determine whether synaptic abnormalities 
are primarily affecting neuronal health or whether are secondary to neuronal disturbances. The 
effect exerted by synaptic plasticity and function to neuronal preservation needs to be elucidated 
if we are to prevent and/or delay neuronal loss progression.  
A novel hybrid protein, the slow Wallerian degeneration (Wlds) protein, has been demonstrated 
to protect against axonal and synaptic degeneration (Wang et al., 2001; Ferri et al., 2003; Sajadi 
et al., 2004).  In fact, proteomic analysis of striatal synaptic fractions from Wlds mice revealed 
altered mitochondrial protein expression, suggesting that differential expression of 
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mitochondrial proteins and mitochondrial function is likely to play a key role in the 
neuroprotective phenotype (Wishart et al., 2007). Crossing transgenic mouse models of 
mitochondrial disease with mice expressing the Wlds protein hold significant promises for 
understanding the impact of synaptic mitochondrial dysfunction in neurodegeneration due to 
mitochondrial disease. Can Wlds expression improve the behaviour of mice with mitochondrial 
disease? And if yes, could this imply that mitochondrial disease is a synaptopathy?   
4.6 Conclusion 
This study further emphasises the vulnerability of the cerebellum to mitochondrial respiratory 
chain impairment. Quantitative quadruple immunofluorescent approaches have enabled a 
comprehensive and accurate analysis of complex I deficiency in neuronal cell bodies, dendritic 
and presynaptic terminal compartments. The distribution of respiratory chain deficiencies was 
assessed, presynaptic terminal characteristics were evaluated and dendritic length was 
quantified. Generally, respiratory chain deficiency is more pronounced in Purkinje cells bodies, 
compared to neuronal dendrites and presynaptic terminals, whereas patients harbouring the 
m.3243A>G point mutation are more severely affected. Inhibitory synapse deficiency is 
strongly related with poor clinical rating of ataxia, whereas structural inhibitory synapse 
changes are reminiscent of altered intracerebellar wiring in patients with mitochondrial disease.  
Regardless, the question still remains: is synaptic pathology the cause or the consequence of 
neuronal loss? 
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Chapter 5 Cerebellar ataxia in patients with mitochondrial disease 
Part 2: Altered intra-cerebellar connectivity in mitochondrial disease 
5.1 Introduction 
5.1.1 Deep cerebellar nuclei and downstream neuronal networks 
The three types of deep cerebellar nuclei (DCN) house a wide variety of projection neurons and 
interneuronal populations each of which contribute to cerebellar synaptic plasticity and learning 
(Uusisaari et al., 2007; Uusisaari and Knopfel, 2011; D'Angelo, 2014; Mapelli et al., 2015).  
Regardless of their neuronal subtype, all neurons located in the DCN receive inhibitory input 
from Purkinje cells, which comprises the main component of intracerebellar circuitry (Teune et 
al., 1998). Neuronal excitation is achieved via glutamatergic innervation from climbing (CF) 
and mossy fibres (MF), which establishes cerebellar connectivity with extracerebellar regions. 
Inferior olivary neurons project their CFs and excite neurons of the DCN (and Purkinje cells), 
as do MFs which arise from the brainstem and spinal cord (Voogd and Glickstein, 1998; Apps 
and Garwicz, 2005; Rajakumar, 2013).   
The cerebellum is involved in feedback and feedforward loops with the cortex, the integration 
of which is important for cognition, emotion and language (D'Angelo and Casali, 2012). 
Feedback information from the cortex and basal ganglia received at the cerebellar cortex, is 
relayed to and integrated by DCN. DCN in turn send their output (via the red nucleus) to motor, 
prefrontal, parietal and temporal cortices (D'Angelo and Casali, 2012).  
5.1.2 Gephyrin and its importance in neuronal function 
Gephyrin is a cytoplasmic scaffold protein ubiquitously present throughout the neuronal soma 
and the inhibitory post synapse (Waldvogel et al., 2003). When located at the postsynaptic 
density, gephyrin interacts with the cytoskeleton and enables clustering of synaptic proteins 
important for inhibitory (GABAergic and glycinergic) neurotransmission including the receptor 
subunits for GABAA and glycine receptors (Giesemann et al., 2003; Bausen et al., 2006; 
Tyagarajan and Fritschy, 2014). Furthermore, via it’s interaction with various adhesion 
molecules, including Neuroligins, Gephyrin has an important role in GABAergic synapse 
structural integrity and thus for synaptic functional preservation (Varoqueaux et al., 2004; 
Poulopoulos et al., 2009).  
It has been suggested that protein localisation and aggregation at the postsynaptic compartment 
is actively regulated in response to changes in the excitatory-inhibitory balance with gephyrin 
therefore acting as a key player in neuronal network function and information processing in the 
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brain (Tyagarajan and Fritschy, 2014). Likewise, gephyrin functional defects in cultured 
hippocampal cells had adverse effects for both inhibitory and excitatory synaptic transmission 
(Varley et al., 2011). 
5.1.3 Synaptic protein expression in the dentate nucleus 
The largest of the DCN is the dentate nucleus (Diedrichsen et al., 2011), which is involved in 
local feedback and global signal transduction networks with extracerebellar regions (Dum and 
Strick, 2003; D'Angelo and Casali, 2012). The occurrence and timing of output signals from 
the dentate nucleus is defined by the balance between neuronal excitation (+) (from CF and 
MF) and inhibition (-) (from Purkinje cells) (Knierim, 1997). A summary of dentate nucleus 
neuronal connectivity and synaptic protein expression is outlined in Figure 5- 1. 
As presented in Chapter 4 of this thesis, Purkinje cell loss is profound in patients with 
mitochondrial disease and often exceeds the percentage of dentate nucleus neuronal 
degeneration (Table 4- 1). However, this is not always the case since the degree of dentate 
nucleus neurodegeneration in some patients surpasses that of Purkinje cell loss. Purkinje cell 
innervation to the dentate nucleus has previously been assessed (Chapter 4) but how 
glutamatergic connectivity of the dentate nucleus is affected in patients with mitochondrial 
disease remains to be established. 
The GABAergic synapse that establishes Purkinje cell to dentate nucleus neuron contact is 
highly sophisticated and depends on the synergistic expression and fine interaction of many 
proteins at the pre- and a post-synaptic level. Inhibitory presynaptic terminals (studied in 
Chapter 4 of this thesis) contain glutamic acid decarboxylase 65/67 (GAD-65/67) (Erlander and 
Tobin, 1991), and are found opposed to inhibitory postsynaptic densities which are enriched 
for GABA receptors and scaffold proteins (Tyagarajan and Fritschy, 2014). Amongst these is 
Gephyrin, a protein that mediates GABAergic (GABAA) (and glycinergic) receptor clustering 
at inhibitory postsynaptic terminals (Kneussel and Betz, 2000b). Hence, employing the 
developed quantitative immunofluorescent technique (Chapter 3) and using antibodies directed 
against GAD-65/67 and gephyrin, the structural properties of inhibitory synapses can be 
studied. 
Vesicular glutamate transporters (VGLUT1-3) are a group of proteins that employ 
electrochemical gradients in order to load synaptic vesicles with the major excitatory 
neurotransmitter, glutamate (Liguz-Lecznar and Skangiel-Kramska, 2007). Despite their 
complementary CNS distribution (Fremeau Jr et al., 2001; Kaneko et al., 2002), all three protein 
isoforms are expressed at excitatory presynaptic terminals (Bellocchio et al., 1998). Studies in 
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mice (Gebre et al., 2012) and rat (Hioki et al., 2003) exhibited that CF collaterals to the 
cerebellum are only positive for VGLUT2, whereas both VGLUT1 and VGLUT2 are expressed 
by MF presynaptic terminals. Upon glutamate release into the synaptic cleft, a series of 
ionotropic glutamate receptors (located at the postsynaptic neuronal membrane) are activated, 
leading to neuronal excitation (Day et al., 1995). Named after the agonist that activates them, 
α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors constitute one of 
the three ionotropic receptor subtypes that mediate fast excitatory post synaptic potentials 
(Collingridge and Lester, 1989; Monaghan et al., 1989; Purves. D et al., 2001). Thus, antibodies 
against VGLUTs and AMPA receptors will facilitate the investigation of glutamatergic 
innervation of the dentate nucleus (Figure 5- 1).      
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Figure 5- 1: Innervation of and synaptic protein expression in the dentate nucleus.  
The dentate nucleus (the largest of the deep cerebellar nuclei – DCN) receives inhibitory input (-) from Purkinje 
cells and is innervated by glutamatergic (+) climbing and mossy fibres. Inhibitory presynaptic terminals to the 
region are positive for GAD-65/67, whereas excitatory synapses express vesicular glutamate transporters 
(VGLUT1+2). Gephyrin is used to detect the inhibitory and AMPA receptors are employed to identify the 
excitatory postsynaptic density respectively.   
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5.2 Aims of the investigation 
The main aim of this study is to understand the impact of mitochondrial defects on 
intracerebellar circuitry, by now focussing on the dentate nucleus, in an attempt to gain further 
insights into the mechanisms responsible for the progression of ataxia. I will achieve this by: 
1. Quantifying neuronal respiratory chain protein expression in the dentate nucleus 
2. Investigating the density of inhibitory postsynaptic terminals and the degree of 
glutamatergic innervation of the dentate nucleus  
5.3 Methodology 
5.3.1 Cerebellar tissue samples 
This study involves the neuropathological investigation of twelve adult patients that have been 
clinically and genetically diagnosed to suffer from mitochondrial disease and 10 age-matched 
controls. Patient clinical and neuropathological details are summarised in Table 4- 1, whereas 
patient and control tissue characteristics are summarised in Table 4- 2.   
5.3.2 Immunofluorescence 
5.3.2.1 Assessing respiratory chain deficiency in dentate nucleus neuronal cell bodies  
5μm-thick FFPE cerebellar tissue sections mounted on SuperFrost slides were subjected to a 
quadruple immunofluorescent protocol as previously described (see section 2.7.1) with the 
following modifications: 
Following antigen retrieval with EDTA, sections were incubated in 3% Hydrogen peroxide 
solution for 1 hour at RT and washed thoroughly with water. After tissue block with 1% NGS 
for 1 hour at RT, the primary antibody (Table 5- 1) solution was applied overnight at 4oC. PBS 
washes (3x5 minutes) the next day were followed by anti-mouse and anti-rabbit secondary 
antibody (coupled with fluorophores) incubation for 1 hour at RT (Table 5- 1). PBS washes 
preceded an HRP-conjugated anti-mouse secondary antibody (Table 5- 1) incubation for 1 hour 
at RT, the signal of which was detected after following the Tyramide signal amplification (TSA) 
method per manufacturer’s instructions (Life Technologies). 
5.3.2.2 Evaluating glutamatergic input to the dentate nucleus 
A double immunofluorescent protocol (section 2.7.1) was followed in order to stain 5μm-thick 
FFPE cerebellar tissue sections against excitatory pre- and postsynaptic markers (Table 2- 3). 
All primary and secondary antibodies (Table 5- 1) applied to the sections were diluted in 10% 
NGS, which was also used to block the sections prior to antibody incubation.
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Table 5- 1: A list of the primary and secondary antibodies used in this study, along with their optimal 
working conditions
Primary antibodies
Host and 
isotype
Source
Catalogue 
No.
Antigen retrieval
Optimal 
dilution
Optimal 
incubation 
conditions
Vesicular glutamate 
transporter 1 
(VGLUT1)
Mouse 
monoclonal - 
IgG1
NeuroMab 73-066
EDTA (1mM); 2100 
antigen retriever
1 in 75 O/N at 4
o
C
Pan-AMPA receptor 
(GluR1-4)
Mouse 
monoclonal – 
IgG2bk
Millipore MABN832
EDTA (1mM); 2100 
antigen retriever
1 in 50 O/N at 4
o
C
Secondary 
antibodies
Host and 
epitope
Source
Catalogue 
No.
Antigen retrieval
Optimal 
dilution
Optimal 
incubation 
conditions
Alexa Fluor® 488
Goat Anti-
Mouse IgG1 
(γ1)
Life 
technologies
A21121 N/A 1 in 100
2 hours, 
4
o
C
Alexa Fluor® 546
Goat Anti-
Mouse IgG2b 
(γ2b)
Life 
technologies
A21143 N/A 1 in 100
2 hours, 
4
o
C
Double immunofluorescence
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5.3.3 Confocal microscopy and image processing  
Immunofluorescently stained sections were imaged using an inverted laser point scanning 
confocal microscope (Nikon A1R) as described earlier (section 2.8.1 and 3.4.5). Twenty large 
glutamatergic dentate nucleus neurons were randomly selected and were employed to assess 
complex I protein expression in the dentate nucleus (see section 3.4.7 and 4.3.3).  
Evaluating the number of Gephyrin-positive puncta around dentate nucleus neurons involved 
image cropping and deconvolution using Volocity® (section 3.4.6), followed by surface 
recreation in IMARIS. Once GAD- and Gephyrin-positive puncta were substituted by surfaces 
that mimic the pattern of staining, a Matlab Xtension was employed in order to filter the surfaces 
created. Thus, only Gephyrin puncta directly opposed to GAD were taken into account, 
allowing for the number of Gephyrin molecules that are associated with GABAergic 
presynaptic terminals to be counted. Gephyrin punctum numbers were normalised per μm2 cell 
surface area. 
Similarly, z stacks from sections stained against excitatory pre- and postsynaptic markers were 
employed to study the degree of glutamatergic innervation of dentate nucleus neurons. 
Volocity® helped identify, crop and measure the length of individual neuronal dendrites, 
whereas processed images were later imported into IMARIS. Surfaces were recreated for each 
pre- or postsynaptic punctum and these were used to obtain average surface number and volume 
measurements. Surface numbers were normalised per μm length of a dendrite. 
5.3.4 Statistical analysis 
The mean optical density (OD) values for NDUFA13 and COX4 immunofluorescence were 
employed to calculate the z score values for respiratory chain protein expression in dentate 
nucleus neuronal cell bodies using SAS 9.3 (Cary, NC) (section 3.4.7).  
Any other statistical testing was performed as previously described (section 4.3.5).  
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5.4 Results 
5.4.1 Complex I deficiency in dentate nucleus neuronal cell bodies 
Control dentate nucleus neuronal cell bodies contain high mitochondrial mass (as judged by 
COX4 immunoreactivity) with matched complex I protein expression (NDUFA13 co-
localisation with COX4) (Figure 5- 2). Although patient cell bodies demonstrated similarly high 
mitochondria mass (two sample t-test for the levels of COX4 protein expression, p value= 
0.376), NDUFA13 protein expression was variably decreased relative to control neurons 
(Figure 5- 2). Z scoring helped define the exact levels of NDUFA13 expression and verified 
decreased complex I protein expression in patient neuronal cell bodies (Figure 5- 3). 
Heterogeneous NDUFA13 protein expression levels were evident within individual patients 
and across patients with the same genetic defect (e.g. patient 2 vs. patient 5; m.3243A>G) 
(Figure 5- 3) as previously documented (Lax et al., 2012). This is exemplified by the 
percentages of dentate nucleus neurons that are normal, low, deficient or very deficient for 
NDUFA13 in each patient (Table 5- 2). Although patient 2 and patient 5 harbour the 
m.3243A>G point mutation, the majority (81%) of dentate nucleus neurons possessed by 
patient 2 have normal complex I protein expression, whereas all of patient 5’s neurons are low, 
deficient or very deficient for complex I (Table 5- 2) (Table 4- 1). Similarly, patient 10 
(recessive POLG mutations) has no dentate nucleus neurons that are very deficient for complex 
I, whilst the majority (65%) of neurons possessed by another patient with the same genetic 
defect (patient 11) have very severe complex I protein expression defects (Table 5- 2) (Table 
4- 1). 
There is no difference in the amount of NDUFA13 between patients with the m.3243A>G point 
mutation and others when genetic defects are grouped (m.8344A>G, m.14709T>C and 
recessive POLG mutations) (Mann Whitney U test, p value = 0.4712). Z score values for 
NDUFA13 protein expression were not affected by either PMI (rho= -0.329, p value= 0.297) 
(Appendix A) or by the length of formalin fixation (rho= 0.326, p value= 0.960) (Spearman’s 
rank correlation).  
Remarkably, there is a strong positive relationship between presynaptic terminal (GABAergic 
synapse) (see section 4.4.1) and postsynaptic neuronal (dentate nucleus neuron) NDUFA13 
protein expression. Those patients with the most severe presynaptic complex I deficiency 
(lower NDUFA13 z score values) possess dentate nucleus neurons with severe somatic complex 
I defects (rho= 0.902, p value= 0.0005) (Figure 5- 4).  Furthermore, percentage dentate nucleus 
neuronal loss (Table 4- 1) was negatively related to somatic NDUFA13 protein expression, 
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since patients with the greatest degree of neuronal loss revealed lower NDUFA13 z scores, 
compatible with complex I deficiency, in remaining cells (rho= -0.717, p value= 0.030). 
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5.4.2 Loss of Gephyrin and GABAergic synapse destabilisation  
Further to the amount of inhibitory input to the dentate nucleus, the number of structurally intact 
GABAergic pre- and postsynaptic compartments found on the periphery and proximal dendrites 
of dentate nucleus neurons was assessed (Video 5-1). Quantification of Gephyrin-positive 
puncta found opposed to GAD immunoreactive presynaptic terminals, demonstrated decreased 
punctum density in all patients (Figure 5- 5), though z score values fall within ±2SD limits for 
normality (Figure 5- 5). Decreased Gephyrin punctum density is in line with decreased Purkinje 
cell efferent density documented in Chapter 4 of this thesis. Indeed, there is a significant 
positive relationship between the number of GABAergic presynaptic terminals and Gephyrin 
punctum density detected on dentate nucleus neurons (rho= 0.625, p value= 0.030) (Spearman’s 
rank correlation) (Figure 5- 6). The volume of inhibitory postsynaptic terminals is displayed in 
Appendix C.  
Neither PMI (rho= -0.422, p value= 0.172) (Appendix A) nor fixation length (rho= -0.339, p 
value= 0.281) exerted an effect on inhibitory postsynaptic terminal counts.  
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5.4.3  Glutamatergic innervation of dentate nucleus neurons 
Further to investigating the numerical and structural characteristics of GABAergic synapses on 
dentate nucleus neurons, the excitatory input to the area was partially evaluated. Control dentate 
nucleus neuronal dendrites (outlined in white boxes) received high density of glutamatergic 
input (VGLUT1-positive puncta; presynaptic terminals) and contained similarly high density 
of glutamate receptors (pan-AMPA-positive puncta; postsynaptic terminals) (Figure 5- 7). On 
the contrary, the majority of patients studied possessed dendrites with variably decreased 
excitatory presynaptic terminals and neurotransmitter receptors verified by decreased punctum 
density (Figure 5- 7). Presynaptic terminal and postsynaptic receptor number quantification 
verified altered glutamatergic signalling to the dentate nucleus of patients with mitochondrial 
disease (Figure 5- 8 and Figure 5- 9). MF input to dentate nucleus neurons was decreased in the 
majority of patients studied (10 out of 12) (Figure 5- 8), so was excitatory receptor number 
(Figure 5- 9) though the majority of z score values were within ±2SD limits for normality. 
Decreased glutamatergic synapse density might be consequent to extracerebellar neuronal loss 
(spinal cord and brainstem), however no data are available for the degree of neuronal loss in 
those areas.   
Interestingly, remaining presynaptic terminals and glutamate receptors were smaller since 
punctum number was positively related to punctum size (volume - μm3) (VGUT1: rho = 0.587, 
p value= 0.045 (Figure 5- 10); AMPA receptors: rho= 0.734, p value= 0.007 (Figure 5- 11) 
(Spearman’s rank correlation). The volume of excitatory presynaptic terminals and AMPA 
receptors detected on dentate nucleus neuronal dendrites is displayed in Appendix D and 
Appendix E respectively.  Presynaptic terminal number and volume was not affected by either 
PMI (Number: rho= -0.081, p value= 0.803; Volume: rho= 0.053, p value= 0.871) (Appendix 
A) or fixation length (Number: rho= 0.001, p value= 0.999; Volume: rho= -0.106, p value= 
0.742). Similarly, neither PMI (Number: rho= 0.002, p value= 0.962; Volume: rho= 0.375, p 
value= 0.230) (Appendix A) nor fixation length (Number: rho= -0.460, p value= 0.132; 
Volume: rho= 0.163, p value= 0.612) affected the number and volume of AMPA receptors 
detected (Spearman’s rank correlation).    
  
 
 
 
 
Chapter 5                                              Cerebellar ataxia in patients with mitochondrial disease 
157 
 
 
Figure 5- 7: Dentate nucleus neurons fluorescently stained against Vesicular Glutamate 
transporter 1 (VGLUT1) and Glutamate receptors 1-4 (pan-AMPA).  
High density of excitatory presynaptic terminals (VGLUT1) synapse onto control neuronal dendrites, 
which are enriched for glutamate receptors (AMPA). Although the excitatory input to and the number 
of neurotransmitter receptors on patient 4 (m.3243A>G) neuronal dendrites are similar to that of 
controls, this is not the case for the majority of patients included in this study. Patients 7 
(m.8344A>G), 9 (POLG) and 13 (m.14709T>C) are demonstrative of severely decreased presynaptic 
terminal and postsynaptic receptor densities. Scale bar: 10μm 
 
Chapter 5                                              Cerebellar ataxia in patients with mitochondrial disease 
158 
 
 
 
 
 
 
 
  
F
ig
u
re
 5
- 
8
: 
S
ta
n
d
a
rd
 d
ev
ia
ti
o
n
 l
im
it
s 
fo
r 
th
e 
n
u
m
b
er
 o
f 
g
lu
ta
m
a
te
r
g
ic
 p
re
sy
n
a
p
ti
c
 t
er
m
in
a
ls
 d
et
ec
te
d
 o
n
 d
e
n
ta
te
 n
u
cl
eu
s 
n
eu
ro
n
a
l 
d
en
d
r
it
es
. 
 
M
o
st
 p
at
ie
n
ts
 (
1
0
 o
u
t 
o
f 
1
2
) 
h
ad
 d
ec
re
as
ed
 g
lu
ta
m
at
er
g
ic
 s
y
n
ap
se
 d
en
si
ty
 c
o
m
p
ar
ed
 t
o
 c
o
n
tr
o
ls
, 
al
th
o
u
g
h
 a
ll
 m
ed
ia
n
 z
 s
co
re
 v
al
u
es
 
fa
ll
 w
it
h
in
 t
h
e 
n
o
rm
al
 l
im
it
s 
(±
2
S
D
s)
. 
E
ac
h
 d
at
a 
p
o
in
t 
re
p
re
se
n
ts
 t
h
e 
n
u
m
b
er
 o
f 
p
u
n
ct
a 
d
et
ec
te
d
 p
er
 μ
m
 l
en
g
th
 o
f 
d
en
d
ri
te
 (
n
=
2
0
 
d
en
ta
te
 n
u
cl
e
u
s 
n
eu
ro
n
s)
. 
Chapter 5                                              Cerebellar ataxia in patients with mitochondrial disease 
159 
 
  
 
 
 
 
 
  
F
ig
u
re
 5
- 
9
: 
T
h
e 
n
u
m
b
er
 o
f 
g
lu
ta
m
a
te
 r
e
ce
p
to
rs
 c
o
u
n
te
d
 o
n
 d
en
ta
te
 n
u
cl
eu
s 
n
eu
ro
n
a
l 
d
en
d
ri
te
s 
ex
p
re
ss
ed
 a
s 
z 
sc
o
re
 v
a
lu
es
. 
 
M
o
st
 o
f 
th
e 
p
at
ie
n
ts
 i
n
cl
u
d
ed
 i
n
 t
h
is
 s
tu
d
y
 (
1
0
 o
u
t 
o
f 
1
2
) 
d
em
o
n
st
ra
te
d
 d
ec
re
as
ed
 i
n
 G
lu
ta
m
at
e 
re
ce
p
to
r 
d
en
si
ty
, 
w
h
il
st
 
o
n
ly
 p
at
ie
n
t 
6
 (
m
.3
2
4
3
A
>
G
) 
w
a
s 
si
g
n
if
ic
a
n
tl
y
 d
if
fe
re
n
t 
to
 c
o
n
tr
o
ls
. 
E
ac
h
 d
at
a 
p
o
in
t 
re
p
re
se
n
ts
 t
h
e 
n
u
m
b
er
 o
f 
p
u
n
ct
a 
d
et
ec
te
d
 p
er
 μ
m
 l
en
g
th
 o
f 
d
en
d
ri
te
 (
n
=
2
0
 d
en
ta
te
 n
u
cl
eu
s 
n
eu
ro
n
s)
. 
Chapter 5                                              Cerebellar ataxia in patients with mitochondrial disease 
160 
 
  
F
ig
u
re
 5
- 
1
0
: 
C
o
rr
el
a
ti
o
n
 b
et
w
ee
n
 t
h
e 
n
u
m
b
er
 o
f 
ex
ci
ta
to
ry
 p
re
sy
n
a
p
ti
c 
te
r
m
in
a
ls
 a
n
d
 t
er
m
in
a
l 
v
o
lu
m
e.
 
In
 t
h
o
se
 p
at
ie
n
ts
 w
h
o
se
 d
en
d
ri
te
s 
p
o
ss
es
s 
th
e 
le
ss
 e
x
c
it
at
o
ry
 p
re
sy
n
ap
ti
c 
te
rm
in
al
s,
 t
h
e 
te
rm
in
al
 p
u
n
ct
u
m
 
v
o
lu
m
e 
(m
ea
su
re
d
 i
n
 μ
m
3
) 
w
a
s 
al
so
 s
m
al
le
r 
(S
p
ea
rm
an
’s
 r
h
o
=
 0
.5
8
7
, 
p
 v
al
u
e=
 0
.0
4
5
).
 
 
Chapter 5                                              Cerebellar ataxia in patients with mitochondrial disease 
161 
 
 
 
 
 
 
 
 
 
 
 
 
F
ig
u
re
 5
- 
1
1
: 
C
o
rr
el
a
ti
o
n
 b
et
w
ee
n
 t
h
e 
n
u
m
b
er
s 
o
f 
A
M
P
A
 r
e
ce
p
to
rs
 d
et
ec
te
d
 o
n
 d
en
ta
te
 n
u
cl
eu
s 
n
eu
ro
n
a
l 
d
en
d
ri
te
s 
a
n
d
 r
ec
ep
to
r 
v
o
lu
m
e.
 
In
 t
h
o
se
 p
at
ie
n
ts
 w
h
o
se
 d
en
d
ri
te
s 
p
o
ss
es
s 
th
e 
le
ss
 A
M
P
A
 r
e
ce
p
to
rs
, 
re
ce
p
to
r 
v
o
lu
m
e 
(m
ea
su
re
d
 i
n
 μ
m
3
) 
w
as
 a
ls
o
 
sm
al
le
r 
(S
p
ea
rm
an
’s
 r
h
o
=
 0
.7
3
4
, 
p
 v
al
u
e=
0
.0
0
7
).
 
Chapter 5                                              Cerebellar ataxia in patients with mitochondrial disease 
162 
 
5.5 Discussion 
Cerebellar ataxia, with associated cognitive and motor balance disturbances, frequently affects 
patients with mitochondrial disease (Hudson et al., 2008; McFarland et al., 2010). The 
progressive nature of the condition emphasizes the need for elucidating the mechanisms behind 
neuronal loss that is documented  across the olivo-cerebellar pathway of ataxic patients (Lax et 
al., 2012). Taking into careful consideration the far-reaching evidence for synaptic pathology 
in common neurodegenerative diseases (Marcello et al., 2012; Picconi et al., 2012) and in fact, 
the proposed mechanisms for synaptic dysfunction occurring early in neurodegeneration (Li et 
al., 2003; Janezic et al., 2013), I have decided to study the intracerebellar circuitry in greater 
detail. Quantitative quadruple immunofluorescence was performed in order to assign the degree 
of complex I deficiency in dentate nucleus neurons and to further characterise the GABAergic 
synapse that link these with Purkinje cells. The degree of glutamatergic innervation to the 
dentate nucleus was also determined to gain further insights into the aetiology of dentate 
nucleus neuronal death and its impact on circuitry. 
Patient dentate nucleus neuronal cell bodies have variably decreased complex I protein 
expression, relative to controls, whilst the great extent of inter-patient variability implies that 
the severity of complex I deficiency occurs independent of genetic defect. The degree of dentate 
nucleus neuronal loss correlates with complex I protein expression in remaining cells, which 
suggests that respiratory chain deficiency is detrimental to neuronal viability and is in 
agreement with previous observations (Lax et al., 2012). Interestingly, there is a strong positive 
relationship for the level of complex I protein expression between Purkinje cell efferents 
(inhibitory presynaptic terminals) (Chapter 4) and dentate nucleus neuronal cell bodies, which 
could be indicative for the presence of trans-synaptic effects exerted between the presynaptic 
terminal and the postsynaptic neuron. Recent evidence for the presence of unique cell-to-cell 
communication mechanisms, namely tunnelling nanotubes, that facilitate small organelle 
transport between neighbouring cells (Gerdes et al., 2007; Wang and Gerdes, 2015), implies 
that mitochondria may well be transported between presynaptic terminals and postsynaptic 
neuronal cells. Though highly speculative, mitochondrial transport via tunnelling nanotubes 
could explain for the comparable protein expression levels between the two subneuronal 
compartments. 
As presented in Chapter 4 of this thesis, patient dentate nucleus neurons lose some of their 
inhibitory input, exemplified by decreased GABAergic synapse contact numbers onto dentate 
nucleus neurons. Presynaptic terminal loss is accompanied by a loss in the number of gephyrin-
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positive puncta located at inhibitory postsynaptic sites demonstrated here. Whilst decreased 
presynaptic terminal density is likely due to Purkinje cell loss in the cerebellar cortex, loss of 
gephyrin from the inhibitory postsynaptic compartment may be unfavourable to the excitatory-
inhibitory homeostatic balance necessary for neuronal preservation and circuitry function 
(Turrigiano, 2011). Previous studies suggest neuronal atrophy within the dentate nucleus since 
shrunken neuron cell bodies are detected (Zhou et al., 1997) and axonal loss is reported in the 
absence of neuronal degeneration (Sparaco et al., 1993). Although no such investigations have 
been performed in this study, it would be interesting to assess dentate nucleus axonal 
morphology in association with neuronal density and inhibitory synapse density/volume.   
Gephyrin’s established role in localizing inhibitory receptors at postsynaptic terminals 
(Kneussel and Betz, 2000a; Tretter et al., 2012), via cytoskeletal interactions, signify that 
decreased gephyrin puncta might negatively affect inhibitory receptor localisation and thus 
GABAergic neurotransmission (Varley et al., 2011). On the contrary, decreased puncta might 
simply reflect failure of protein transport to the postsynaptic compartments and/or failure of 
protein aggregation at the site, despite GABAA receptor presence (Levi et al., 2004; Lorenzo et 
al., 2014).  Remarkably, there is a significant positive relationship between inhibitory 
presynaptic terminal (GAD-positive puncta) density and gephyrin punctum density which is 
suggestive of GABAergic synapse destabilisation via potentially trans-synaptic effects. This is 
in agreement with gephyrin knock-down experiments performed in cultured hippocampal 
neurons and demonstrate further presynaptic terminal structural abnormalities with consequent 
inhibitory neurotransmission defects (Yu et al., 2007). Trans-synaptic effects are likely to be 
exerted via pre- and postsynaptic transmembrane proteins that are responsible for holding the 
two terminals in close proximity, namely Neurexins and Neuroligins (Krueger et al., 2012). 
Regardless of the mechanism that accounts for inhibitory synapse destabilisation, the observed 
changes suggest dentate nucleus neuronal disinhibition in patients with mitochondrial disease.  
Further to dentate nucleus neuronal disinhibition, glutamatergic signalling to the region is in 
part also altered. Excitatory MF presynaptic terminal density is decreased, so is the density of 
glutamate receptors detected on dentate nucleus neuronal dendrites. These changes may be 
secondary to extracerebellar neuronal loss within the brainstem and spinal cord, or may reflect 
an adaptive response to decreased dentate nucleus neuronal inhibition. Maintenance of the 
excitatory-inhibitory balance is likely to be neuroprotective since it prevents excitotoxic cell 
death, contrary to what is the speculated mechanisms of neuronal loss in other 
neurodegenerative disorders (Doble, 1999; Dong et al., 2009). Moreover, decreased 
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glutamatergic innervation of the dentate nucleus may be beneficial to already impaired 
mitochondria since excess glutamatergic signalling would result in neuronal Ca2+ overload 
(Prentice et al., 2015). These hypotheses are in agreement with what is discussed in Chapter 4 
of this thesis and suggests that neurodegeneration in patients with mitochondrial disease is not 
due to excitotoxicity. Nevertheless, residual excitatory synapses are smaller which is in contrast 
to what was previously found for inhibitory presynaptic terminals to the dentate nucleus, 
suggesting that excitatory and inhibitory synapses are differentially affected in mitochondrial 
disease. This may well disturb cerebellar synaptic plasticity and thus cerebellar learning with 
downstream effects on cognitive and motor tasks (D'Angelo and Casali, 2012; D'Angelo, 2014; 
Mapelli et al., 2015). 
Notwithstanding the observed changes in neuronal respiratory chain protein expression, 
synaptic density and structure, this study has important limitations that need to be taken into 
careful consideration. Dentate nucleus neurons were identified on the basis of morphology and 
localisation, whereas mainly large glutamatergic cells were sampled. Since cerebellar output 
signals are defined by synergistic DCN function, no definitive conclusions regarding 
extracerebellar signalling can be drawn after only studying large glutamatergic dentate nucleus 
neurons. Furthermore, glutamatergic input to the region was assessed using an anti-VGLUT1 
antibody which is specific to MF excitatory presynaptic terminals and hence only provides 
partial information on dentate nucleus excitation. Finally, the above studies are performed on 
post-mortem human brain and represent end-stage disease, thus results should be interpreted 
with caution whereas conclusions drawn are hypotheses-driven. 
5.5.1 Future work 
Given cerebellar vulnerability to mitochondrial disease, its significance in integrating upstream 
sensory input and fine-tuning downstream motor output and the observed changes that point 
towards altered intra- and extracerebellar circuitry in mitochondrial disease, one appreciates the 
necessity for closely investigating cerebellar circuitry. 
Recent advances in technologies used to control neuronal excitation and inhibition, known as 
optogenetics, can be used in conjunction with custom made microfluidic champers in order to 
understand neuronal connectivity and synaptic function in mitochondrial disease. It would be 
particularly interesting if induced pluripotent stem cells (iPSCs), reprogrammed from patient 
skin fibroblasts, could be differentiated into neurons and even into functional Purkinje cells 
(Wang et al., 2015). These could then be allowed to grow in one site of a microfluidic culture 
platform (Taylor et al., 2005). The perfusion of media across the chamber combined with 
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axonal polarity would drive unidirectional synapse formation (Taylor et al., 2010), the 
structural and physiological properties of which can be assessed. Moreover, manipulation of 
the excitatory-inhibitory balance by optogenetic approaches (Liske et al., 2013) may shed light 
into possible mechanisms that account for neuronal loss in patients with mitochondrial disease.  
Additional to investigating synaptic connectivity, microfluidic chambers can be employed in 
an attempt to test for the presence of trans-synaptic effects. Can wild-type cells, grown on one 
site of the chamber, “correct” the deficiency of the cybrids via anterograde effects or do the 
cybrids retrogradely negatively affect wild-type neurons?  
The above experiments may be performed using different neuronal populations depending on 
the experimental layout. Further to iPSCs, trans-mitochondrial embryonic cybrids 
differentiated into neurons (Kirby et al., 2009; Trevelyan et al., 2010) or primary cultures from 
mouse models for mitochondrial disease may be employed in order to model synaptic pathology 
in mitochondrial disease. 
5.6 Conclusions 
In this study I have shown that dentate nucleus neurons have variably decreased complex I 
protein expression which is independent to the genetic defect. Neuronal complex I deficiency 
strongly correlated with presynaptic terminal deficiency and proposes the presence of trans-
synaptic effects. The loss of inhibitory pre- and postsynaptic compartments suggests for 
GABAergic synapse destabilisation and thus, dentate nucleus neuronal disinhibition. Similarly, 
glutamatergic innervation of dentate nucleus neurons is partially decreased, likely to protect 
remaining cells from excitotoxicity. Nonetheless, altered intra- and extracerebellar circuitry 
detected might be responsible for the cognitive and motor disturbances observed in patients 
with mitochondrial disease.  
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Chapter 6 The microvasculature and its effect on neurodegeneration 
Understanding the mechanisms contributing to stroke-like cortical lesions in patients with 
mitochondrial disease 
6.1 Introduction 
6.1.1 Stroke-like episodes in patients with mitochondrial disease 
The complexity of mitochondrial disease is further exemplified by the plethora of neurological 
symptoms exhibited by patients, amongst which are stroke-like episodes (SLEs) (McFarland et 
al., 2002). Though a crucial feature of patients with the syndromic diagnosis of mitochondrial 
encephalomyopathy with lactic acidosis and stroke-like episode (MELAS), due to the 
m.3243A>G point mutation, SLEs have also been reported in patients with the m.8344A>G 
point mutation and with secondary mtDNA changes due to mutations in the polymerase gamma 
(POLG) gene (Pavlakis et al., 1984; Tanji et al., 2003; Deschauer et al., 2007; Tzoulis et al., 
2014). The term stroke-like is used to describe recurrent neurological deficits that resemble but 
do not mimic ischemic stroke. Instead, SLEs are associated with lesions that do not follow the 
major vascular territories of the brain (Ohama et al., 1987; Suzuki et al., 1990; Sue et al., 1998; 
Tzoulis et al., 2010), they slowly progress to neighbouring brain regions (Iizuka et al., 2003) 
and are more likely to be reversible (Iizuka et al., 2002). Approximately 20% of patients with 
the m.3243A>G point mutation present with the classical MELAS phenotype (SLE 
manifestation) (DiMauro S, 2001) and SLEs can present at any age (Gorman, Shiau Ng et al 
unpublished observation), contrary to what was previously believed (Sproule and Kaufmann, 
2008). They are clinically associated with gradual headache, vomiting, seizures and visual 
abnormalities and are considered to be the underlying cause of focal stroke-like cortical lesions.   
 Stroke-like cortical lesions are present in posterior cortical regions, involving the occipital, 
temporal and parietal lobes, as demonstrated upon neuroradiological imaging (Suzuki et al., 
1990; Sue et al., 1998; Tanji et al., 2003; Tzoulis et al., 2010). Lesions primarily affect grey 
matter areas with relative sparing of the white matter and predominate in different cortical 
regions depending on the genetic defect (occipito-parietal involvement in MELAS and occipital 
lobe involvement for m.8344A>G and POLG mutations) (Tanji et al., 2003; Haas and Dietrich, 
2004; Tzoulis et al., 2010; Gropman, 2013). Histopathological examination in affected areas 
reveals extensive neuronal loss, gliosis plus astrocytic and capillary proliferation (Mizukami et 
al., 1992; Sue et al., 1998; Betts et al., 2006; Tzoulis et al., 2014). 
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6.1.2 Theories of the aetiology of stroke-like episodes 
The hypothesised mechanisms to account for stroke-like episodes have long been proposed and 
an extensive amount of evidence exists to support each of the three hypotheses. These are 
known as the primary vascular, the primary metabolic and the non-ischemic neurovascular 
hypotheses (Ohama et al., 1987; Gilchrist et al., 1996; Iizuka and Sakai, 2005). 
According to the primary vascular hypothesis, mitochondrial dysfunction within the vascular 
smooth muscle and endothelial cells triggers stroke-like lesion formation. Electron microscopy 
observations suggest formation of enlarged mitochondria within the smooth muscle and 
endothelial cells of pial arterioles and small arteries in brain and skeletal muscle  (Ohama et al., 
1987; Sakuta and Nonaka, 1989; Hasegawa et al., 1991; Mizukami et al., 1992), as well as the 
presence of morphologically abnormal mitochondria in capillary pericytes of muscle specimens 
(Sakuta and Nonaka, 1989) serve as the main supporting evidence to this hypothesis. 
Furthermore, high heteroplasmy levels for the m.3243A>G point mutation in COX-deficient 
blood (Betts et al., 2006) and pronounced vascular COX-deficiency (relative to neuronal) in the 
cerebellum of patients with mitochondrial disease favour this theory (Lax et al., 2012). 
Additionally, smooth muscle and endothelial cell loss along with evidence of blood-brain 
barrier breakdown strengthens the notion for mitochondrial angiopathic phenomena (Lax et al., 
2012). Lastly, changes in regional blood flow as a consequence of decreased cerebrovascular 
reactivity in patients with the MELAS syndrome (Rodan et al., 2015) and improvement of 
stroke-like episode severity following L-arginine supplementation (Koga et al., 2005; Koga et 
al., 2012) hint towards endothelial-driven vasodilatory defects. 
The primary metabolic hypothesis suggests that stroke-like episodes are a consequence of a 
generalised metabolic crisis, likely an additive effect of neuronal, glial and vascular dysfunction 
(Gropen et al., 1994; Gilchrist et al., 1996). Work performed by Gilchrist and colleagues was 
supportive of this hypothesis since neuronal and vascular (both in endothelial and smooth 
muscle cell layers) mitochondria had abnormal cristae organisation upon electron microscopic 
investigation. Moreover, high levels for the m.3243A>G point mutation in brain were unlikely 
to solely be due to high heteroplasmic levels in blood vessels (Gilchrist et al., 1996). Similarly, 
molecular genetic analysis performed by Betts and co-workers revealed high heteroplasmic 
levels (for the m.3243A>G point mutation) in neurons, though these did not correlate with 
lesion severity (Betts et al., 2006).  
Lastly, the concept that mitochondrial dysfunction in capillaries, neurons or astrocytes results 
in neuronal hyperexcitability is the basis to the non-ischemic neurovascular hypothesis (Iizuka 
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and Sakai, 2005). Acute focal hyperperfusion and local neuronal hyperexcitability may initiate 
a cascade of depolarising events in neighbouring cortical regions shifting the balance between 
energetic demand and supply (Iizuka et al., 2002; Iizuka et al., 2003). This leads to capillary 
permeability, local neuronal loss and progressive lesion spreading (Iizuka et al., 2002; Iizuka 
and Sakai, 2005). 
Despite the fact that SLEs has been at the centre stage for many years none of the proposed 
hypotheses for the aetiology of these episodes is universally accepted, thus the mechanisms 
underpinning SLE manifestation remain unresolved. The pathological changes associated with 
SLEs have previously been characterised (Mizukami et al., 1992; Betts et al., 2006; Lax et al., 
2012; Tzoulis et al., 2014). However there needs to be a more detailed investigation of the 
vascular abnormalities in the CNS of patients who present with SLEs if we are to unravel the 
mechanisms activated and the molecular pathways involved in SLE manifestation. Extended 
pathological studies combined with direct clinical observations are likely to help identify good 
candidates for drug targeting and reverse (at least in part) the symptoms of patients who present 
with SLEs.       
6.1.3 The neurovascular unit 
The high energetic demand of the brain necessitates a highly sophisticated and dynamic blood 
supply system to couple blood flow to neural activity. Blood vessels are hierarchically divided 
into the pial arteries, parenchymal arterioles and capillaries, each of which provides different 
structural and functional characteristics (Jones, 1970; Cipolla, 2009). Whilst pial arteries 
contain a single inner endothelial cell layer and an outer layer composed of smooth muscle cells 
(Cipolla et al., 2004), parenchymal arterioles are composed of a single smooth muscle and 
endothelial cell layer and an outermost layer made up of astrocytic end-feet (Iadecola, 2004). 
The former receive extrinsic input from the peripheral nervous systems, whereas the latter 
communicate with intrinsic neuronal populations. Capillaries on the other hand, establish 
coupling between neurons and vessels, giving rise to the so-called neurovascular unit. This is 
composed of an innermost endothelial cell layer engulfed by capillary pericytes and encased by 
the end feet of astrocytes (Zlokovic, 2008) and is responsible for the exchange of oxygen and 
nutrients between the capillary bed and neurons. 
The synergistic relationship between pial arteries, arterioles and capillaries along with the 
constant integration of signals arriving from neurons and astrocytes, assures for homeostatic 
blood supply to the brain. The anatomy of the neurovascular unit is summarised in Figure 6- 1. 
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Figure 6- 1: The neurovascular unit.  
Pial arteries run along the surface of the brain and branch into arterioles and capillaries that penetrate deeper into 
the brain. Pial arteries consist of an endothelial cell layer, multiple smooth muscle cell layers (2-3) and an 
outermost layer of perivascular nerves. Penetrating arterioles are composed of a single endothelial and smooth 
muscle cell layer and receive intrinsic input through contact with astrocytic end-feet and local neurons. Intrinsic 
input is also conferred to capillaries which are composed of an innermost endothelial cell layer ensheathed by 
pericytes.  
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6.1.4 Mitochondrial function and the vasculature 
Although mitochondria are widely known for their capacity for energy production, their 
function goes beyond ATP synthesis and includes cellular signalling and apoptosis (Quintero 
et al., 2006; Dromparis and Michelakis, 2013; Tang et al., 2014). The relatively low energetic 
requirements of the vasculature are met by glycolytic ATP production (Lynch and Paul, 1983; 
Culic et al., 1997), and vascular mitochondrial density is moderate compared to other tissues 
(Oldendorf et al., 1977).  
The major signalling mechanism utilised by vascular mitochondria involves the production of 
reactive oxygen species (ROS). Under physiological conditions, ROS production affects 
vascular tone and cerebral blood flow via regulation of vasoconstrictive and vasodilatory 
events. Decreased ROS levels promote vascular remodelling, whereas excess ROS drives 
apoptotic cell death (Dromparis and Michelakis, 2013). Indeed, mitochondrial dysfunction due 
to excessive ROS production has been demonstrated to contribute to vascular disease (Algahim 
et al., 2012; Hill et al., 2012). 
Likewise, the mitochondrial calcium buffering capacity might have important implications for 
endothelial function and its response to pathological stimuli (Kluge et al., 2013; Tang et al., 
2014), particularly since calcium plays an important role in arteriole dilation (Bubolz et al., 
2012) and microvascular response to inflammation (Rowlands et al., 2011). Lastly, 
mitochondria are crucial to endothelial senescence and apoptosis. Cell senescence is mediated 
via altered mitochondrial dynamics and elevated mitochondrial ROS in response to normal 
ageing and/or exposure to cellular stressors (Jendrach et al., 2005; Minamino and Komuro, 
2007; Mai et al., 2010; Tang et al., 2014). The apoptotic cell death pathway and consequent 
endothelial cell loss is triggered by damaging signals and/or disturbed oxygen and nutrient 
supply to the mitochondria which depolarize the organelles or release pro-apoptotic factors 
respectively (Wang and Youle, 2009). 
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6.2 Aims of the investigation 
This study primarily aims to explore the consequences of mtDNA defects on the brain 
vasculature in order to improve our understanding of the aetiology of stroke-like episodes and 
the underlying pan-necrotic lesions seen in patients with mitochondrial disease. I will achieve 
this by: 
1. Investigating respiratory chain protein abundance in endothelial capillaries and 
arterioles of posterior cortical regions. 
2. Associating neuropathological observations with clinical data available for these 
patients. 
Additionally, since a number of controls were not age-matched, I explored the effect of 
physiological ageing respiratory chain protein expression and complex IV activity in the 
vasculature of cognitively normal controls. 
6.3 Methodology 
6.3.1 Brain tissue samples 
For the purposes of this study FFPE cerebellar, occipital and temporal lobe tissue sections from 
eleven patients who received a genetic and clinical diagnosis confirming mitochondrial disease 
were neuropathologically investigated (Table 6- 1). Ten cognitively-normal controls acquired 
from the NBTR were employed to assess the extent of respiratory chain protein deficiency in 
patients, whereas ten neurologically-normal controls obtained from the MRC Sudden Death 
Brain and Tissue bank in Edinburgh were used to test for age-related changes in respiratory 
chain protein expression in the vasculature. Control and patient tissue neuropathological details 
are summarised in Table 6- 2.
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 Type 
Age 
(years) 
Sex 
Length of 
fixation 
(weeks) 
Post-
mortem 
delay 
(hours) 
Cause of death Source 
Control 1 69 Female 6 16 Gastric cancer NBTR 
Control 2 68 Male 8 54 Bowel cancer NBTR 
Control 3 78 Female 5 23 
metastatic oesophageal 
carcinoma 
NBTR 
Control 4 74 Female 13 67 Lung cancer NBTR 
Control 5 55 Male 14 41 Liver cancer NBTR 
Control 6 74 Female 9 53 Heart failure and lung cancer NBTR 
Control 7 70 Male 11 72 Metastatic prostate cancer NBTR 
Control 8 73 Male 7 25  NBTR 
Control 9 78 Female 8 34 Metastatic cancer  NBTR 
Control 10 45 Male 13 13  NBTR 
Control 11 43 Male 1 96 
Coronary artery thrombosis 
and atherosclerosis 
Edinburgh 
Control 12 74 Female 1 41 
Pulmonary 
thromboembolism 
Edinburgh 
Control 13 70 Male 1  
Hypertensive and ischaemic 
heart disease, Type 2 
diabetes and Fatty 
degeneration of the liver 
Edinburgh 
Control 14 52 Male 1 52 
Ischaemic heart disease, 
Coronary artery 
atherosclerosis and Type 2 
Diabetes Mellitus 
Edinburgh 
Control 15 71 Female 1 41 
Ischaemic and hypertensive 
heart disease 
Edinburgh 
Control 16 75 Male 1 78 
Ischaemic heart disease and 
Coronary artery 
atherosclerosis 
Edinburgh 
Control 17 51 Male 1 71 
Ischaemic heart disease and 
Coronary artery 
atherosclerosis 
Edinburgh 
Control 18 41 Female 1 50 Unascertained Edinburgh 
Control 19 33 Male 1 47 
Ischaemic heart disease and 
Coronary artery 
atherosclerosis 
Edinburgh 
Control 20 68 Male 1 96 
Complications of familial 
amyloid polyneuropathy 
Edinburgh 
Patient 1 36 Female 1 42 Cardiac arrest NBTR 
Patient 2 60 Female 6 10 Multi-organ failure NBTR 
Patient 3 30 Male 10 69 Mitochondrial disease NBTR 
Patient 4 45 Female 8 43 Mitochondrial disease NBTR 
Patient 5 20 Male 6 187 
Aspiration, pneumonia and 
MELAS 
NBTR 
Patient 7 42 Male 8 59 Respiratory failure NBTR 
Patient 8 58 Male 6 66 Stroke-like episodes NBTR 
Patient 9 59 Female 4 67 Pneumonia NBTR 
Patient 10 79 Female 8 85 Respiratory failure NBTR 
Patient 11 55 Male 7 112 Respiratory failure NBTR 
Patient 12 24 Female 18 83 
Suppurative 
tracheobronchitis 
NBTR 
Table 6- 2: Neuropathological details of control and patient tissue included in the study 
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6.3.2 Dual COX/SDH histochemistry 
15μm-thick frozen brain tissue sections (cerebellum, occipital and temporal lobe) from 
cognitively normal controls (nine acquired from the NBTR and four from the MRC Sudden 
Death Brain and Tissue bank, Edinburgh) were subjected to a dual COX/SDH histochemical 
assay as previously described (section 2.5).  
Microvessels were rated according to a semi-quantitative rating scale to ascertain the level of 
deficiency as follow: 
Rating scale Criteria 
+ Mild vascular COX-deficiency (~10% of vessels deficient) 
++ Intermediate vascular COX-deficiency (~30% of vessels deficient) 
+++ Pronounced vascular COX-deficiency (~60% of vessels deficient) 
++++ Severe vascular COX-deficiency (~80% vessels deficient) 
+++++ COX-deficient vessels present throughout neuropil 
 
The rating system described above relies on the subjective categorisation of vascular COX 
deficiency, highlighting the need to study respiratory chain protein expression in the brain 
vasculature using a more reliable, objective and quantitative method.  
6.3.3 Immunofluorescence, confocal microscopy and image processing 
A previously developed quantitative quadruple immunofluorescent technique (Chapter 3 of this 
thesis) was used to ascertain the loss of respiratory chain protein subunits within the vasculature 
of patients with mitochondrial disease compared to cognitively normal controls (section 2.7.1). 
Glucose transporter 1 (GLUT-1) and alpha smooth muscle actin (α-SMA) were employed to 
detect the endothelial and smooth muscle cell layer of capillaries and arterioles respectively. 
The outer mitochondrial membrane protein porin (VDAC1) was used as a mitochondrial mass 
marker, whereas NADH dehydrogenase [ubiquinone] I beta subcomplex subunit 8 (NDUFB8) 
and cytochrome c oxidase (COX) subunit 1 (COXI) were used to investigate complex I and IV 
protein expression respectively. All primary and secondary antibodies employed along with 
their optimal working conditions are listed in Table 6- 3. 
Twenty cortical arterioles and twenty cortical capillaries were randomly selected using a point 
scanning confocal microscope (Nikon A1R) (section 2.8.1). Laser settings were kept constant 
throughout imaging and z stacking was performed according to the recommended microscope 
settings (section 2.8.1).  
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Complex I and IV subunit expression in microvessels was assessed using Volocity®. Once 
arterioles and capillaries were identified (using α-SMA and GLUT-1 as a reference channel 
respectively), mitochondria were detected based on their immunoreactivity with porin. 
Vascular mitochondria were isolated after compartmentalising the mitochondrial population 
between the vascular population (either arterioles or capillaries). These were then used to obtain 
fluorescent intensity measurements for porin, NDUFB8 and COXI.   
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Table 6- 3: Primary and secondary antibodies used in this study and their optimised working conditions. 
* Indicates antibodies used in alteration.  
Primary antibodies
Host and 
isotype
Source
Catalogue 
No.
Antigen 
retrieval
Optimal 
dilution
Optimal 
incubation 
conditions
Alpha- Smooth 
muscle actin 
(SMA)*
Rabbit 
polyclonal - IgG
Abcam ab5694
EDTA (1mM); 
2100 antigen 
retriever
1 in 100 O/N at 4
o
C
Voltage-dependent 
anion channel 1 
(VDAC1)
monoclonal - 
IgG2b
Abcam ab14734
EDTA (1mM); 
2100 antigen 
retriever
1 in 200 O/N at 4
o
C
Complex I subunit 
NDUFB8
Mouse 
monoclonal - 
IgG1
Abcam ab110242
EDTA (1mM); 
2100 antigen 
retriever
1 in 100 O/N at 4
o
C
Complex IV 
subunit I
Mouse 
monoclonal - 
IgG2a
Abcam ab14705
EDTA (1mM); 
2100 antigen 
retriever
1 in 200 O/N at 4
o
C
Secondary 
antibodies
Host and 
epitope
Source
Catalogue 
No.
Antigen 
retrieval
Optimal 
dilution
Optimal 
incubation 
conditions
Biotin-SP 
Goat Anti-Mouse 
IgG1 (γ1)
Jackson 
ImmunoRe
search
115-065-
205
N/A 1 in 200
2 hours, 
4
o
C
Streptavidin, Alexa 
Fluor® 647 
Conjugate
N/A
Life 
technologi
es
S32357 N/A 1 in 100
2 hours, 
4
o
C
Alexa Fluor® 405
Goat Anti-Rabbit 
IgG (H+L)
Life 
technologi
es
A31556 N/A 1 in 100
2 hours, 
4
o
C
Alexa Fluor® 488
Goat Anti-Mouse 
IgG2a (γ2a)
Life 
technologi
es
A21131 N/A 1 in 100
2 hours, 
4
o
C
Alexa Fluor® 546
Goat Anti-Mouse 
IgG2b (γ2b)
Life 
technologi
es
A21143 N/A 1 in 100
2 hours, 
4
o
C
Quadruple immunofluorescence
Rabbit 
polyclonal - IgG
Thermo 
Scientific
PA1-
21041
EDTA (1mM); 
2100 antigen 
retriever
1 in 100 O/N at 4
o
C
Glucose 
transporter 1 
(GLUT-1)*
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6.3.4 Statistical analysis 
The mean OD values for porin, NDUFB8 and COXI were employed to derive z score for 
complex I and IV protein expression. A previously described protocol was used (section 3.4.7) 
with the following modifications: 
For each arteriole or capillary the z score for NDUFB8 and COXI levels deviated from the 
linear regression based on the level of porin.  
Each microvessel was classified based on the standard deviation limits for NDUFB8 and COX1 
as normal, low, deficient or very deficient. Any other statistical testing was performed as before 
(section 4.3.5). 
6.4 Results 
6.4.1 COX-deficiency in the vasculature of neurologically normal controls 
Controls obtained from the NBTR and from the MRC Sudden Death Brain and tissue Bank, 
Edinburgh, exhibited different vascular porin protein expression levels. This was initially 
speculated to be due to intrinsic tissue processing differences between the two brain tissue 
resources, thus the controls used to ascertain respiratory chain protein deficiencies in the 
vasculature of patients with mitochondrial disease were obtained from the same resource as 
patient samples (NBTR).  
Prior to investigating the level of respiratory chain protein expression in the vasculature of 
patients with mitochondria disease, the accuracy/validity of the dual COX/SDH histochemical 
assay in determining vascular respiratory chain protein deficiency was tested. Surprisingly, 
controls obtained both from the NBTR and the MRC Sudden Death Brain and Tissue Bank, 
Edinburgh, (where frozen tissue was available – 13 out of 20 controls) harboured COX-
deficient vessels in the cerebellum, occipital and temporal lobe as observed following 
COX/SDH histochemistry (Figure 6- 2). Remarkably, some microvessels had absence of COX 
and SDH reactivity implying that they might be depleted of mitochondria   (control 7 – occipital 
lobe (Figure 6- 2)). Semi-quantitative scores for the severity of vascular COX-deficiency is 
suggestive of considerable mitochondrial dysfunction in the cerebellar, occipital lobe and 
temporal lobe vasculature of neurologically normal controls (Table 6- 4). 
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Figure 6- 2: Respiratory chain deficiency in the control vasculature. 
Grey matter microvessels stained brown are positive for COX activity, those stained blue  (control 11, temporal 
lobe) are COX deficient, whist microvessels stained purple/grey (control 9, occipital lobe) display intermediate 
COX deficiency. Scale bar: 50μm. NT- no tissue available 
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Sample ID Cerebellum Occipital Temporal 
Control 1 +++ ++++ +++ 
Control 2 ++ ++ +++ 
Control 3 +++ + NT 
Control 4 ++++ + ++++ 
Control 5 ++++ ++ +++++ 
Control 6 +++ ++ ++++ 
Control 7 +++ +++ ++ 
Control 9 ++++ +++++ +++++ 
Control 10 ++++ ++++ +++ 
Control 11 NT +++++ ++++ 
Control 14 ++++ +++ ++++ 
Control 17 NT ++++ ++++ 
Control 18 +++ +++ ++++ 
Table 6- 4: The severity of COX deficiency in control microvessels.  
Though neurologically normal, all controls sampled have some degree of vascular COX deficiency 
in the cerebellum, occipital and temporal lobes.  NT – no tissue available. 
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6.4.2 Respiratory chain protein expression in the cerebellar vasculature 
Control cerebellar endothelial capillaries, as judged by the expression of GLUT-1, contained 
distinct porin-positive puncta indicative of mitochondrial mass (Figure 6- 3). In control 
capillaries, these mitochondria co-localised with NDUFB8 and COXI implying that 
mitochondria in control capillaries have intact complex I and IV protein expression respectively 
(Figure 6- 3). Similarly, a patient harbouring the m.8344A>G point mutation (Patient 7) and a 
patient with recessive POLG mutations (Patient 11) (Table 6- 1) demonstrated matched porin, 
COXI and NDUFB8 protein expression. On the contrary, capillaries that belonged to Patient 5 
(m.3243A>G) lacked NDUFB8 and COXI immunoreactivity, compatible with deficiencies of 
complexes I and IV (Figure 6- 3). Protein expression quantification and z score analysis helped 
assign the level of respiratory chain protein deficiency and precisely determine the percentage 
of microvessels that were normal, low, deficient or very deficient for each of the two proteins 
(NDUFB8 and COXI). As demonstrated in Figure 6- 4A, patients harbouring the m.3243A>G 
point mutation have variably decreased levels of NDUFB8 (coloured boxplots) and COXI (clear 
boxplots), whereas patients harbouring the m.8344A>G point mutation (patient 7 and 8) and 
those with recessive POLG mutations (Patients 9-12) are generally comparable to controls. 
Patient 8 (m.8344A>G) has isolated COXI defects and patient 12 is the only patient amongst 
those with recessive POLG mutations to show mildly decreased NDUFB8 and COXI protein 
expression (Table 6- 1) (Figure 6- 4A). Microvessel characterisation exemplifies the presence 
of combined complex I and IV defects in patients harbouring the m.3243A>G point mutation 
relative to others (m.8344A>G point mutation and recessive POLG mutations) (Table 6- 5).  
Z scores derived for complex I and IV protein expression in the cerebellar endothelial cell layer 
were not affected by PMI (NDUFB8: rho= -0.155, p value= 0.65; COXI: rho= -0.091, p value= 
0.79) (Appendix A) or by the length of formalin fixation (NDUFB8: rho= 0.046, p value= 
0.892; COXI: rho= 0.593, p value= 0.055) (Spearman’s rank correlation). 
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Figure 6- 4: Respiratory chain protein expression quantification in the cerebellar vasculature. 
Z score values for the levels of NDUFB8 (coloured boxplots) and COXI (clear boxplots) in the 
cerebellar endothelial (A) and smooth muscle (B) cell layers. (A) Patients with the m.3243A>G point 
mutation have combined complex I and IV defects, whereas patient 5 is the one most severely affected. 
Amongst patients with other genetic defects, mild protein expression changes are evident in patient 8 
(m.8344A>G) and 12 (recessive POLG). (B) Likewise, patients harbouring the m.3243A>G point 
mutation demonstrate marked changes in NDUFB8 and COXI protein expression in cerebellar 
arterioles relative to controls. Protein expression changes are also evident in patients 8 (m.8344A>G) 
and 12 (recessive POLG), though to a lesser extent. Each data point reflects a single arteriole or 
capillary (n=20). 
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Similar to endothelial capillaries, cerebellar arterioles, identified by the expression of α-SMA,  
contained puncta that were positive for porin, indicative of arteriolar mitochondria (Figure 6- 
5). Control arterioles had intact complex I and IV protein expression since porin puncta 
colocalised with NDUFB8 and COXI respectively (Figure 6- 5). Interestingly, mitochondria in 
patient arterioles were seemingly aggregated closer to the nuclei (vacuole-like pockets), 
whereas evidence for nuclear proliferation arise from increased density of vacuole-like nuclear 
pockets (Patient 3, m.3243A>G; Patient 12, recessive POLG) (Figure 6- 5).  Additional to 
morphological abnormalities, arteriolar mitochondria had an absence of NDUFB8 and COXI 
reactivity in a patient harbouring the m.3243A>G point mutation (patient 3), whereas those that 
belonged to patients 7 (m.8344A>G) and 12 (recessive POLG) demonstrated severely 
decreased protein expression levels (Figure 6- 5). Standard deviation limits for the amount of 
respiratory chain protein expression in the smooth muscle cell layer shows variable NDUFB8 
and COXI expression, with low protein expression levels in patients with the m.3243A>G point 
mutation, a patient with the m.8344A>G point mutation (patient 8) and one with recessive 
POLG mutations (patient 12) (Figure 6- 4B). The observed changes are confirmed by the 
percentage of arterioles that are normal, low, deficient or very deficient for either of the two 
proteins (Table 6- 5). Indeed, only 30% of patient 3’s (m.3243A>G) arterioles have normal 
NDUFB8 and COXI protein expression, whereas approximately half (~55%) the arterioles 
sampled from patient 1 and 5 (m.3243A>G) are normal for either of the two proteins (Table 6- 
5). Patient 2 and 4 (m.3243A>G) possess arterioles that have normal COXI protein expression 
levels, though some blood vessels are low (patient 2 and 4) and/or very deficient (patient 4) for 
NDUFB8 (Table 6- 5). Likewise, the majority (>60%) of arterioles sampled from patient 8 
(m.8344A>G) and 12 (recessive POLG) have normal respiratory chain protein expression 
levels (NDUFB8 and COXI), whereas a small proportion of these are low, deficient or very 
deficient for NDUFB8 and COXI (Table 6- 5).  
Neither PMI (NDUFB: rho= 0.173, p value= 0.612; COXI: rho= 0.291, p value= 0.385) 
(Appendix A) nor fixation length (NDUFB8: rho= -0.056, p value= 0.871; COXI: rho= 0.093, 
p value= 0.787) exerted any effect on the z score values for respiratory chain protein expression 
in cerebellar arterioles (Spearman’s rank correlation).  
When only taking into consideration respiratory chain protein expression in the vasculature of 
patients with the m.3243A>G point mutation it is evident that the smooth muscle cell layer is 
more severely affected. Both complex I and IV deficiencies are more pronounced at the arteriole 
(median NDUFB8z = -1.640, median COXIz = -1.653) compared to the capillary level (median 
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NDUFB8z = -1.056, median COXIz = -1.591), though respiratory chain protein expression is 
not statistically different between the two cellular populations (endothelial vs. smooth muscle 
cell layer) (Wilcoxon Signed-Rank test).  
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6.4.3 Respiratory chain protein expression in the occipital lobe vasculature 
Similar to the cerebellum, control capillaries in the occipital lobe contained mitochondria with 
intact complex I and IV expression (Figure 6- 6). The same was true for patients 7 
(m.8344A>G) and 9 (recessive POLG) who contained capillaries with matched porin, NDUFB8 
and COXI protein expression (Figure 6- 6). Patient 5 (m.3243A>G) on the other hand, 
possessed capillaries with severely decreased complex I and IV protein expression since porin 
puncta (mitochondria) did not co-localise with either NDUFB8 or with COXI (Figure 6- 6). 
Indeed, respiratory chain protein expression quantification indicated severe complex I 
deficiencies in 4 out of 5 patients carrying the m.3243A>G point mutation (patients 1, 2, 3 and 
5) accompanied with milder COXI protein expression changes (Figure 6- 7A). Of the remaining 
patients (patients 7-12), only patient 8 (m.8344A>G) and 12 (recessive POLG mutations) 
demonstrated protein expression levels with z scores at the lower range of normal ±2 SD limits 
(Figure 6- 7A). Categorizing occipital lobe capillaries according to z score values for NDUFB8 
and COXI protein expression highlights extensive complex I and milder complex IV 
deficiencies in patients harbouring the m.3243A>G point mutation, whereas remaining patients 
have very low (if any) percentage of microvessels that are abnormal for either of the two 
proteins (Table 6- 6). 
Z scores for the level of NDUFB8 and COXI protein expression in occipital lobe capillaries 
were not affected by either PMI (NDUFB8: rho= -0.018, p value= 0.958; COXI: rho= -0.045, 
p value= 0.894) (Appendix A) or fixation length (NDUFB8: rho= 0.185, p value= 0.586; COXI: 
rho= 0.176, p value= 0.605) (Spearman’s rank correlation).
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Figure 6- 7: Z score values for the levels of NDUFB8 and COXI expression  in occipital lobe vasculature. 
(A) Patients harbouring the m.3243A>G point mutation have pronounced NDUFB8 (coloured boxplots) and COXI 
(clear boxplots) protein expression defects in occipital lobe capillaries. Amongst patients with other genetic 
defects, mild respiratory chain protein expression decrease is observed in patients 8 (m.8344A>G) and 12 
(recessive POLG).  (B) Occipital lobe arterioles that belong to patients 1-5 (m.3243A>G) have combined complex 
I and IV protein expression changes. Of patients with other genetic defects, decreased protein expression is only 
evident in patients 7 and 8 (m.8344A>G). Each data point reflects a single arteriole or capillary (n=20).
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Arterioles located at the occipital lobe of controls contained distinct mitochondrial puncta with 
equally high immunoreactivity for NDUFB8 and COXI (Figure 6- 8). In contrast, 
“mitochondrial aggregates” located in close proximity to the nuclei were evident in the 
arterioles of patients harbouring the m.3243A>G and m.8344A>G point mutations (Figure 6- 
8). These mitochondria were complex I (for both patient 3 and 8) and IV (mainly in patient 8) 
deficient since they lacked antibody immunoreactivity overall (Figure 6- 8). Instead, patient 9 
(recessive POLG mutations) possessed arterioles with morphologically normal mitochondria 
with intact complex I and IV protein expression (Figure 6- 8). Z score analysis indicated 
decreased NDUFB8 and COXI expression levels in patients with the m.3243A>G point 
mutation, compatible with high percentage of vessels that are low, deficient and very deficient 
for the two proteins (Figure 6- 7B and Table 6- 6). Of the other patients, mild protein expression 
changes were present in patients 7, 8 (m.8344A>G) 11 and 12 (recessive POLG) (Figure 6- 7B 
and Table 6- 6).  
Protein expression was not affected by PMI (NDUFB8: rho= 0.391, p value= 0.235; COXI: 
rho= 0.327, p value= 0.326) (Appendix A) or by the length of formalin fixation (NDUFB8: 
rho= -0.009, p value= 0.987; COXI: rho= 0.028, p value= 0.935) (Spearman’s rank correlation).  
Remarkably, respiratory chain protein deficiencies in patients with the m.3243A>G are more 
severe in the endothelial cell layer relative to the smooth muscle layer as exemplified by the 
lower z score values for NDUFB8 and COXI protein expression (Endothelial cell layer: 
NDUFB8z= -2.67. COXIz= -1.621; Smooth muscle cell layer: NDUFB8z= -2.161, COXIz= -
1.349). Complex I protein expression in arterioles (smooth muscle layer) is not significantly 
different  from that in capillaries (endothelial cell layer), neither is complex IV protein 
expression (Wilcoxon Singned-Rank test). 
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6.4.4 Respiratory chain protein expression in temporal lobe vasculature 
Whilst control temporal lobe capillaries contain mitochondria immuno-positive for NDUFB8 
and COXI indicating intact complex I and IV protein expression, patient 5 (m.3243A>G) 
possesses arterioles with marked complex I and IV deficiencies (Figure 6- 9). Capillary 
complex I deficiency is also evident in patient 12 (recessive POLG mutations), whereas patient 
7 (m.8344A>G) contains capillaries with retained respiratory chain protein expression (Figure 
6- 9). In agreement with observations made in the cerebellum and occipital lobe, patients 
harbouring the m.3243A>G point mutation have marked reduction of complex I and IV protein 
expression relative to controls as revealed by z score analysis (Figure 6- 10A). Patients with 
other genetic defects (m.8344A>G and recessive POLG mutations) possess microvessels with 
mainly preserved respiratory chain protein expression as demonstrated by the high percentage 
(90-100%) of vessels that are normal for both NDUFB8 and COXI (Figure 6- 10A and Table 
6- 7). 
Z scores for respiratory chain protein expression in temporal lobe capillaries were not affected 
by PMI (NDUFB8: rho= -0.036, p value= 0.915; COXI: rho= -0.136, p value= 0.689) 
(Appendix A) or fixation length (NDUFB8: rho= -0.056, p value= 0.445, p value= 0.171) 
(Spearman’s rank correlation). 
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Figure 6- 10: Z score analysis and standard deviation limits for respiratory chain protein expression 
in temporal lobe vasculature. 
(A) Patients 2-5 (m.3243A>G) have decreased NDUFB8 (coloured boxplots) and – to a lesser extent- 
COXI (clear boxplots) protein expression in temporal lobe capillaries, whereas protein expression defects 
are also evident for patients 8 (m.8344A>G), 9 and 10 (recessive POLG). (B) Arteriolar respiratory chain 
protein expression is decreased in patients 1-5 (m.3243A>G), while moderate changes also occur in patient 
8 (m.8344A>G). Each data point reflects a single arteriole or capillary (n=20). 
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In spite of complex I- and IV- intact mitochondria present in control temporal lobe arterioles, 
the arterioles of patients harbouring the m.3243A>G point mutation contained groupings of 
mitochondria that are deficient for both complex I and IV (Figure 6- 11). On the contrary, the 
smooth muscle cell layer in the arterioles of patient 7 (m.8344A>G) contained mitochondria 
with mildly decreased NDUFB8, whereas patient 10 (recessive POLG mutations) possessed 
arterioles with complex I- and IV-intact mitochondria (Figure 6- 11). Quantification of 
immunofluorescence demonstrates altered NDUFB8 and COXI protein expression only in the 
arterioles of patients with the m.3243A>G point mutation (Figure 6- 10B), reflected by the 
variable percentage of arterioles that are normal, low, deficient or very deficient in these 
patients (Table 6- 7). Amongst patients with other genetic defects, only patient 8 (m.8344A>G) 
contained vessels with abnormal respiratory chain protein expression (Figure 6- 10B and Table 
6- 7).  
Neither PMI (NDUFB8: rho= 0.391, p value= 0.235; COXI: rho= -0.118, p value= 0.729) 
(Appendix A) nor fixation length (NDUFB8: rho= -0.046, p value= 0.892; COXI: rho= -0.083, 
p value= 0.808) affected respiratory chain protein expression in temporal lobe arterioles. 
Interestingly, in patients with the m.3243A>G point mutation there is more complex I 
expression defects in the endothelial cell layer (Median NDUFB8z: endothelium= -1.703, 
smooth muscle= -1.233), whilst complex IV protein expression abnormalities are more 
pronounced in the smooth muscle cell layer (Median COXIz: endothelium= -0.587, smooth 
muscle cell layer= -1.052). Nevertheless, the level of NDUFB8 and COX1 expression between 
the two vascular cell populations is not significantly different (Wilcoxon Signed-Rank test).  
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For both the endothelial and smooth muscle cell layer there is considerable variation in the 
degree of complex I and IV deficiency observed between patients. Patients with the 
m.3243A>G point mutation have significantly more severe vascular respiratory chain protein 
expression defects across all brain regions investigated (cerebellum, occipital and temporal 
lobe) compared to patients with other genetic defects (m.8344A>G and recessive POLG 
mutations). Complex IV deficiency is more pronounced in the cerebellar vasculature, whereas 
the occipital and temporal lobe microvessels have more complex I protein expression defects. 
Moreover, the smooth muscle cell layer of cerebellar arterioles harbours the more severe defects 
(relative to the endothelial cell layer) contrary to severe respiratory chain deficiency observed 
in the endothelial cell layer of occipital and temporal lobe capillaries. Generally, and when only 
taking into account patients with the m.3243A>G point mutation, the occipital lobe vasculature 
was most severely affected followed by defects in the cerebellum and the temporal lobe. 
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6.4.5 Investigating respiratory chain protein expression in ageing brain vasculature 
Since the controls employed to assess respiratory chain protein expression in the vasculature 
were not age-matched to patients with mitochondrial disease, we examined whether age exerts 
any effect on vascular mitochondrial mass and/or respiratory chain protein expression. For this 
purpose, occipital lobe tissue from ten cognitively normal controls (obtained from the MRC 
Sudden Death Brain and Tissue Bank in Edinburgh) was subjected to quadruple 
immunofluorescence (see section 6.3.3). The control age-range varied between 33-75 years of 
age whilst all controls had a standard 1 week of formalin fixation (Controls 11-20) (Table 6- 
2). As demonstrated in Figure 6- 12, all controls contained distinct porin–positive puncta, 
representing mitochondria, with matched NDUFB8 and COXI protein expression. No changes 
in protein expression within the smooth muscle cell layer were evident between controls of 
different ages (Figure 6- 12). Indeed, z scores for the level of porin (Figure 6- 13A), NDUFB8 
(Figure 6- 13B) and COXI (Figure 6- 13C) expression are indicative of equally high protein 
expression regardless of age (Figure 6- 13). Likewise, the vast majority of control arterioles 
have normal mitochondrial mass and intact respiratory chain protein expression (Table 6- 8).  
This is further exemplified by the lack of correlation between age and median z scores for the 
level of porin, NDUFB8 and COXI expression (Age vs. porin: rho= -0.018, p value= 0.973; age 
vs. NDUFB8: rho= -0.006 p value= 1; age vs. COXI: rho= -0.042, p value= 0.919) (Spearman’s 
rank correlation). 
The derived z score values were not affected by PMI (porin: rho= -0.109, p value= 0.780; 
NDUFB8: rho= -0.728, p value= 0.056; COXI: rho= -0.597, p value= 0.089). 
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6.5 Discussion 
Stroke-like episodes are prominent, but not restricted, to patients with a clinical diagnosis of 
MELAS and are believed to contribute to the development of ischaemic-like cortical lesions 
seen neuropathologically in these patients (Sue et al., 1998; Tanji et al., 2003; Deschauer et al., 
2007). Posterior cortices are typically affected, within which morphological and functional 
neuronal and vascular abnormalities have been extensively documented (Betts et al., 2006; 
Tzoulis et al., 2006; Tzoulis et al., 2010; Lax et al., 2012). Theories on the aetiology of the 
episodes and mechanisms that account to the progression of the condition have been proposed, 
yet no single mechanism is universally accepted which negatively impacts the way in which 
patients with the condition are treated. The above highlight the necessity for an in depth 
investigation of the extent of vascular respiratory chain defects in patients with mitochondrial 
disease in an attempt to unravel the mechanisms underpinning SLEs. Dual COX/SDH 
histochemistry was employed to assess respiratory chain activity in the vasculature of 
neurologically normal controls and explore the validity of the method in documenting vascular 
deficiencies. To understand the potential contribution of mitochondrial impairments in the 
vasculature, a previously developed quantitative quadruple immunofluorescent technique 
(Chapter 3 of this thesis) was modified to investigate respiratory chain protein expression in 
cortical blood vessels within the cerebellar, occipital and temporal lobe of eleven patients with 
mitochondrial disease. Finally, the effect of ageing on mitochondrial mass, complex I and IV 
protein expression was evaluated using cognitively normal controls. 
COX/SDH has initially been developed in order to examine respiratory chain activity (COX 
activity relative to SDH) in single muscle fibres (Old and Johnson, 1989) and primarily 
employed to assess the level of COX-deficiency in patients with mitochondrial myopathy 
(Sciacco et al., 1994). Since then COX/SDH has served as an invaluable tool for detecting cells 
that are deficient for COX (Ross, 2011) and has been employed in the past to document 
enzymatic deficiencies in the vessels of patients with mitochondrial disease (Betts et al., 2006; 
Lax et al., 2012). Surprisingly, COX/SDH histochemistry employed for the purposes of this 
study revealed that cognitively normal controls possess a significant proportion of microvessels 
that are deficient for COX. This is true for all posterior brain regions studied (cerebellum, 
occipital lobe and temporal lobe), for controls obtained from both the NBTR and the MCR, 
Sudden Death Brain and Tissue Bank (Edinburgh) and for a control cohort with a wide age 
range (41-78 years of age). Thus, COX/SDH histochemistry is not a trustworthy method for 
assigning vascular respiratory chain deficiency in patients with mitochondrial disease and any 
results obtained from the use of this technique alone should be interpreted with caution.   
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Regardless, there are a number of factors that can explain for vascular COX-deficiency detected 
in controls included in this study. As mentioned previously, COX/SDH histochemistry was 
developed to assess respiratory chain activity in muscle fibres and was later optimised for its 
use in the brain. However, the technique has not been specifically optimised for brain 
microvessels, thus the results might be reflective of a lack of method optimisation for its use in 
the vasculature. Moreover, the use of post-mortem tissue is itself an important shortcoming. 
Post-mortem tissue processing and/or interval might negatively affect respiratory chain activity 
in the brain vasculature, which might overall be more susceptible to acquiring deficiencies 
relative to neurons. Lastly, the controls’ cause of death (Table 6- 2) might also explain for the 
results obtained in this study. Vascular disease in some and possible exposure to 
chemotherapeutics in others, which negatively impacts mitochondrial function, may account 
for the profound enzymatic deficiencies detected here (Tang et al., 2014; Yoshida et al., 2015).  
Quantitative quadruple immunofluorescence has been the preferred method for assessing 
respiratory chain protein expression in the vasculature of patients with mitochondrial disease 
and neurologically normal controls. This technique demonstrated the existence of vascular 
respiratory chain deficiency in patients harbouring the m.3243A>G point mutation. More 
specifically, capillaries and arterioles located in the cerebellum, occipital and temporal lobe of 
patients with the m.3243A>G point mutation, have combined complex I  and IV protein 
expression defects, in agreement with severe complex I and milder complex IV deficiencies 
detected in inhibitory interneurons located in the occipital, temporal and frontal lobe cortices 
of these patients (Lax et al., 2015). Decreased respiratory chain protein expression is also 
documented for a patient harbouring the m.8344A>G point mutation (patient 8) and one with 
recessive POLG mutations (patient 12), though to a lesser extent. Vascular respiratory chain 
protein expression defects detected in this study are in line with vascular COX-deficiency 
previously reported in patients with the m.3243A>G and m.8344A>G point mutation (Betts et 
al., 2006; Lax et al., 2012) 
When only considering those patients who harbour the m.3243A>G point mutation (patients 1-
5), it appears that the occipital lobe vasculature is the one most severely affected since both the 
endothelial and smooth muscle cell layers have marked complex I and IV deficiencies relative 
to the same cellular populations of the cerebellum and temporal lobe. This is in agreement with 
neuroradiological observations in patients with the MELAS syndrome that signify the presence 
of focal occipital lobe lesions (Sue et al., 1998). Fascinatingly, the cerebellar vasculature (both 
cell layers) has decreased complex IV protein expression (relative to complex I), whereas 
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complex I deficiencies are more prominent in the microvessels of the occipital and temporal 
lobe cortices. Furthermore, respiratory chain protein expression deficiencies are more 
pronounced in the endothelial cell layer of occipital and temporal lobe microvessels (relative to 
the smooth muscle layer), whereas the reverse is true for the cerebellum. These could be 
denotive of differing vulnerability to respiratory chain protein expression deficiencies amongst 
different brain regions and in fact amongst the two vascular cell layers. 
Altered respiratory chain protein expression in the vasculature of patients with mitochondrial 
disease generally coincides with the incidence of stroke-like episodes and epilepsy across the 
patient cohort but not necessarily with stroke-like cortical lesions recorded macroscopically 
(Table 6- 1) (Lax et al., 2012) (unpublished data). Interestingly, respiratory chain protein 
expression defects have been detected in the microvasculature of patient 3 (m.3243A>G), 
although there is no clinical history of stroke-like episodes or epilepsy for this patient. In 
contrast, patient 7 (m.8344A>G) and 11 (recessive POLG) have a clinical history of epilepsy, 
though no vascular respiratory chain protein expression defects are detected and no stroke-like 
episodes are being reported. These suggest that vascular respiratory chain defects alone cannot 
explain the presence of stroke-like episodes in patients with mitochondrial disease. This is 
strengthened by the detection of COX-deficient microvessels in cognitively normal controls 
and proposes that multiple hits (likely an additive effect between neuronal/interneuronal and 
vascular deficiency) are required for stroke-like episode manifestation. 
Further to vascular respiratory chain protein deficiencies, mitochondrial density and/or 
dynamics was also altered. Though not quantified, observations suggest mitochondrial 
accumulation/proliferation mainly in patients harbouring the m.3243A>G point mutation, 
similar to ragged-red fibres documented in patients with mitochondrial disease (Berkovic et al., 
1989; Tokunaga et al., 1993). These mitochondria were mostly deficient for both NDUFB8 and 
COXI protein expression, implying that nuclear proliferation might occur in affected arterioles 
in order to support increased mitochondrial biogenesis (Duguez et al., 2002; Trinei et al., 2006), 
which might occur as means to compensate for mitochondrial deficiency. However, newly 
synthesised mitochondria are still dysfunctional. Similarly, electron microscopic studies on 
cerebral and cerebellar blood vessels have reported the presence of enlarged, aggregated and 
morphologically abnormal mitochondria within the smooth muscle and endothelium of small 
arteries and within capillary pericytes (Ohama et al., 1987; Sakuta and Nonaka, 1989; 
Mizukami et al., 1992) . 
Chapter 6                                         The microvasculature and its effects on neurodegeneration 
209 
 
Mitochondria have previously been shown to act as signalling organelles within the vasculature, 
acting to maintain calcium homeostasis, produce reactive oxygen species and regulate apoptotic 
cell death (Quintero et al., 2006; Zhang and Gutterman, 2007; Dromparis and Michelakis, 2013; 
Tang et al., 2014).  Respiratory chain deficiencies detected in the blood vessels of patients with 
mitochondrial disease combined with inhibitory interneuronal deficiency (Lax et al., 2015) is 
likely to negatively impact upon vascular tone regulation and cerebral blood flow. Local 
inhibitory interneurons are known to be important in coupling neuronal activity to blood flow 
(Vaucher et al., 2000; Cauli et al., 2004; Rancillac et al., 2006), hence failure of interneurons 
to regulate microvascular tone in combination with aberrant signalling within the microvessels 
could collectively contribute to stroke-like episode manifestation and stroke-like lesion 
formation in patients with mitochondrial disease. 
Additional to examining respiratory chain protein expression in the vasculature of patients with 
mitochondrial disease, the effect of age on arteriolar mitochondrial mass and respiratory chain 
protein expression was assessed. Surprisingly, no changes are observed with regards to 
mitochondrial mass or respiratory chain protein expression in occipital lobe arterioles of aged 
controls. This is in contrast to studies performed on aged animals that report age-related decline 
in vascular mitochondrial mass and function (Burns et al., 1979; Ungvari et al., 2008) or with 
studies that document age-related structural changes in vascular cell layers and altered regional 
blood flow in older adults (Martin et al., 1991; Dohi et al., 1995; Chen et al., 2011). However, 
the control group employed here is small and further research is required before we can 
extrapolate on these results. 
Notwithstanding respiratory chain protein expression deficiencies detected in cerebellar, 
occipital and temporal lobe microvessels of patients with mitochondrial disease, this study 
holds significant drawbacks that need to be taken into account. Firstly, pathological 
examination is performed on post-mortem brain tissue and represents end-stage disease, thus 
any changes detected are due to chronic abnormalities and should be interpreted with caution. 
Secondly, studies were performed on FFPE tissue that originates from the right cerebral 
hemisphere, whereas the majority of patients employed in this study present with left 
hemisphere changes. Hence, the epicentre of pathology is missed. Thirdly, a clear 
discrimination of the arteriolar level investigated at the time is needed if we are to comment on 
the vascular bed more severely affected and develop drug-targeting strategies. Lastly, vascular 
COX-deficiency was detected in cognitively normal controls upon histochemical examination, 
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therefore the extent of respiratory chain protein expression defects in patient microvessels may 
be underestimated highlighting the need to use a more appropriate control group. 
6.5.1 Future work 
Currently, many theories exist on the triggers, the chronological order and the sequence of 
events that lead to stroke-like episodes and stroke-like cortical lesion formation in patients with 
mitochondrial disease. The exact mechanisms that account for the aetiology of stroke-like 
episodes need to be elucidated if we are to prevent stroke-like episode manifestation and/or 
improve patient care following an episode. 
Impairment of mtDNA transcription in the smooth muscle cell layer of a transgenic mouse 
model could be greatly beneficial if it was to successfully replicate the human MELAS 
syndrome (Jawien et al., 2008).  Behavioural and physiological mouse testing in parallel with 
quantitative immunofluorescent techniques would enable the investigation of vascular and 
neuronal changes, prior, during and after stroke-like episode presentation. Furthermore, the 
success of therapeutic compounds currently speculated to improve the condition and minimise 
its severity would be tested, providing the possibility to unravel the compound’s mode of action 
and even the condition mechanisms (Kubota et al., 2004; Koga et al., 2005).  
Although transgenic mouse models have significant advances over post-mortem end-stage 
disease patient samples, the importance of using patient tissue should not be neglected. 
Investigating respiratory chain protein expression in capillary pericytes might provide with 
evidence regarding the arteriolar level that accounts for the vascular changes in patients with 
mitochondrial disease, whereas assessing mitochondrial biogenesis and/or mitochondrial mass 
in arterioles may help gain further insights into the mechanisms behind stroke-like episodes. 
Additionally, respiratory chain protein expression investigation in the gut vasculature can be 
beneficial, since patients with stroke-like episodes usually also present with gastrointestinal 
dysmotilities (Shimotake et al., 1998). 
6.6 Conclusions 
In this study I have presented evidence for the occurrence of respiratory chain protein 
expression defects in the posterior brain region vasculature of patients harbouring the 
m.3243A>G point mutation accompanied by changes in vascular mitochondrial density and/or 
localisation. Complex I deficiency is generally more severe compared to complex IV protein 
expression defects, whereas the endothelial cell layer appears to be more vulnerable to 
mitochondrial dysfunction. The occipital lobe is most severely affected, followed by vascular 
defects in the cerebellum and temporal lobe. Vascular respiratory chain defects detected in this 
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study combined with mitochondrial dysfunction in inhibitory interneurons are likely to 
additively lead to vascular tone dysregulation and aberrant cerebral blood flow in patients with 
mitochondrial disease. COX-deficiency in the blood vessels of cognitively normal controls 
suggests that respiratory chain protein expression deficiency in patients with mitochondrial 
disease is likely to be underestimated, while it further strengthens the notion that stroke-like 
episodes result as a consequence of combined neuronal/interneuronal and vascular deficiencies. 
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Chapter 7 Final Discussion 
The complex and multisystemic nature of mitochondrial disease is exemplified by the presence 
of neurological and non-neurological symptoms, which progress throughout the patients’ life 
and often lead to disability and death. Neurological deficits are the most frequently reported 
manifestation in patients with mitochondrial disease and neuropathological investigations 
performed in the past extensively document brain structural and functional abnormalities. These 
have contributed significantly towards unravelling the molecular mechanisms responsible for 
neurodegeneration in patients with mitochondrial disease. Nonetheless no universally accepted 
hypotheses have been proposed.  
The principal aim of this thesis was to further our understanding on the impact of synapses and 
microvessels upon neuronal degeneration. Synaptic disturbances are increasingly being 
detected in patients with cerebellar ataxia and vascular abnormalities are prominent in those 
presenting with stroke-like episodes. Both ataxia and stroke-like episodes are common in 
patients with mitochondrial disease and are microscopically associated with profound neuronal 
loss. It is fundamental to identify the cellular and/or subcellular compartments affected early in 
disease pathogenesis if we are to develop drug targeting strategies which will ultimately prevent 
and/or delay the degenerative process.  
7.1 Quadruple immunofluorescence for investigating protein expression  
During the course of this thesis a quantitative quadruple immunofluorescent technique was 
developed which enables the precise and reliable quantification of protein expression in human 
post-mortem brain tissues (Chapter 3). This method relies upon conjugation of primary 
antibodies (targeted against proteins of interest) with spectrally unmixed fluorescent tags, the 
signal of which is detected following laser excitation. The amount of signal transmitted is 
linearly related to the amount of protein present, thus allowing quantification of protein 
expression.  
The developed method presents significant advantages over histochemical and 
immunohistochemical assays, previously employed to study respiratory chain activity and 
protein expression at the single cell level respectively. Conventional histochemical assays only 
allow the identification of cells that are positive, intermediate or negative for COX (Old and 
Johnson, 1989; Ross, 2011), which (the cells) are subjectively and semi-quantitatively 
classified for respiratory chain enzymatic activity. Likewise, subtle changes in protein 
expression are likely to be overlooked through indirect immunohistochemistry (Taylor and 
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Levenson, 2006; Nguyen, 2013), which facilitates the investigation of a singular protein 
expression without accounting for mitochondrial mass. 
In contrast, the newly developed immunofluorescent technique holds the capacity to study the 
simultaneous expression of four proteins, in a reliable, precise and reproducible manner 
(Grunewald et al., 2014). Specific neuronal and cellular populations and neuronal domains may 
be investigated, within which respiratory chain protein expression is quantified and adjusted to 
mitochondrial presence. Moreover, high-resolution microscopic techniques and three-
dimensional image analysis software helped reconstruct and examine the morphological 
characteristics of sub-cellular compartments. The technique’s versatility allowed the 
incorporation of different markers and/or its use in different tissues depending on the research 
question at the time, constituting it a valuable tool for the studies performed throughout this 
thesis. 
7.2 Cerebellar ataxia and mitochondrial disease 
The high frequency of cerebellar ataxia reported to manifest in patients recruited to the UK 
MRC Mitochondrial Disease Patient cohort (~70%) (Lax et al., 2012a) highlight the necessity 
for dissecting out the mechanisms responsible for motor and cognitive impairments in patients 
with mitochondrial disease. This study provides the first comprehensive documentation of 
synaptic abnormalities in the intracerebellar circuitry of patients with mitochondrial disease, 
with a focus on the GABAergic and glutamatergic innervation of the dentate nucleus 
(summarised in Figure 7- 1).   
Variably decreased complex I protein expression is detected in Purkinje cell bodies, their 
dendrites expanding to the molecular cell layer and their inhibitory presynaptic terminals 
contacting dentate nucleus neurons (Chapter 4). Protein expression defects are more 
pronounced in patients harbouring the m.3243A>G point mutation though patients with other 
genetic defects (m.8344A>G, m.14709T>C and recessive POLG mutations) have altered 
complex I protein expression relative to controls. The level of complex I deficiency was 
comparable amongst the different neuronal sub-compartments, as were the heteroplasmic levels 
for the m.3243A>G and m.8344A>G point mutation (where this was applicable) suggesting 
that synaptic sites are not selectively protected from mitochondrial dysfunction. Taking into 
account the importance of mitochondria (mainly their capacity to generate ATP and buffer 
Ca2+) in synaptic activity and plasticity (Brodin et al., 1999; Attwell and Laughlin, 2001; 
Billups and Forsythe, 2002; Levy et al., 2003), it is likely that synaptic mitochondrial 
dysfunction will be detrimental to synaptic remodelling and neuronal communication and thus 
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result in altered information processing in the brain. Indeed, synaptic complex I deficiency is 
related with poor clinical rating of ataxia implying that mitochondrial deficiency at the synapses 
contributes to the progression of ataxia. 
Three-dimensional reconstruction of GABAergic synapses revealed loss of inhibitory contacts 
to the dentate nucleus and enlarged remaining presynaptic terminals, providing evidence for 
the existence of compensatory mechanisms acting to maintain synaptic contact area upon 
synapse loss (Scheff and Price, 2003). Decreased GABAergic input to the dentate nucleus is 
accompanied by drop off in the number of Gephyrin-positive puncta located around the 
periphery of dentate nucleus neuronal cell bodies and directly opposed to inhibitory presynaptic 
terminals (Chapter 5). Protein loss from inhibitory postsynaptic compartments is reminiscent 
of GABAergic synapse destabilization - via potential trans-synaptic effects - and subsequent 
defects in inhibitory neurotransmission (Yu et al., 2007; Varley et al., 2011). Further to dentate 
nucleus neuronal disinhibition, glutamatergic innervation of these neurons is also partially 
disturbed. The density of mossy fibre presynaptic terminals and AMPA receptors on dentate 
nucleus neuronal dendrites is decreased, indicating atypical cerebellar connectivity with 
precerebellar nuclei. 
Postsynaptic neuronal deficiencies (dentate nucleus neurons) are detected and were strongly 
related to inhibitory presynaptic protein expression defects. Similarly, respiratory chain 
deficiency in synapses is associated with pronounced dentate nucleus neuronal degeneration, 
supportive of theories on the exertion of anterograde trans-synaptic effects and potential 
transneuronal degenerative mechanisms (Cowan, 1970; Linden and Perry, 1983).    
Data presented in this study propose for altered intra- and extracerebellar connectivity and 
consequent loss of trophic support to the dentate nucleus (Figure 7- 1), however the extent of 
dentate nucleus innervation from climbing fibres remains to be elucidated. When considering 
the importance of deep cerebellar nuclei in forming local feedback and global signal 
transduction networks (D'Angelo and Casali, 2012), one can appreciate that aberrant neuronal 
function and synaptic circuitry detected in patients with mitochondrial disease may contribute 
to the genesis and progression of ataxia.  
These observations are similar to those detected in patients with hereditary ataxias, including 
Friedrich’s ataxia (FRDA). Post-mortem examination of patients with FRDA reveals 
degeneration of the dentate nucleus accompanied by loss of inhibitory and excitatory input to 
the region (Koeppen et al., 2011; Koeppen et al., 2013; Koeppen et al., 2015). However, 
contrary to what is true for mitochondrial disease, no degenerative changes are detected in the 
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inferior olive or Purkinje cells of patients with FRDA implying that degeneration in 
mitochondrial disease is likely due to mechanisms unique to patients with the condition.  
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7.3 The vasculature of patients with mitochondrial disease 
Additional to neurodegeneration across the olivo-cerebellar pathway, neuropathological 
investigation of patients with mitochondrial disease reveals the presence of necrotic foci in 
posterior brain regions. These foci are prominent, but not restricted, to patients with the MELAS 
syndrome, due to m.3243A>G, and are though to be consequent to stroke-like episodes that 
manifest in these patients (Pavlakis et al., 1984; Ohama et al., 1987; Tanji et al., 2003; 
Deschauer et al., 2007). Vasogenic oedema and cerebral hyperperfusion are characteristic acute 
changes which progress into cytotoxic oedema and hypoperfusion during the chronic state 
(Yonemura et al., 2001; Iizuka et al., 2007; Kim et al., 2011). This study provides important 
insights regarding respiratory chain protein expression in the cerebellar, occipital and temporal 
lobe vasculature of patients with a wide range of genetic diagnoses (m.3243A>G, m.8344A>G 
and recessive POLG mutations). Not all patients included in the study have a clinical history of 
stroke-like episodes and focal stroke-like cortical lesions, documented macroscopically, do not 
necessarily coincide with the incidence of stroke-like features (Chapter 6). 
Combined complex I and IV protein deficiencies are detected in the microvessels of patients 
harbouring the m.3243A>G point mutation across all brain regions studied. When present, 
respiratory chain deficiencies in patients with other genetic defects (m.8344A>G and recessive 
POLG mutations) are mild. Interestingly, complex IV protein expression defects predominate 
in the cerebellar vasculature, whereas complex I deficiency prevails in the occipital and 
temporal lobe. This might be suggestive of differential vulnerability to respiratory chain 
deficiency amongst different brain regions. Furthermore, protein expression defects are most 
noticeable in the smooth muscle cell layer of cerebellar arterioles, whilst the endothelial cells 
of occipital and temporal lobe capillaries are more severely affected. Vascular respiratory chain 
deficiency was detected in cognitively-normal controls (upon dual COX/SDH histochemistry) 
and protein expression defects have also been detected in patients without a clinical history of 
stroke-like episodes. These data are not in favour of the primary vascular hypothesis and instead 
suggest that vascular respiratory chain defects alone are not sufficient for the induction of 
stroke-like episodes.  
Generally, microvessels located in the occipital lobe harbour the most severe respiratory chain 
deficiencies in agreement with stroke-like cortical lesion predilection for this region. Additional 
to electron transport chain protein expression defects, the arterioles of patients harbouring the 
m.3243A>G point mutation have altered mitochondrial distribution and/or mass. Mitochondrial 
clusters deficient for complex I and IV have been detected around smooth muscle cell nuclei, 
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reminiscent of increased mitochondrial biogenesis and/or aberrant mitochondrial transport. 
Mitochondrial proliferation may be activated to compensate for vascular mitochondrial 
dysfunction, though newly synthesised organelles are also malfunctional. Capillary 
proliferation is not evident, though microvascular density quantification was not the focus of 
this study and needs to be assessed in greater detail.     
Despite the fact that the vascular cell populations are highly glycolytic and do not rely on 
mitochondria for energy supply, microvascular mitochondria are involved in major signalling 
pathways affecting cellular survival and function (Quintero et al., 2006; Dromparis and 
Michelakis, 2013; Tang et al., 2014). Nevertheless, the factors contributing to the development 
of lesions during a stroke-like episode are likely to be manifold. Respiratory chain deficiency 
detected in various inhibitory cellular types and sub-cellular domains (Lax et al., 2012a; 
Chrysostomou et al., 2015; Lax et al., 2015) may result in atypical inhibitory neurotransmission 
in the brain of patients with mitochondrial disease and consequent lower thresholds for seizure 
generation. Dysfunctional inhibitory interneurons (Lax et al., 2015) fail to couple blood flow 
to neuronal hyperexcitability, which combined with mitochondrial dysfunction within and 
structural abnormalities of microvessels (Lax et al., 2012b) render the seizure foci vulnerable 
to degeneration. The hypothesised mechanism for stroke-like episode presentation in patients 
with mitochondrial disease is summarised in Figure 7- 2 and is in agreement with the non-
ischemic neurovascular hypothesis proposed by Iizuka and colleagues (Iizuka and Sakai, 2005). 
According to this, focal neuronal hyperexcitability (as a result of neuronal/interneuronal and/or 
vascular mitochondrial dysfunction) shifts the balance between energetic demand and supply 
and results in local neuronal loss (Iizuka and Sakai, 2005).  
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7.4 Implications of this study  
Studies in this thesis explore the synaptic and vascular abnormalities in a genetically diverse 
group of patients presenting with cerebellar ataxia and stroke-like episodes. The 
neuropathological and molecular investigation of neuronal, synaptic and vascular cell 
populations helped gain further insights into the degenerative changes observed in association 
with these two different cellular compartments. 
Research involving the cerebellar circuitry improved our knowledge with regards to the exact 
synaptic abnormalities occurring in the cerebellum of ataxic patients. Atypical cerebellar 
connectivity may be detrimental to local information processing with adverse effects on 
downstream neuronal signalling, explaining for the cognitive and motor disturbances in a high 
percentage of patients with mitochondrial disease. However, there is still a lot left to be done 
before we can confidently report on synaptic anomalies as being the primary event in the 
degenerative process and the main source of network disruption. Similar experiments in the 
inferior olive and the thalamus may help unravel whether synaptic changes exist across the 
olivo- and ponto-cerebellar pathways, whereas investigation of areas with less pronounced 
neuronal loss will facilitate the assessment of synaptic pathology in the absence of 
neurodegeneration. Moreover, the use of transgenic mouse models will enable the temporal 
documentation of synaptic changes with regards to behavioural abnormalities. Regardless, 
synaptic connections do not appear to be selectively protected from the effects of mitochondrial 
dysfunction, constituting synapses good candidates for drug targeting. Indeed, the 
neuroprotective effects of a cold-shock protein (RBM3) have been demonstrated in mouse 
models of neurodegenerative disease, where maintained structural synaptic plasticity prevented 
behavioural deficits (Peretti et al., 2015).  
The precise quantification of respiratory chain protein expression in the microvascular 
environment of posterior brain regions has contributed to a better understanding of the aetiology 
of stroke-like episodes in patients with mitochondrial disease. More severe deficiencies 
detected primarily in the endothelial cell layer and potentially altered mitochondrial dynamics 
in the smooth muscle of arterioles may represent pathological changes which might impact 
upon vascular tone regulation, resulting in abrupt changes in cerebral blood flow. Further 
characterisation of respiratory chain protein expression defects, including investigation of 
pericytes, will be crucial for identifying the vascular bed most severely affected holding 
promises for identifying a valid target for therapeutic intervention.     
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Mitochondrial dysfunction is directly implicated in the pathophysiology of common 
neurodegenerative disorders (Duchen, 2004) including Alzheimer’s (Du et al., 2010), 
Parkinson’s (Klein and Westenberger, 2012) and Huntington’s (Shirendeb et al., 2011) disease. 
Taking into consideration that neurodegenerative diseases have many parallels and share 
common themes across neurodegenerative processes, the work performed in this thesis might 
have wider implications concerning future studies in other neurodegenerative diseases.       
7.5 Limitations of this study 
Additional to significant advances, this study holds important limitations that need to be 
considered. These include: 
i. Neuropathological investigation is performed on end-stage disease brain tissue, thus 
does not allow the evaluation of changes during disease progression. 
ii. Profound neuronal degeneration is detected prior to the time of neuropathological 
investigation and implies that interesting cells have already been lost. 
iii. Tissue is available for a limited number of patients harbouring the same genetic defect, 
hence no firm conclusions can be drawn with regards to pathogenic mechanisms specific 
to a single genetic defect. 
7.6 Concluding remarks 
In conclusion, the data presented in this thesis expand on current knowledge regarding the 
extent of synaptic and vascular abnormalities in patients with cerebellar ataxia and stroke-like 
episodes respectively. The inhibitory synaptic connections linking Purkinje cells to dentate 
nucleus neurons and the endothelial cell layer of posterior cortical region microvessels could 
potentially serve as candidates for therapeutic intervention, however further studies are needed 
in order to fully understand the impact of synaptic and vascular mitochondrial dysfunction in 
the initiation and progression of neuronal degeneration. 
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8.2 Appendix B: Inhibitory presynaptic terminal volume  
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